Modulators of g-protein coupled receptors

Peptide-based modulators of GLP-1R and GIPR enhance insulin secretion and glucose regulation, addressing the limitations of current treatments for diabetes and NASH by reducing side effects and improving metabolic outcomes.

JP2024156720AActive Publication Date: 2024-11-06CARMOT THERAPEUTICS INC
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
JP2024116690
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2018-03-23
Filing Date
2024-07-22
Publication Date
2024-11-06
Estimated Expiration
2039-03-22

AI Technical Summary

Technical Problem

Current treatments for conditions such as Type 2 diabetes, nonalcoholic steatohepatitis (NASH), and obesity lack effective modulators of glucagon-like peptide 1 receptor (GLP-1R) and gastric inhibitory polypeptide receptor (GIPR) that can improve insulin secretion, glucose regulation, and reduce side effects like nausea without causing aversion.

Method used

Development of peptide-based chemical entities that modulate GLP-1R and GIPR activity, including agonists, antagonists, and partial agonists, which enhance insulin secretion and glucose clearance while minimizing β-arrestin signaling and aversion.

Benefits of technology

The peptide-based modulators effectively improve insulin levels and glucose regulation, reduce symptoms of diabetes and NASH, and minimize side effects like nausea, offering a more targeted and effective treatment approach.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024156720000689
    Figure 2024156720000689
  • Figure 2024156720000690
    Figure 2024156720000690
  • Figure 2024156720000691
    Figure 2024156720000691
Patent Text Reader

Abstract

To provide a compound that acts as an agonist at a GLP-1 receptor.SOLUTION: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and / or hydrate and / or a prodrug of the compound) that modulate (e.g., agonize or partially agonize or antagonize) a glucagon-like peptide-1 receptor ("GLP-1R") and / or a gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, a disorder, or a condition in which modulation (e.g., agonism, partial agonism or antagonism) of GLP-1R and / or GIPR activities is beneficial for the treatment or prevention of the underlying pathology and / or symptoms and / or progression of the disease, the disorder, or the condition.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] Claiming priority This application claims the benefit of U.S. Provisional Application No. 62 / 647,604, filed March 23, 2018, which is incorporated by reference in its entirety.

[0002] Sequence Listing This application contains a Sequence Listing, which has been submitted electronically in ASCII format and is incorporated by reference in its entirety. Said ASCII copy, created on Mar. 22, 2019, is named 41517-0002WO1_SL.txt and is 39,811 bytes in size.

[0003] Technical Field The present disclosure features chemical entities (e.g., compounds, or pharma- ceutically acceptable salts and / or hydrates and / or prodrugs of the compounds) that modulate (e.g., stimulate, partially stimulate, or antagonize) the glucagon-like peptide 1 receptor ("GLP-1R") and / or gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, for example, for treating subjects (e.g., humans) with a disease, disorder, or condition, where modulation (e.g., agonism, partial agonism, or antagonism) of GLP-1R and / or GIPR activity is beneficial in treating or preventing the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition. In some embodiments, modulation improves (e.g., increases) the current level (e.g., normal or below normal) of GLP-1R and / or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to that observed with the natural ligand. The disclosure also features compositions and other methods of using and making the chemical entities. [Background technology]

[0004] background Type 2 diabetes mellitus (T2DM) is characterized by high blood glucose levels and insulin resistance. Tens of millions of people in the United States alone suffer from T2DM and conditions that are comorbidities or sequelae of T2DM. T2DM is often associated with obesity.

[0005] Nonalcoholic steatohepatitis (NASH) is inflammation and damage of the liver caused by fat accumulation in the liver. It is part of a group of conditions called nonalcoholic fatty liver disease (NAFLD). NASH and NAFLD tend to occur in patients with one of the risk factors, such as obesity, dyslipidemia, and glucose intolerance, and appear to be related to insulin resistance (such as obesity or metabolic syndrome).

[0006] Incretin hormones are hormones that control blood glucose in response to food intake. Gastric inhibitory polypeptide ("GIP") and glucagon-like peptide 1 ("GLP-1") are the primary incretin hormones secreted from L cells and K cells, respectively, of the small intestine upon ingestion of glucose or nutrients to stimulate insulin secretion from pancreatic β cells. GIP and GLP-1 are degraded by dipeptidyl peptidase 4 (DPP-4) and rapidly lose their biological activity (see, for example, Y. Sieno, et. al, Journal of Diabetes Investigation 2013, 4, 108-130 (Non-Patent Document 1)).

[0007] The actions of GIP and GLP-1 are believed to be mediated by specific receptors, GIP receptor (GIPR) and GLP-1 receptor (GLP-1R), respectively, both of which belong to the G protein-coupled receptor family and are expressed in pancreatic β cells and various tissues and organs.GLP-1 activities include, but are not limited to, stimulating insulin synthesis and secretion, inhibiting glucagon secretion, and inhibiting food intake.GIP activities include, but are not limited to, stimulating glucose-dependent insulin secretion, increasing β-cell mass, stimulating glucagon secretion, and reducing gastric acid secretion.See, for example, WO 2016 / 131893 (Patent Document 1).

[0008] GLP-1 and GLP-1 analogs acting as agonists at the GLP-1 receptor have been shown to be effective in glycemic control, for example in type 2 diabetes. See, for example, WO 2016 / 131893. Besides their insulin secretory effects, GIP and GLP-1 are thought to be involved in various biological processes in different tissues and organs that express GIPR and GLP-1R, including, for example, pancreas, fat, bone, brain, heart, kidney, eye, nerve, and liver. For example, studies using mice lacking GIPR and / or GLP-1R, as well as mice lacking DPP-4, have shown that GIP and GLP-1 are involved in diverse biological activities. The results of these studies indicate that GIP and GLP-1 are involved in the treatment and / or prevention of diabetes-related microvascular complications (e.g., retinopathy, nephropathy, and neuropathy) and macrovascular complications (e.g., coronary artery disease, peripheral artery disease, and cerebrovascular disease), as well as diabetes-related comorbidities (e.g., obesity, nonalcoholic fatty liver disease, bone fractures, and cognitive impairment). See, for example, Sieno, p. 108. [Prior art documents] [Patent documents]

[0009] [Patent Document 1] WO 2016 / 131893 [Non-patent literature]

[0010] [Non-Patent Document 1] Y. Sieno, et. al, Journal of Diabetes Investigation 2013, 4, 108-130 Summary of the Invention

[0011] overview The present disclosure features chemical entities (e.g., compounds, or pharma- ceutically acceptable salts and / or hydrates and / or prodrugs of the compounds) that modulate (e.g., stimulate, partially stimulate, or antagonize) the glucagon-like peptide 1 receptor ("GLP-1R") and / or gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, for example, for treating subjects (e.g., humans) with a disease, disorder, or condition, where modulation (e.g., agonism, partial agonism, or antagonism) of GLP-1R and / or GIPR activity is beneficial in treating or preventing the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition. In some embodiments, modulation improves (e.g., increases) the current level (e.g., normal or below normal) of GLP-1R and / or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to that observed with the natural ligand. The disclosure also features compositions and other methods of using and making the chemical entities.

[0012] An "agonist" of GLP-1R includes compounds that bind directly to or modify GLP-1R at the protein level such that GLP-1R activity is increased, e.g., by activation, stabilization, altered distribution, or in other ways, compared to GLP-1R activity in the absence of ligand.

[0013] Certain compounds described herein that stimulate GLP-1R to a lesser extent than GLP-1R full agonists (e.g., natural GLP-1) (partial agonists) can function as antagonists and agonists in assays. These compounds antagonize the activation of GLP-1R by GLP-1R full agonists, since they prevent the full effect of GLP-1R interaction. However, the compounds also activate some GLP-1R activity by themselves, usually less than the corresponding amount of GLP-1R full agonists. These compounds may be referred to herein as "GLP-1R partial agonists."

[0014] An "antagonist" of GLP-1R includes compounds that bind directly to or modify GLP-1R at the protein level such that GLP-1R activity is reduced compared to GLP-1R activity in the absence of ligand, e.g., by inhibiting, blocking, or attenuating agonist-mediated responses, altering distribution, or otherwise.

[0015] In some embodiments, the compounds described herein are agonists (e.g., full agonists) of GLP-1R. In other embodiments, the compounds described herein are partial agonists or antagonists of GLP-1R.

[0016] An "agonist" of GIPR includes a compound that binds directly to or modifies GIPR at the protein level such that GIPR activity is increased, e.g., by activation, stabilization, altered distribution, or otherwise, compared to GIPR activity in the absence of ligand.

[0017] Certain compounds described herein stimulate GIPR to a lesser extent than native GIP (full agonist) and can function as antagonists and agonists.These compounds are partial antagonists because they reduce the activation of GIPR by native GIP, because they reduce the full effect of native GIP.However, the compounds also activate some GIPR activity by themselves, usually less than the corresponding amount of native GIP.In this specification, these compounds may be referred to as "GIPR partial agonists".

[0018] An "antagonist" of GIPR includes compounds that bind directly to or modify GIPR at the protein level such that GIPR activity is decreased compared to GIPR activity in the absence of ligand, e.g., by inhibiting, blocking, or attenuating agonist-mediated responses, altering distribution, or otherwise.

[0019] In some embodiments, the compounds described herein are agonists (e.g., full agonists) of GIPR. In other embodiments, the compounds described herein are partial agonists of GIPR. In yet other embodiments, the compounds described herein are antagonists of GIPR.

[0020] In some embodiments, the compounds described herein are full agonists of both GLP-1R and GIPR. In some embodiments, the compounds described herein are partial agonists of both GLP-1R and GIPR. The present disclosure also contemplates a chemical entity that (i) stimulates one of GLP-1R and GIPR (e.g., GLP-1R); and antagonizes the other of GLP-1R and GIPR (e.g., GIPR). For example, the present disclosure contemplates a chemical entity that (i) fully stimulates one of GLP-1R and GIPR (e.g., GLP-1R); and partially stimulates or antagonizes the other of GLP-1R and GIPR (e.g., GIPR). In certain embodiments, the chemical entity is a full agonist of GLP-1R and a partial agonist or antagonist of GIPR; or a partial agonist or antagonist of GLP-1R and a full agonist of GIPR.

[0021] In general, receptors exist in active (Ra) and inactive (Ri) conformations. Certain compounds that affect receptors can change the Ra to Ri ratio (Ra / Ri). For example, full agonists increase the Ra / Ri ratio and can cause a "maximal" saturation effect. Partial agonists, upon binding to the receptor, give a response that is lower than that induced by a full agonist (e.g., endogenous agonist). Thus, the Ra / Ri of a partial agonist is less than that of a full agonist. However, the potency of a partial agonist can be greater or less than that of a full agonist.

[0022] In some embodiments, the chemical entities described herein further modulate (e.g., reduce, e.g., attenuate, interfere, inhibit) β-arrestin conjugation and / or b-arrestin signaling, and internalization of GLP-1R and / or GIPR. In certain embodiments, the chemical entities described herein modulate (e.g., reduce, e.g., attenuate, interfere, inhibit) β-arrestin recruitment to a G protein-coupled receptor (e.g., GLP-1R). In certain embodiments, the chemical entities described herein modulate (e.g., reduce, e.g., attenuate, interfere, inhibit) the formation ("coupling") of a complex (e.g., a signaling complex) between β-arrestin and a G protein-coupled receptor (e.g., GLP-1R or GIPR). The effect of the chemical entities described herein on β-arrestin signaling and associated downstream processes (e.g., processes described above) can be assessed using conventional methods, such as the PathHunter β-arrestin assay to determine β-arrestin conjugation (see Examples section). For example, a β-arrestin (GLP-1R) EC value of less than 1 μM in the above assay indicates a compound that induces β-arrestin recruitment to the GLP-1R. GLP-1, the natural ligand of GLP-1R, and its therapeutic analogs, such as liraglutide, are potent recruiters of β-arrestin. As another example, a β-arrestin (GLP1R) EC value of more than 1 μM (e.g., more than 10 μM) indicates a compound that induces β-arrestin recruitment to the GLP-1R. 50The values ​​indicate compounds that do not substantially induce β-arrestin recruitment to GLP-1R. Therapeutic agents that modulate G protein-coupled receptors (e.g., GLP-1R and / or GIPR) can produce different effects on β-arrestin-based signaling that depend on the degree of cAMP activation. b-arrestin conjugation has been shown to be a key strap in receptor internalization and subsequent desensitization and attenuation of signaling. Both GLP-1 (and liraglutide analogs) and GIP have been shown to produce rapid receptor internalization. Thus, compounds that activate GLP-1R and / or GIPR cAMP signaling but do not substantially conjugate with β-arrestin show the potential to prolong receptor signaling and prolong pharmacological benefits. In some embodiments, the chemical entities described herein show relatively strong GLP-1R and / or GIPR-mediated cAMP activation with minimal or undetectable β-arrestin conjugation. In some embodiments, the chemical entities described herein exhibit relatively potent GLP-1R-mediated cAMP activation with minimal or undetectable β-arrestin conjugation, and little or no GIPR-mediated cAMP activation.

[0023] In some embodiments, the compounds described herein show reduced activity in rodent aversion models while maintaining relatively high potency in glucose clearance assays.Aversion models such as conditioned taste aversion are commonly used to identify compounds that show adverse effects such as nausea.Nausea-inducing agents such as Exendin-4 and Liraglutide are known to show strong signals in conditioned taste aversion models.Therefore, advantageously, some chemical entities described herein are expected to show reduced potential to cause undesirable side effects such as nausea when administered to patients while maintaining full pharmacological benefits.

[0024] Thus, in one aspect, the disclosure features peptide-based chemical entities (e.g., N-protected peptide-based chemical entities; e.g., peptide-based chemical entities having 30-50 amino acids, 30-45 amino acids, 30-40 amino acids, 35-40 amino acids; e.g., N-protected peptide-based chemical entities having 30-50 amino acids, 30-45 amino acids, 30-40 amino acids, 35-40 amino acids). As described herein, the peptide-based chemical entities modulate (e.g., stimulate, partially stimulate, or antagonize) the glucagon-like peptide 1 receptor ("GLP-1R") and / or gastric inhibitory polypeptide receptor ("GIPR"), and further, in some cases, modulate (e.g., uncouple, attenuate) β-arrestin signaling and / or aversion.

[0025] In some embodiments, the peptide-based chemical entity agonizes or partially agonizes the GLP-1R.

[0026] In some embodiments, the peptide-based chemical entity agonizes, partially agonizes, or antagonizes the GIPR.

[0027] In some embodiments, the peptide-based chemical entity reduces (e.g., uncouples, attenuates, inhibits) β-arrestin signaling, e.g., reduces (e.g., uncouples, attenuates, inhibits) the recruitment of β-arrestin to a G protein-coupled receptor (e.g., GLP-1R), e.g., reduces (e.g., attenuates, interferes with, inhibits) the formation of a complex (e.g., a signaling complex) between β-arrestin and a G protein-coupled receptor (e.g., GLP-1R).

[0028] In certain embodiments, the peptide-based chemical entity is · stimulates or partially stimulates GLP-1R; · Stimulate or partially agonize or antagonize the GIPR; · reducing (e.g., uncoupling, attenuating, inhibiting) β-arrestin signaling, e.g., reducing (e.g., attenuating, interfering, inhibiting) the recruitment of β-arrestin to G protein-coupled receptors (e.g., GLP-1R and / or GIPR), e.g., reducing (e.g., attenuating, interfering, inhibiting) the formation of a complex (e.g., signaling complex) between β-arrestin and G protein-coupled receptors (e.g., GLP-1R and / or GIPR); and Stimulates glucose clearance in vivo (GTT test) without inducing aversion.

[0029] In some embodiments, the peptide-based chemical entities exhibit a cAMP (GLP1R) EC50 value of less than about 10 nM, less than about 5 nM, or less than about 1 nM (eg, less than about 1 nM).

[0030] In some embodiments, the peptide-based chemical entity exhibits a cAMP(GIPR) EC50 value of less than about 100 nM, less than about 50 nM, or less than about 10 nM (eg, less than about 10 nM).

[0031] In some embodiments, the peptide-based chemical entities inhibit GIP-induced cAMP production (GIPR antagonism).

[0032] In some embodiments, the compounds described herein exhibit β-arrestin (GLP1R) EC50 values ​​greater than 1 μM.

[0033] In some embodiments, the peptide-based chemical entity is exhibits a cAMP (GLP1R) EC50 value of less than about 10 nM, less than about 5 nM, or less than about 1 nM (e.g., less than about 1 nM); exhibits a cAMP (GIPR) EC50 value of less than about 100 nM, less than about 50 nM, or less than about 10 nM (e.g., less than about 10 nM) or is a GIPR antagonist; exhibits a β-arrestin (GLP1R) EC50 value of greater than 1 μM; and Stimulates glucose clearance in vivo (GTT test) without inducing aversion (nausea).

[0034] In one aspect, the featured peptide-based chemical entities include a compound of formula (IAA), or a pharma- ceutically acceptable salt thereof: TIFF2024156720000001.tif36128In formula, rings A, G, L, W, R 1 , R 2 , R 2' , and R 4 may be as defined anywhere herein.

[0035] In one aspect, the invention features a pharmaceutical composition that includes a chemical entity described herein (e.g., a compound described generally or specifically herein, or a pharma- ceutically acceptable salt thereof, or a composition comprising same) and one or more pharma- ceutically acceptable excipients.

[0036] In one aspect, the present invention features a method for modulating (e.g., stimulating, partially stimulating, or antagonizing) GLP-1R and / or GIPR activity, comprising contacting GLP-1R and / or GIPR with a chemical entity described herein (e.g., a compound generally or specifically described herein or a pharma- ceutically acceptable salt thereof, or a composition comprising the same).The method includes in vitro methods, such as contacting the chemical entity with a sample comprising one or more cells, each of which independently comprises one or more of GLP-1R and / or GIPR.The method also includes in vivo methods, such as administering the chemical entity to a subject (e.g., a human) having a disease, disorder, or condition, where the modulation of GLP-1R and / or GIPR signaling is beneficial for treating the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition (e.g., diabetes; e.g., NASH; e.g., obesity). In vivo methods include, but are not limited to, regulating (e.g., increasing) insulin levels and regulating (e.g., decreasing) glucose levels in a subject (e.g., a human). In some of the above embodiments, the regulating method is achieved without substantially stimulating signaling of β-arrestin, e.g., without stimulating recruitment of β-arrestin to a G protein-coupled receptor (e.g., GLP-1R), e.g., without stimulating the formation of a complex (e.g., a signaling complex) between β-arrestin and a G protein-coupled receptor (e.g., GLP-1R). In some of the above embodiments, the regulating method is achieved without causing aversion or nausea.

[0037] A further aspect features a method for treating a disease, disorder, or condition, in which the modulation of GLP-1R and / or GIPR signal transduction is beneficial for treating the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition.The method comprises administering to a subject in need of the treatment an effective amount of a chemical entity described herein (e.g., a compound generally or specifically described herein, its pharma- ceutically acceptable salt, or a composition comprising it).

[0038] In another aspect, the disclosure features a method for treating a subject having a disease, disorder, or condition, in which modulation of GLP-1R and / or GIPR signaling is beneficial for treating the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition. The method includes administering a chemical entity described herein (e.g., a compound generally or specifically described herein, a pharma- ceutically acceptable salt thereof, or a composition comprising the same) in an amount effective to treat the disease, disorder, or condition.

[0039] In a further aspect, the present invention features a method of treatment comprising administering to a subject a chemical entity described herein (e.g., a compound generally or specifically described herein, a pharma- ceutically acceptable salt thereof, or a composition comprising same).The method comprises administering the chemical entity in an amount effective to treat a disease, disorder, or condition, wherein modulation of GLP-1R and / or GIPR is beneficial to treat the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition.

[0040] In another aspect, the method of treatment comprises (i) administering to a subject, as defined anywhere herein, a first therapeutic agent that modulates (e.g., stimulates, partially stimulates, or antagonizes) GLP-1R and / or GIPR; (ii) determining that the subject is suffering from one or more side effects (e.g., nausea, vomiting, or discomfort); and (iii) discontinuing administration of the first therapeutic agent and administering a chemical entity described herein (e.g., a compound having formula (IAA), (IA), or (I)).

[0041] Non-limiting examples of such diseases, disorders, and conditions include metabolic syndrome; diabetes (e.g., type 2 diabetes); obesity; obesity-related disorders; impaired glucose tolerance; insulin resistance; non-alcoholic steatohepatitis (NASH); fatty liver disease; steatohepatitis; and other forms of inflammation in metabolically important tissues, including the liver, adipose, pancreas, kidney, and intestine.

[0042] Other non-limiting examples of such diseases, disorders, and conditions include neurological disorders, including brain insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety, dementia (e.g., senile dementia), brain trauma, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, Morbus Parkinson, Steele-Richard syndrome, Down's syndrome, myasthenia gravis, neurotrauma, brain trauma, vascular amyloidosis, cerebral hemorrhage with amyloidosis, encephalitis, Friedreich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated degenerative diseases of the central nervous system (e.g., Creutzfeldt-Jakob disease, bovine spongiform encephalopathy (mad cow disease), and chronic wasting syndrome).

[0043] Further non-limiting examples of said diseases, disorders and conditions include bone disorders characterized by altered bone metabolism, such as osteoporosis, including postmenopausal osteoporosis, reduced bone strength, osteopenia, Paget's disease, osteolytic metastases in cancer patients, osteodystrophy in liver disease, and altered bone metabolism caused by renal failure or hemodialysis, fractures, bone surgery, aging, pregnancy, protection against fractures, and malnutrition.

[0044] In certain embodiments, the disease, disorder, or condition is diabetes.

[0045] In other embodiments, the disease, disorder, or condition is NASH.

[0046] In yet another aspect, the disease, disorder, or condition is obesity.

[0047] In other embodiments, the disease, disorder, or condition is Alzheimer's disease (AD) or Parkinson's disease (PD).

[0048] In yet other aspects, the disease, disorder, or condition is a bone disorder characterized by altered bone metabolism, such as osteoporosis, including postmenopausal osteoporosis, decreased bone strength, osteopenia, Paget's disease, osteolytic metastases in cancer patients, osteodystrophy in liver disease, and altered bone metabolism caused by renal failure or hemodialysis, fracture, bone surgery, aging, or pregnancy.

[0049] In certain aspects, the chemical entities described herein are useful in protecting against bone fracture.

[0050] The method described herein may further comprise treating one or more conditions that are associated, comorbid or secondary to any one or more conditions described herein.As a non-limiting example, the method may further comprise treating one or more conditions that are comorbid or secondary to diabetes (e.g., type 2 diabetes), such as obesity, obesity-related disorders, metabolic syndrome, impaired glucose tolerance, insulin resistance, cardiovascular risk factors (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors associated with uncontrolled cholesterol and / or lipid levels, and / or inflammation), retinopathy, nephropathy, neuropathy, NASH, bone fracture, and cognitive impairment.

[0051] In another aspect, the disclosure features a method for screening a candidate compound for the treatment of a disease, disorder, or condition, where modulation of GLP-1R and / or GIPR is beneficial for treating the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition, the method comprising the steps of: (a) contacting the candidate compound with (i) a β-arrestin-coupled GPCR receptor signaling complex, or (ii) one or more GPCR receptor signaling complexes that are not complexed with β-arrestin (e.g., uncoupled GLP-1R and / or uncoupled GIPR); and (b) (i) detecting the disruption of a b-arrestin conjugate complex; or (ii) detecting the formation of a signaling complex in the absence of b-arrestin conjugation, wherein the candidate compound modulates (e.g., stimulates, partially stimulates) GLP-1R and / or GIPR.

[0052] In certain embodiments, the method further comprises selecting candidate compounds that exhibit a β-arrestin (GLP-1R) EC50 value of greater than 1 μM.

[0053] The method may further include identifying the subject.

[0054] The methods may further include administering one or more other therapeutic agents (eg, in combination with the chemical entities described herein).

[0055] Embodiments may include one or more of the following advantageous features.

[0056] In some embodiments, the compounds described herein exhibit AUC score values ​​of 0-25% versus vehicle, which corresponds to the finding of maximal reduction in glycemic excursion compared to the control.

[0057] In some embodiments, the compounds described herein exhibit cAMP (GLP-1R) EC50 values ​​of less than about 1 nM, indicating that the compounds are relatively potent GLP-1R agonists.

[0058] In some embodiments, the compounds described herein exhibit cAMP (GLP-1R) Emax values ​​of greater than about 80%, indicating that the compounds are agonists capable of fully activating GLP-1R.

[0059] In some embodiments, the compounds described herein have a cAMP(GIPR)EC of less than about 10 nM. 50 values ​​are shown, indicating that the compounds are relatively potent GIPR agonists.

[0060] In some embodiments, the compounds described herein have a cAMP(GIPR)EC of less than about 10 nM. 50 values ​​are shown, indicating that the compounds are relatively potent GIPR antagonists.

[0061] GLP-1 and GIP are easily degraded rapidly by dipeptidyl peptidase IV (DPP-IV) (see, for example, Deacon, et al. Journal of Clinical Endocrinology & Metabolism, 1995, 80, 952-957).Therefore, GLP-1 and GIP have been shown to have a relatively short half-life in humans due to degradation by DPP-IV.Advantageously, the compounds described herein have a relatively long half-life in the presence of DPP-IV compared to the half-life of GLP-1 and GIP.

[0062] In some embodiments, the compounds described herein exhibit a β-arrestin conjugate (GLP-1R) EC50 value of greater than 1 μM in a β-arrestin (GLP1R) assay that measures the formation of a complex between GLP-1R and β-arrestin in cells. A β-arrestin (GLP1R) EC50 value of greater than 1 μM indicates a compound that does not substantially induce β-arrestin recruitment to GLP-1R.

[0063] In some embodiments, the compounds described herein exhibit a conditioned taste aversion ("CTA") value of 0.6-1.0, indicating no measurable aversion to the compound, which is desirable. A CTA value of 0.0-0.6 indicates a significant aversion to the compound. The conditioned taste aversion assay measures preference for a dilute saccharin solution in association with compound administration.

[0064] In some aspects, the compounds described herein exhibit a reduced likelihood of causing undesirable side effects when administered to a patient, a non-limiting example of which is nausea.

[0065] [The present invention 1001] A compound having the formula (IAA), or a pharma- ceutically acceptable salt thereof: TIFF2024156720000002.tif36128 formula, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where G is C(O), S(O), or SO 2 and; G and N * and the circular dotted line connecting (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and each independently are C, CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, or CH 2 , C.R. b , C(R b ) 2 , and C.H.R. band (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p(Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R cC which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d heterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 2' is as defined by (AA) or (BB) below: (AA) R 2' teeth TIFF2024156720000003.tif25128, wherein R 3-C(O)OH, -C(O)OR 31 , -CH(C(O)OH) 2 or a carboxylic acid isostere (e.g., amide or tetrazolyl); a is 0 to 5; a' is 0 or 1; R 3a and R 3b are each independently H or C 1~3 is alkyl; (BB) R 2' and R 4 together with the atoms connecting them form a ring containing 5-8 ring atoms, where 3-7 are H, halo, hydroxy, oxo, and C 1~3 each ring carbon atom is substituted with 1 to 2 substituents independently selected from alkyl; 0 to 1 are O, -NH, -N(C 1~3 (R alkyl), and S 1 (e.g., R 4 and R 3 form, together with the atom to which each is attached, a ring containing 5 to 8 ring atoms); R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C) containing 5 to 10 ring atoms 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5wherein W' is a sequence of 5 to 60 amino acids, and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group), However, one or more of the compound definitions detailed herein apply. [The present invention 1002] The compound of the present invention has the formula (IA), or a pharma- ceutically acceptable salt thereof: TIFF2024156720000004.tif38128In formula, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where G is C(O), S(O), or SO 2 and; G and N * and the circular dotted line connecting (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and each independently are C, CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R.b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, and CR. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d heterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 3 -C(O)OH, -C(O)OR 31 , -CH(C(O)OH)2 or a carboxylic acid isostere (e.g., amide or tetrazolyl); a is 0 to 5; a' is 0 or 1; R 3a and R 3b are each independently H or C 1~3 is alkyl; R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C) containing 5 to 10 ring atoms 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a)(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 wherein W' is a sequence of 5 to 60 amino acids, and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group), However, one or more of the compound definitions detailed herein apply. [The present invention 1003] Any of the compounds of the present invention 1001 to 1002 having the formula (I), or a pharma- ceutically acceptable salt thereof: TIFF2024156720000005.tif36128 formula, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where G is C(O), S(O), or SO 2 and; G and N * and the circular dotted line connecting (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and each independently are C, CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, and CR. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d heterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 3 -C(O)OH, -C(O)OR 31 , or a carboxylic acid isostere; where R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R dheterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C) containing 5 to 10 ring atoms 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; a is 0 to 5; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 wherein W' is a sequence of 5 to 60 amino acids, and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group), However, one or more of the compound definitions detailed herein apply. [The present invention 1004] Formula (IIA) Any of compounds 1001 to 1002 of the present invention having TIFF2024156720000006.tif38128. [The present invention 1005] The compound of any one of claims 1001 to 1004, wherein G is C(O). [The present invention 1006] G is S(O) or SO 2 The compound of any one of the present inventions 1001 to 1004, [The present invention 1007] The compound according to any one of claims 1001 to 1006, wherein ring A is a saturated or unsaturated monocyclic ring containing 3 to 8 (eg, 4 to 8) ring atoms. [The present invention 1008] The compound according to any one of claims 1001 to 1007, wherein ring A is a saturated monocyclic ring containing 3 to 8 (eg, 4 to 8) ring atoms. [The present invention 1009] The compound according to any one of claims 1001 to 1008, wherein ring A is a saturated monocyclic ring containing 5 to 7 ring atoms. [The present invention 1010] Any of the compounds 1001, 1002, 1004, 1005, and 1007 to 1009 of the present invention, wherein ring A has the following formula (III): TIFF2024156720000007.tif33128 formula, A 1 is a bond, A 1A -A 1B, C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 1A and A 1B are independently C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 2 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 3 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; SO 2 ; or N(R a ) and; A 4 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; or N(R a ), where A 3 and A 4 are all O; S; or N(R a ); or any combination thereof. [The present invention 1011] A 1 C(O), CH 2 , C.H.R. b , or C(R b ) 2 and ring A is a 6-membered ring. [The present invention 1012] A 1 CH 2 , C.H.R. b , or C(R b ) 2 The compound of the present invention 1010 or 1011, [The present invention 1013] A1 CH 2 The compound of any one of the present inventions 1010 to 1012, [The present invention 1014] A 1 The compound of claim 1010 or 1011, wherein is C(O). [The present invention 1015] A 2 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 1010 to 1014, [The present invention 1016] A 2 CH 2 The compound of any one of 1010 to 1015 according to the present invention, [The present invention 1017] A 3 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 1010 to 1016, [The present invention 1018] A 3 CH 2 The compound of any one of claims 1010 to 1017, [The present invention 1019] A 3 O; S; SO 2 ; or N(R a ) Any of the compounds of the present invention 1010 to 1016. [The present invention 1020] A 4 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of 1010 to 1019 of the present invention, [The present invention 1021] A 4 CH 2 The compound of any one of 1010 to 1020 according to the present invention, [The present invention 1022] A 2 , A3 , and A 4 are independent of each other, CH 2 , C.H.R. b , and C(R b ) 2 The compound of the present invention 1010 or 1011, selected from the group consisting of: [The present invention 1023] A 2 , A 3 , and A 4 One or two of these are independently CHR b and C(R b ) 2 and the rest are selected from the group consisting of CH 2 The compound of the present invention 1022, [The present invention 1024] A 2 , A 3 , and A 4 are CH 2 The compound of the present invention 1022, [The present invention 1025] A 1 , A 2 , A 3 , and A 4 are independent of each other, CH 2 , C.H.R. b , and C(R b ) 2 The compound of the present invention 1010 or 1011, selected from the group consisting of: [The present invention 1026] A 1 , A 2 , A 3 , and A 4 One or two of these are independently CHR b and C(R b ) 2 selected from, others are CH 2 The compound of the present invention 1025, [The present invention 1027] A 1 , A 2 , A 3 , and A 4 are CH 2 The compound of the present invention 1026, [The present invention 1028] A 1 is a bond, and ring A is of the formula Compound of the present invention 1010 having TIFF2024156720000008.tif28128. [The present invention 1029] A 2 The compound of the present invention 1028, wherein is C(=O). [The present invention 1030] A 3 is O; S; or N(R e ) and A 4 CH 2 , C.H.R. b , or C(R b ) 2 The compound of the present invention, wherein [The present invention 1031] A 3 The compound of the present invention 1030, wherein is S. [The present invention 1032] A 3 N(R a ) (e.g. A 3 is NH), the compound of the present invention 1030. [The present invention 1033] A 4 CH 2 The compound of any one of the present inventions 1030 to 1032, [The present invention 1034] A 4 CHR b or C(R b ) 2 The compound of any one of the present inventions 1030 to 1032, [The present invention 1035] A 3 and A 4 are each independently CH 2 , C.H.R. b , or C(R b ) 2 The compound of the present invention 1029 selected from: [The present invention 1036] A 3 and A 4 are CH 2The compound of the present invention 1035, [The present invention 1037] A 3 and A 4 One of them is CH 2 And A 3 and A 4 The other is CHR b or C(R b ) 2 The compound of the present invention 1035, [The present invention 1038] A 3 and A 4 are each independently CHR b or C(R b ) 2 The compound of the present invention 1035 selected from: [The present invention 1039] A 2 CH 2 , C.H.R. b , or C(R b ) 2 The compound of the present invention, 1028, [The present invention 1040] A 2 CH 2 The compound of the present invention 1039, [The present invention 1041] A 3 and A 4 are each independently CH 2 , C.H.R. b , or C(R b ) 2 (e.g., A 3 and A 4 are CH 2 ), the compound of the present invention 1039 or 1040. [The present invention 1042] A 1 A 1A -A 1B The compound of the present invention, [The present invention 1043] A 1A and A 1B are each independently CH 2 , C.H.R. b, or C(R b ) 2 The compound of the present invention 1042, [The present invention 1044] A 1A and A 1B are each independently CH 2 The compound of the present invention 1043, [The present invention 1045] A 2 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 1042 to 1044 of the present invention, [The present invention 1046] A 2 CH 2 The compound of the present invention 1045, [The present invention 1047] A 3 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 1042 to 1046, [The present invention 1048] A 3 CH 2 The compound of the present invention 1047, [The present invention 1049] A 4 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 1042 to 1048 of the present invention, [The present invention 1050] A 4 CH 2 The compound of the present invention 1049, [The present invention 1051] The compound according to any one of claims 1001 to 1006, wherein ring A is an unsaturated monocycle containing 3 to 8 (eg, 4 to 8) ring atoms. [The present invention 1052] The compound of any one of 1001 to 1006 and 1051 of the present invention, wherein ring A is an unsaturated monocycle containing 5 to 6 ring atoms. [The present invention 1053] The compound of any one of claims 1001 to 1006, 1051, and 1052, wherein ring A is an unsaturated monocycle containing 6 ring atoms. [The present invention 1054] Any of the compounds of 1051 to 1053 of the present invention, wherein ring A has the formula (IV): TIFF2024156720000009.tif33128 formula, A 6 and A 7 are independently CH and CR b More selected; A 5 and A 8 are each independently N, CH, or CR b It is. [The present invention 1055] A 5 , A 6 , A 7 , and A 8 are independently CH and CR b The compound of the present invention 1054 selected from: [The present invention 1056] A 5 , A 6 , A 7 , and A 8 One or two of the CRs are independently selected. b and the others are CH. [The present invention 1057] A 5 , A 6 , A 7 , and A 8 The compound of the present invention 1054, wherein each is CH. [The present invention 1058] A 5 , A 6 , and A 7 are independently CH and CR b Selected from A 8The compound of the present invention 1054, wherein is N. [The present invention 1059] A 5 is N; A 6 , A 7 , and A 8 are independently CH and CR b (e.g., A 6 , A 7 , and A 8 One of them is CR b (e.g., C-OH), compound 1054 of the present invention. [The present invention 1060] R b Each occurrence of is independently 31 -OH; -N(R a )(R''); C 1~4 Alkoxy; and C 1~4 The compound of any one of 1054 to 1056 and 1058 to 1059 of the present invention, selected from the group consisting of haloalkoxy. [The present invention 1061] R b Each entity of (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with (iii) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C1~4 haloalkoxy; and (viii) -F The compound of the present invention, any one of 1054 to 1056 and 1058 to 1059, selected from the group consisting of: [The present invention 1062] R b Each occurrence of is independently 31 -OH; -N(R a )(R''); C 1~4 Alkoxy; and C 1~4 The compound of any one of 1010 to 1050 of the present invention, selected from the group consisting of haloalkoxy. [The present invention 1063] R b Each entity of (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with (iii) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii) -F The compound of any one of 1010 to 1050 of the present invention, selected from the group consisting of: [The present invention 1064] R b Each entity of (I C 1~6 Alkyl; (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii) -F The compound of any one of 1010 to 1050 of the present invention, selected from the group consisting of: [The present invention 1065] The compound according to any one of claims 1001 to 1006, wherein ring A is a saturated or unsaturated bicyclic or tricyclic ring containing 6 to 14 (eg, 8 to 10) ring atoms. [The present invention 1066] The compound according to any one of claims 1001 to 1006, wherein ring A is an unsaturated bicyclic or tricyclic ring containing 6 to 14 (eg, 8 to 10) ring atoms. [The present invention 1067] The compound of the present invention 1065 or 1066 to which (A) applies. [The present invention 1068] The compound of any one of 1065 to 1067 according to the present invention, wherein ring A is optionally further substituted with one oxo. [The present invention 1069] Ring A is represented by formula (VI) Any of compounds 1065 to 1068 of the present invention having TIFF2024156720000010.tif35128. [The present invention 1070] The fused ring B is selected from 1 to 5 independently selected R c Optionally substituted condensation C 6~10 The compound of the present invention 1069, which is aryl. [The present invention 1071] The fused ring B is selected from 1 to 5 independently selected R c The compound of the present invention 1069 or 1070, which is a fused phenyl optionally substituted with [The present invention 1072] Any of the compounds of the present invention 1069 to 1071, wherein ring A has the formula (VI-A): TIFF2024156720000011.tif35128 in formula, R c' is H or R c (For example, C 1~6 Alkyl, e.g. CH 3 ). [The present invention 1073] Ring B is 1 to 5 independently selected R c Optionally substituted (e.g. unsubstituted) fused C 10 The compound of any one of 1069 to 1070, which is aryl. [The present invention 1074] Ring B is a fused heteroaryl containing 5 to 10 (e.g., 6) ring atoms, in which 1 to 4 (e.g., 1) ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c The compound of the present invention 1069, which is heteroaryl, optionally substituted with [The present invention 1075] Ring A is: Any of the compounds of the present invention 1065 to 1068 selected from one of TIFF2024156720000012.tif35139. [The present invention 1076] Each fused ring B is independently: A fused heteroaryl containing 5 to 10 (e.g., 6) ring atoms, wherein 1 to 4 (e.g., 1) ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with; 1 to 5 (e.g., 1 to 2) independently selected R c Optionally substituted condensation C 6~10 (For example, C 6 ) Aryl The compound of the present invention 1075 selected from: [The present invention 1077] Each fused ring B is independently selected from 1 to 5 (e.g., 1 to 2) R c Optionally substituted condensation C 6~10 (For example, C 6 ) aryl, the compound of the present invention 1075. [The present invention 1078] The compound according to any one of claims 1001 to 1006, wherein ring A is a saturated bicyclic or tricyclic ring containing 8 to 10 ring atoms. [The present invention 1079] (A) is applied to the compound of the present invention 1078. [The present invention 1080] The compound of the present invention 1078 or 1079, wherein ring A is optionally further substituted with one oxo. [The present invention 1081] Ring A is represented by formula (VI) Any of compounds of the present invention 1078 to 1080 having TIFF2024156720000013.tif35128. [The present invention 1082] The fused ring B is selected from 1 to 4 independently selected R d Optionally substituted condensation C 3~10 The compound of the present invention 1081 which is cycloalkyl. [The present invention 1083] The fused ring B is selected from 1 to 4 independently selected R d (For example, C 1~3 Optionally substituted with alkyl) 3~6 Cycloalkyl (e.g. C 3~4 The compound of the present invention 1081 or 1082, wherein [The present invention 1084] (B) is applied to the compound of the present invention 1078. [The present invention 1085] 1084. Compounds of the invention 1084, wherein Ring A contains 5-6 ring atoms and is optionally further substituted with one oxo. [The present invention 1086] Ring A is represented by formula (VII) Compound 1084 or 1085 of the present invention having TIFF2024156720000014.tif41128. [The present invention 1087] The spiro-fused ring B is selected from 1 to 4 independently selected R d Optionally substituted spiro-fused C 3~10 The compound of the present invention 1086, which is cycloalkyl. [The present invention 1088] The spiro-fused ring B is selected from 1 to 4 independently selected R d (For example, C 1~3 spiro-fused C optionally substituted with alkyl 3~6 Cycloalkyl (e.g. C 3~4 The compound of any one of claims 1084 to 1087, wherein R is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 2 [The present invention 1089] L is of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p Any of the compounds of 1001 to 1088 of the present invention, [The present invention 1090] The compound of the present invention 1089, wherein m is 2 to 6. [The present invention 1091] The compound of claim 1089 or 1090, wherein m is 2. [The present invention 1092] The compound of the present invention 1089, wherein m is 1. [The present invention 1093] X 1 The compound according to any one of claims 1089 to 1092, wherein is -N(R')C(O)-. [The present invention 1094] X 1 Any of the compounds of claims 1089 to 1093, wherein is -N(H)C(O)-. [The present invention 1095] The compound of any one of claims 1089 to 1094, wherein n + p ≧ 2. [The present invention 1096] The compound of any one of claims 1089 to 1094, wherein n + p = 2 (for example, n and p are each 1). [The present invention 1097] Any of the compounds of claims 1089 to 1094, wherein n + p<2. [The present invention 1098] Any of the compounds of claims 1089 to 1094, wherein n + p = 0. [This invention 1099] X 2 -O-; -S-; or -S(O) t -, wherein t is 1 or 2. [The present invention 1100] X 2 Any of the compounds of claims 1089 to 1099 of the present invention, wherein is -S-. [The present invention 1101] X 2 -C(Q 1 )(Q 2 )-, any one of the compounds of the present invention 1089 to 1098. [The present invention 1102] Q 1 and Q 2 are independently H and C 1~4 The compound of the present invention 1101, which is alkyl. [The present invention 1103] Q 1 and Q 2 Each of the compounds of the present invention is H. [The present invention 1104] Q 1 and Q 2 are each independently selected C 1~4 The compound of the present invention 1101, which is alkyl. [The present invention 1105] Q 1 is H; Q 2 C 1~4 The compound of the present invention 1102, which is alkyl. [The present invention 1106] Q 1 and Q 2Together with the carbon atom to which each is bonded, they form C 3~10 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d and optionally fused to phenyl. [The present invention 1107] Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 3~6 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d The compound of the present invention 1106, which may be substituted with and fused to phenyl. [The present invention 1108] Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 4~6 (For example, C 4 ) forms a cycloalkyl, the cycloalkyl being selected from 1 to 2 independently selected R d The compound of the present invention 1107, which may be substituted with [The present invention 1109] X 2 but, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 cycloalkylene; or (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with The compound of any one of claims 1089 to 1098, [The present invention 1110] X 2 but, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene; or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene The compound of any one of claims 1089 to 1098, [The present invention 1111] X 2 but, (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with The compound of the present invention 1109, [The present invention 1112] X 2 but, (viii) heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, wherein 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with (For example, X 2 but TIFF2024156720000015.tif7128), a compound of the present invention 1111. [The present invention 1113] m is 2 to 6; n + p ≧ 2; X 2 -O-; -S-; -S(O) t -; or CH 2 That is, Any of the compounds of the present invention 1001 to 1089. [The present invention 1114] The compound of the present invention 1113, wherein m is 2. [The present invention 1115] X 1 is -N(R')C(O)- (e.g., X 1 is -N(H)C(O)-, the compound of the present invention 1113 or 1114. [The present invention 1116] The compound according to any one of claims 1113 to 1115, wherein n + p>2. [The present invention 1117] The compound according to any one of claims 1113 to 1115, wherein n+p=2 (for example, n and p are each 1). [The present invention 1118] X 2 The compound according to any one of claims 1113 to 1117, wherein is -S-. [The present invention 1119] m is 2 to 6; n + p<2; X 2 but, (i) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently selected C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 cycloalkylene; or (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with The compound of any one of claims 1001 to 1089 of the present invention, [The present invention 1120] The compound of the present invention 1119, wherein m is 2. [The present invention 1121] X 1 The compound of claim 1119 or 1120, wherein is -N(R')C(O)- (e.g. -N(H)C(O)-). [The present invention 1122] The compound of any one of claims 1119 to 1121, wherein n + p = 0. [The present invention 1123] X 2 -C(Q 1 )(Q 2 )-, any one of the compounds of the present invention Nos. 1119 to 1122. [The present invention 1124] Q 1 and Q 2 The compound of the present invention 1123, wherein each of [The present invention 1125] Q 1 C 1~4 The compound of the present invention 1123, which is alkyl. [The present invention 1126] Q 2 C1~4 The compound of the present invention 1125, which is alkyl. [The present invention 1127] Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 3~6 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d The compound of any one of claims 1119 to 1122 of the present invention, which may be substituted with and may be fused with phenyl. [The present invention 1128] X 2 but, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene; or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene The compound of any one of claims 1119 to 1122 of the present invention, [The present invention 1129] X 2 but, (viii) heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, wherein 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with (For example, X 2 but TIFF2024156720000016.tif7128), any of compounds of the present invention 1119 to 1122. [The present invention 1130] m is 1; n + p ≦ 2; X 2 -O-; -S-; -S(O) t -; or C(Q 1 )(Q 2 ), Any of the compounds of the present invention 1001 to 1089. [The present invention 1131] The compound of the present invention 1130, wherein n + p = 2. [The present invention 1132] X 2 The compound of the present invention 1131, wherein is -S-. [The present invention 1133] The compound of the present invention 1130, wherein n + p<2 (eg, n + p = 0; alternatively, n + p = 1). [The present invention 1134] X 2 C(Q 1 )(Q 2 ) The compound of the present invention 1133. [This invention 1135] Q 1 and Q 2 The compound of the present invention 1134, wherein each of [The present invention 1136] Q 1 and Q 2 are C 1~4 The compound of the present invention 1134, which is alkyl. [This invention 1137] Q 1 is H; Q 2 C 1~4 The compound of the present invention 1134, which is alkyl. [The present invention 1138] L is of formula (IX): -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p Any of the compounds of 1001 to 1089 of the present invention, [The present invention 1139] The compound of the present invention 1138, wherein n + p ≧ 2. [The present invention 1140] The compound of claim 1138 or 1139, wherein n+p=2 (eg, n and p are each 1). [This invention 1141] X 3The compound according to any one of claims 1138 to 1140, wherein is -S-. [This invention 1142] R 1 The compound of any one of 1001 to 1141 according to the present invention, wherein [This invention 1143] R 2 The compound according to any one of claims 1001 to 1142, wherein [This invention 1144] R 4 The compound of any one of claims 1001 to 1143, wherein [This invention 1145] R 1 , R 2 , and R 4 The compound according to any one of claims 1001 to 1144 of the present invention, wherein each of [This invention 1146] R 2 is unsubstituted C 1~3 The compound of any one of claims 1001 to 1142, wherein the alkyl group is alkyl (eg, methyl). [This invention 1147] R 1 and R 4 The compound of the present invention 1146, wherein each of [This invention 1148] R 2' The compound of any of claims 1001 and 1005 to 1147, wherein is as defined by (AA). [This invention 1149] The compound of any one of 1001 to 1002 and 1004 to 1148, wherein a' is 1. [The present invention 1150] R 3a and R 3b Each of the compounds of the present invention Nos. 1001 to 1002 and 1004 to 1149 is H. [This invention 1151] R 3a and R 3b are C 1~3 Any of compounds 1001, 1002, and 1004 to 1149 of the present invention, which is alkyl (e.g., methyl). [This invention 1152] The compound of any one of 1001, 1002, and 1004 to 1148 of the present invention, wherein a' is 0. [This invention 1153] R 3 Any of the compounds of the present invention Nos. 1001 to 1152, wherein is -C(O)OH. [This invention 1154] R 3 The compound according to any one of claims 1001 to 1152, wherein is a carboxylic acid isostere. [This invention 1155] R 3 is optionally substituted tetrazolyl, amido, or optionally substituted isoxazolyl Any of compounds 1001 to 1152 and 1154 of the present invention, which is TIFF2024156720000017.tif14128. [This invention 1156] The compound of any one of claims 1001 to 1155, wherein a is 0, 1, 2, or 3 (e.g., a = 0; or a = 1; or a = 2). [This invention 1157] The compound of the present invention 1157, wherein a is 1. [This invention 1158] Any of the compounds of the present invention 1001 to 1157, wherein W is a sequence of 25 to 45 (eg, 30 to 45) amino acids. [This invention 1159] The compound of any one of claims 1001 to 1158, wherein W is a sequence of 36 amino acids. [The present invention 1160] W is of the formula (X): -GTF-W''-R 5 wherein W″ is a sequence of 30 to 40 (eg, 31 to 36, 33) amino acids. [The present invention 1161] Any of compounds 1001 to 1158 and 1160 of the present invention, wherein W is represented by any one of SEQ IDs 1 to 34 (e.g., SEQ. IDs 5 to 27; e.g., SEQ IDs 5 to 29; (e.g., SEQ ID 6); e.g., SEQ IDs 28 to 29; e.g., SEQ IDs 30 to 34). [The present invention 1162] R 5 is a C-terminal amino acid amide, optionally substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group). [The present invention 1163] R 5 is a C-terminal lysylamide residue, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group). [The present invention 1164] R 5 is a C-terminal L-lysylamide residue, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group). [The present invention 1165] R 5 Any of the compounds of claims 1001 to 1164 of the present invention, having the formula (XI): TIFF2024156720000018.tif68128 in formula, R * is H or a modifying group (e.g., acyl groups and PEG groups). [The present invention 1166] Any of the compounds of claims 1001 to 1165, wherein W has the formula (XII): TIFF2024156720000019.tif68128Where W'' is a sequence of 30 to 40 (e.g., 31 to 36, 33) amino acids, R * is H or a modifying group (e.g., acyl groups and PEG groups). [The present invention 1167] R 5is a C-terminal amino acid, which may be substituted with 1 to 2 modifying groups (for example, 1 to 2 groups selected from an acyl group and a PEG group). [The present invention 1168] R 5 is a C-terminal lysine, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group). [The present invention 1169] R 5 is a C-terminal L-lysine, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group). [The present invention 1170] R 5 Any of the compounds of the present invention 1001 to 1161 and 1168 to 1169, wherein the compound has the formula (XI-OH): TIFF2024156720000020.tif71128In formula, R * is H or a modifying group (e.g., acyl groups and PEG groups). [This invention 1171] Compounds according to any one of claims 1001 to 1161 and 1168 to 1170, wherein W has the formula (XII-OH): TIFF2024156720000021.tif71128Where W'' is a sequence of 30 to 40 (e.g., 31 to 36, 33) amino acids, R * is H or a modifying group (e.g., acyl groups and PEG groups). [This invention 1172] R * The compound according to any one of claims 1165 to 1166 and 1170 to 1171, wherein [This invention 1173] R * is 1 to 2 independently selected R f C which may be substituted with 2~30 (For example, C 2~20 ) an acyl group; where R fEach occurrence of -C(=O)(OH); -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); -S(O) 1~2 (C 1~6 alkyl); oxo; F; C 1~10 Alkoxy; C 1~10 haloalkoxy; and -N(R g )(R h R g and R h Each occurrence of is independently H; C 1~4 Alkyl; -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); and -S(O) 1~2 (C 1~6 The compound of any one of Nos. 1165 to 1166 and Nos. 1170 to 1171 of the present invention, selected from the group consisting of alkyl. [This invention 1174] R * is 1 to 2 independently selected R f C replaced with 2~30 (For example, C 2~20 ) An acyl group. [This invention 1175] R f Each occurrence of is independently -C(=O)(OH) and -N(R g )(R h 1174. The compound of the present invention, selected from the group consisting of: [The present invention 1176] R * but, A compound of any one of compounds 1165 to 1166, 1170 to 1171, and 1173 to 1175 of the present invention, which is TIFF2024156720000022.tif36143. [This invention 1177] R * but, Compound 1176 of the present invention is TIFF2024156720000023.tif35128. [This invention 1178] R * but, TIFF2024156720000024.tif10128, compound of the present invention 1176. [This invention 1179] R 5 is a C-terminal amino acid selected from serine, glycine, and arginine. [The present invention 1180] R 5 is a C-terminal amino acid amide selected from serinylamide, glycylamide, and arginylamide. [This invention 1181] having the formula (IA-A), (IA-AA), or (IA-AB); Ring A is a saturated monocyclic ring containing 3 to 8 (e.g., 4 to 8, 4 to 7, 5 to 6) ring atoms; L is of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -Having The compound of any one of 1001 to 1002 and 1162 to 1180 of the present invention. [The present invention 1182] Compounds of any one of claims 1001 to 1002 and 1162 to 1181, wherein W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ IDs 1 to 34. [The present invention 1183] The compound of any one of claims 1001 to 1002 and 1162 to 1182, wherein W is represented by any one of SEQ IDs 5 to 29. [This invention 1184] The compound of any one of claims 1001 to 1002 and 1162 to 1183, wherein W is represented by SEQ ID 6. [This invention 1185] (i) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or (ii) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 3~6 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d and optionally fused to phenyl; or (iii) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are selected independently, C 1~4 Alkyl (e.g. CH 3 ) or (iv) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 but (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g. phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene That is, The compound of any one of Nos. 1001 to 1002 and 1162 to 1184 of the present invention. [The present invention 1186] (iv) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 is a heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, wherein 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with X 2 but TIFF2024156720000025.tif7128), The compound of any one of Nos. 1001 to 1002 and 1162 to 1184 of the present invention. [This invention 1187] m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 The compound of any one of Nos. 1001 to 1002 and Nos. 1162 to 1185 of the present invention, wherein [The present invention 1188] L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 - Any of compounds of the present invention Nos. 1001 to 1002, 1162 to 1184, and 1187, [The present invention 1189] The compound according to any one of claims 1001 to 1002 and 1162 to 1188, wherein ring A has the formula (III). [The present invention 1190] A compound of any one of 1001 to 1002 and 1162 to 1189 of the present invention, wherein ring A is defined as any one of 1011 to 1027 of the present invention. [The present invention 1191] The compound according to any one of claims 1001 to 1002 and 1162 to 1189, wherein ring A has the formula (III-A). [This invention 1192] The compound of any one of claims 1001 to 1002 and 1162 to 1188 and 1190, wherein ring A is defined as any one of claims 1029 to 1041. [The present invention 1193] A compound of any one of 1001 to 1002 and 1162 to 1189 of the present invention, wherein ring A is defined as any one of 1042 to 1050 of the present invention. [This invention 1194] R 1 , R 2 , and R 4 The compound of any one of 1001 to 1002 and 1162 to 1193, wherein one, two, or three of the following are H: [The present invention 1195] R 1 , R 2 , and R 4 The compound of any one of 1001 to 1002 and 1162 to 1194, wherein one, two, or three of the following are H: [The present invention 1196] R 3 Any of compounds of 1001 to 1002 and 1162 to 1195 of the present invention, wherein is -C(O)OH. [The present invention 1197] a' is 1; R 3a and R 3b Each of the compounds according to the present invention, 1001 to 1002 and 1162 to 1196, is independently H. [The present invention 1198] The compound of any one of claims 1001 and 1162 to 1197, wherein a is 0, 1, or 2 (for example, 1). [The present invention 1199] R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 Any of compounds of the present invention Nos. 1001 to 1002 and 1162 to 1198, wherein is -C(O)OH. [The present invention 1200] 1001. A compound of the present invention selected from the group consisting of the compounds depicted in FIG. [The present invention 1201] A pharmaceutical composition comprising any one of the compounds or salts of the present invention 1001 to 1200 and one or more pharma- ceutically acceptable excipients. [The present invention 1202] A method for regulating GLP-1R and / or GIPR activity, comprising contacting GLP-1R and / or GIPR with any of the compounds of the present inventions 1001 to 1200. [The present invention 1203] The method of claim 1202, wherein modulating comprises stimulating GLP-1R and / or GIPR. [The present invention 1204] The method of claim 1202, wherein modulating comprises partially stimulating or antagonizing GLP-1R and / or GIPR. [The present invention 1205] Any of the methods of 1202 to 1204 of the present invention, which is carried out in vitro. [The present invention 1206] Any of the methods of 1202 to 1204 of the present invention, which is carried out in vivo. [The present invention 1207] A method for regulating GLP-1R and / or GIPR induced aversion, nausea, and / or vomiting, comprising contacting GLP-1R and / or GIPR with any of the compounds of the present invention 1001 to 1200. [The present invention 1208] A method for regulating (e.g., increasing) insulin levels in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the compounds of the present inventions 1001 to 1200. [This invention 1209] A method for regulating (e.g., decreasing) glucose levels in a subject in need thereof, the method comprising administering to the subject an effective amount of any of the compounds of the present inventions 1001 to 1200. [The present invention 1210] A method for treating a disease, disorder, or condition, comprising administering to a subject in need thereof an effective amount of any of the compounds of the present inventions 1001-1200, wherein modulation of GLP-1R and / or GIPR signaling may alter the pathology and / or symptoms and / or progression of the disease, disorder, or condition. [The present invention 1211] The method of the present invention 1210, wherein the disease, disorder, or condition or disorder is diabetes. [The present invention 1212] The method of the present invention 1210, wherein the disease, disorder, or condition or disorder is NASH. [The present invention 1213] The method of the present invention 1210, wherein the disease, disorder, or condition or disorder is obesity. [The present invention 1214] The method of the present invention 1210, wherein the disease, disorder, or condition or disorder is fatty liver disease. [The present invention 1215] The method of claim 1210, wherein the disease, disorder, or condition or disorder is steatohepatitis. [The present invention 1216] Any of the methods of 1210 to 1215, further comprising a step of identifying the subject. [The present invention 1217] The method according to any one of claims 1210 to 1216, wherein the subject is a human. [The present invention 1218] A method for treating a disease, disorder, or condition comprising administering to a subject in need thereof an effective amount of any of the compounds of the present inventions 1001-1200, wherein modulation of GLP-1R and / or GIPR signaling causes aversion, nausea, or vomiting. Other aspects include those aspects described in the detailed description, drawings, and / or claims. [Brief description of the drawings]

[0066] [Figure 1-1] Representative compounds of formula (IAA) are shown below. [Figure 1-2] Representative compounds of formula (IAA) are shown below. [Figure 1-3] Representative compounds of formula (IAA) are shown below. [Figure 1-4] Representative compounds of formula (IAA) are shown below. [Figure 1-5] Representative compounds of formula (IAA) are shown below. [Figure 1-6] Representative compounds of formula (IAA) are shown below. [Figure 1-7] Representative compounds of formula (IAA) are shown below. [Figure 1-8] Representative compounds of formula (IAA) are shown below. [Figure 1-9] Representative compounds of formula (IAA) are shown below. [Figure 1-10] Representative compounds of formula (IAA) are shown below. [Figure 1-11] Representative compounds of formula (IAA) are shown below. [Figure 1-12] Representative compounds of formula (IAA) are shown below. [Figure 1-13] Representative compounds of formula (IAA) are shown below. [Figure 1-14] Representative compounds of formula (IAA) are shown below. [Figure 1-15] Representative compounds of formula (IAA) are shown below. [Figure 1-16] Representative compounds of formula (IAA) are shown below. [Figure 1-17] Representative compounds of formula (IAA) are shown below. [Figure 1-18] Representative compounds of formula (IAA) are shown below. [Figure 1-19] Representative compounds of formula (IAA) are shown below. [Figure 1-20] Representative compounds of formula (IAA) are shown below. [Figure 1-21] Representative compounds of formula (IAA) are shown below. [Figure 1-22]Representative compounds of formula (IAA) are shown below. [Figure 1-23] Representative compounds of formula (IAA) are shown below. [Figure 1-24] Representative compounds of formula (IAA) are shown below. [Figure 1-25] Representative compounds of formula (IAA) are shown below. [Figure 1-26] Representative compounds of formula (IAA) are shown below. [Figure 1-27] Representative compounds of formula (IAA) are shown below. [Figure 1-28] Representative compounds of formula (IAA) are shown below. [Figure 1-29] Representative compounds of formula (IAA) are shown below. [Figure 1-30] Representative compounds of formula (IAA) are shown below. [Figure 1-31] Representative compounds of formula (IAA) are shown below. [Figure 1-32] Representative compounds of formula (IAA) are shown below. [Figure 1-33] Representative compounds of formula (IAA) are shown below. [Figure 1-34] Representative compounds of formula (IAA) are shown below. [Figure 1-35] Representative compounds of formula (IAA) are shown below. [Figure 1-36] Representative compounds of formula (IAA) are shown below. [Figure 1-37] Representative compounds of formula (IAA) are shown below. [Figure 1-38] Representative compounds of formula (IAA) are shown below. [Figure 1-39] Representative compounds of formula (IAA) are shown below. [Figure 1-40] Representative compounds of formula (IAA) are shown below. [Diagram 1-41] Representative compounds of formula (IAA) are shown below. [Figure 1-42] Representative compounds of formula (IAA) are shown below. [Figure 1-43] Representative compounds of formula (IAA) are shown below. [Figure 1-44] Representative compounds of formula (IAA) are shown below. [Figure 1-45]Representative compounds of formula (IAA) are shown below. [Figure 1-46] Representative compounds of formula (IAA) are shown below. [Figure 1-47] Representative compounds of formula (IAA) are shown below. [Figure 1-48] Representative compounds of formula (IAA) are shown below. [Figure 1-49] Representative compounds of formula (IAA) are shown below. [Figure 1-50] Representative compounds of formula (IAA) are shown below. [Figure 1-51] Representative compounds of formula (IAA) are shown below. [Figure 1-52] Representative compounds of formula (IAA) are shown below. [Figure 1-53] Representative compounds of formula (IAA) are shown below. [Diagram 1-54] Representative compounds of formula (IAA) are shown below. [Figure 1-55] Representative compounds of formula (IAA) are shown below. [Diagram 1-56] Representative compounds of formula (IAA) are shown below. [Diagram 1-57] Representative compounds of formula (IAA) are shown below. [Diagram 1-58] Representative compounds of formula (IAA) are shown below. [Diagram 1-59] Representative compounds of formula (IAA) are shown below. [Figure 1-60] Representative compounds of formula (IAA) are shown below. [Figure 1-61] Representative compounds of formula (IAA) are shown below. [Figure 1-62] Representative compounds of formula (IAA) are shown below. [Fig.1-63] Representative compounds of formula (IAA) are shown below. [Fig.1-64] Representative compounds of formula (IAA) are shown below. [Figure 1-65] Representative compounds of formula (IAA) are shown below. [Figure 1-66] Representative compounds of formula (IAA) are shown below. [Figure 1-67] Representative compounds of formula (IAA) are shown below. [Figure 1-68]Representative compounds of formula (IAA) are shown below. [Figure 1-69] Representative compounds of formula (IAA) are shown below. [Figure 1-70] Representative compounds of formula (IAA) are shown below. [Diagram 1-71] Representative compounds of formula (IAA) are shown below. [Diagram 1-72] Representative compounds of formula (IAA) are shown below. [Diagram 1-73] Representative compounds of formula (IAA) are shown below. [Diagram 1-74] Representative compounds of formula (IAA) are shown below. [Diagram 1-75] Representative compounds of formula (IAA) are shown below. [Diagram 1-76] Representative compounds of formula (IAA) are shown below. [Diagram 1-77] Representative compounds of formula (IAA) are shown below. [Diagram 1-78] Representative compounds of formula (IAA) are shown below. [Diagram 1-79] Representative compounds of formula (IAA) are shown below. [Figure 1-80] Representative compounds of formula (IAA) are shown below. [Fig.1-81] Representative compounds of formula (IAA) are shown below. [Fig.1-82] Representative compounds of formula (IAA) are shown below. [Fig.1-83] Representative compounds of formula (IAA) are shown below. [Fig.1-84] Representative compounds of formula (IAA) are shown below. [Fig.1-85] Representative compounds of formula (IAA) are shown below. [Fig.1-86] Representative compounds of formula (IAA) are shown below. [Fig.1-87] Representative compounds of formula (IAA) are shown below. [Fig.1-88] Representative compounds of formula (IAA) are shown below. [Fig.1-89] Representative compounds of formula (IAA) are shown below. [Figure 1-90] Representative compounds of formula (IAA) are shown below. [Figure 1-91]Representative compounds of formula (IAA) are shown below. [Fig.1-92] Representative compounds of formula (IAA) are shown below. [Fig.1-93] Representative compounds of formula (IAA) are shown below. [Figure 1-94] Representative compounds of formula (IAA) are shown below. [Figure 1-95] Representative compounds of formula (IAA) are shown below. [Figure 1-96] Representative compounds of formula (IAA) are shown below. [Fig.1-97] Representative compounds of formula (IAA) are shown below. [Fig.1-98] Representative compounds of formula (IAA) are shown below. [Fig.1-99] Representative compounds of formula (IAA) are shown below. [Figure 1-100] Representative compounds of formula (IAA) are shown below. [Fig.1-101] Representative compounds of formula (IAA) are shown below. [Fig.1-102] Representative compounds of formula (IAA) are shown below. [Fig.1-103] Representative compounds of formula (IAA) are shown below. [Fig.1-104] Representative compounds of formula (IAA) are shown below. [Fig.1-105] Representative compounds of formula (IAA) are shown below. [Fig.1-106] Representative compounds of formula (IAA) are shown below. [Fig.1-107] Representative compounds of formula (IAA) are shown below. [Fig.1-108] Representative compounds of formula (IAA) are shown below. [Fig.1-109] Representative compounds of formula (IAA) are shown below. [Fig.1-110] Representative compounds of formula (IAA) are shown below. [Fig.1-111] Representative compounds of formula (IAA) are shown below. [Fig.1-112] Representative compounds of formula (IAA) are shown below. [Fig.1-113] Representative compounds of formula (IAA) are shown below. [Fig.1-114]Representative compounds of formula (IAA) are shown below. [Fig.1-115] Representative compounds of formula (IAA) are shown below. [Fig.1-116] Representative compounds of formula (IAA) are shown below. [Fig.1-117] Representative compounds of formula (IAA) are shown below. [Fig.1-118] Representative compounds of formula (IAA) are shown below. [Fig.1-119] Representative compounds of formula (IAA) are shown below. [Fig.1-120] Representative compounds of formula (IAA) are shown below. [Fig.1-121] Representative compounds of formula (IAA) are shown below. [Fig.1-122] Representative compounds of formula (IAA) are shown below. [Fig.1-123] Representative compounds of formula (IAA) are shown below. [Fig.1-124] Representative compounds of formula (IAA) are shown below. [Fig.1-125] Representative compounds of formula (IAA) are shown below. [Fig.1-126] Representative compounds of formula (IAA) are shown below. [Fig.1-127] Representative compounds of formula (IAA) are shown below. [Fig.1-128] Representative compounds of formula (IAA) are shown below. [Fig.1-129] Representative compounds of formula (IAA) are shown below. [Fig.1-130] Representative compounds of formula (IAA) are shown below. [Fig.1-131] Representative compounds of formula (IAA) are shown below. [Fig.1-132] Representative compounds of formula (IAA) are shown below. [Fig.1-133] Representative compounds of formula (IAA) are shown below. [Fig.1-134] Representative compounds of formula (IAA) are shown below. [Fig.1-135] Representative compounds of formula (IAA) are shown below. [Fig.1-136] Representative compounds of formula (IAA) are shown below. [Fig.1-137]Representative compounds of formula (IAA) are shown below. [Fig.1-138] Representative compounds of formula (IAA) are shown below. [Fig.1-139] Representative compounds of formula (IAA) are shown below. [Fig.1-140] Representative compounds of formula (IAA) are shown below. [Fig.1-141] Representative compounds of formula (IAA) are shown below. [Fig.1-142] Representative compounds of formula (IAA) are shown below. [Fig.1-143] Representative compounds of formula (IAA) are shown below. [Fig.1-144] Representative compounds of formula (IAA) are shown below. [Fig.1-145] Representative compounds of formula (IAA) are shown below. [Fig.1-146] Representative compounds of formula (IAA) are shown below. [Fig.1-147] Representative compounds of formula (IAA) are shown below. [Fig.1-148] Representative compounds of formula (IAA) are shown below. [Fig.1-149] Representative compounds of formula (IAA) are shown below. [Fig.1-150] Representative compounds of formula (IAA) are shown below. [Fig.1-151] Representative compounds of formula (IAA) are shown below. [Fig.1-152] Representative compounds of formula (IAA) are shown below. [Fig.1-153] Representative compounds of formula (IAA) are shown below. [Fig.1-154] Representative compounds of formula (IAA) are shown below. [Fig.1-155] Representative compounds of formula (IAA) are shown below. [Fig.1-156] Representative compounds of formula (IAA) are shown below. [Fig.1-157] Representative compounds of formula (IAA) are shown below. [Fig.1-158] Representative compounds of formula (IAA) are shown below. [Fig.1-159] Representative compounds of formula (IAA) are shown below. [Fig.1-160]Representative compounds of formula (IAA) are shown below. [Fig.1-161] Representative compounds of formula (IAA) are shown below. [Fig.1-162] Representative compounds of formula (IAA) are shown below. [Fig.1-163] Representative compounds of formula (IAA) are shown below. [Fig.1-164] Representative compounds of formula (IAA) are shown below. [Fig.1-165] Representative compounds of formula (IAA) are shown below. [Fig.1-166] Representative compounds of formula (IAA) are shown below. [Fig.1-167] Representative compounds of formula (IAA) are shown below. [Fig.1-168] Representative compounds of formula (IAA) are shown below. [Fig.1-169] Representative compounds of formula (IAA) are shown below. [Fig.1-170] Representative compounds of formula (IAA) are shown below. [Fig.1-171] Representative compounds of formula (IAA) are shown below. [Fig.1-172] Representative compounds of formula (IAA) are shown below. [Fig.1-173] Representative compounds of formula (IAA) are shown below. [Fig.1-174] Representative compounds of formula (IAA) are shown below. [Fig.1-175] Representative compounds of formula (IAA) are shown below. [Fig.1-176] Representative compounds of formula (IAA) are shown below. [Fig.1-177] Representative compounds of formula (IAA) are shown below. [Fig.1-178] Representative compounds of formula (IAA) are shown below. [Fig.1-179] Representative compounds of formula (IAA) are shown below. [Fig.1-180] Representative compounds of formula (IAA) are shown below. [Fig.1-181] Representative compounds of formula (IAA) are shown below. [Fig.1-182] Representative compounds of formula (IAA) are shown below. [Fig.1-183]Representative compounds of formula (IAA) are shown below. [Fig.1-184] Representative compounds of formula (IAA) are shown below. [Fig.1-185] Representative compounds of formula (IAA) are shown below. [Fig.1-186] Representative compounds of formula (IAA) are shown below. [Fig.1-187] Representative compounds of formula (IAA) are shown below. [Fig.1-188] Representative compounds of formula (IAA) are shown below. [Fig.1-189] Representative compounds of formula (IAA) are shown below. [Fig.1-190] Representative compounds of formula (IAA) are shown below. [Fig.1-191] Representative compounds of formula (IAA) are shown below. [Fig.1-192] Representative compounds of formula (IAA) are shown below. [Fig.1-193] Representative compounds of formula (IAA) are shown below. [Fig.1-194] Representative compounds of formula (IAA) are shown below. [Fig.1-195] Representative compounds of formula (IAA) are shown below. [Fig.1-196] Representative compounds of formula (IAA) are shown below. [Fig.1-197] Representative compounds of formula (IAA) are shown below. [Fig.1-198] Representative compounds of formula (IAA) are shown below. [Fig.1-199] Representative compounds of formula (IAA) are shown below. [Fig.1-200] Representative compounds of formula (IAA) are shown below. [Fig.1-201] Representative compounds of formula (IAA) are shown below. [Fig.1-202] Representative compounds of formula (IAA) are shown below. [Fig.1-203] Representative compounds of formula (IAA) are shown below. [Fig.1-204] Representative compounds of formula (IAA) are shown below. [Fig.1-205] Representative compounds of formula (IAA) are shown below. [Fig.1-206]Representative compounds of formula (IAA) are shown below. [Fig.1-207] Representative compounds of formula (IAA) are shown below. [Fig.1-208] Representative compounds of formula (IAA) are shown below. [Fig.1-209] Representative compounds of formula (IAA) are shown below. [Fig.1-210] Representative compounds of formula (IAA) are shown below. [Fig.1-211] Representative compounds of formula (IAA) are shown below. [Fig.1-212] Representative compounds of formula (IAA) are shown below. [Fig.1-213] Representative compounds of formula (IAA) are shown below. [Fig.1-214] Representative compounds of formula (IAA) are shown below. [Fig.1-215] Representative compounds of formula (IAA) are shown below. [Fig.1-216] Representative compounds of formula (IAA) are shown below. [Fig.1-217] Representative compounds of formula (IAA) are shown below. [Fig.1-218] Representative compounds of formula (IAA) are shown below. [Fig.1-219] Representative compounds of formula (IAA) are shown below. [Fig.1-220] Representative compounds of formula (IAA) are shown below. [Fig.1-221] Representative compounds of formula (IAA) are shown below. [Fig.1-222] Representative compounds of formula (IAA) are shown below. [Fig.1-223] Representative compounds of formula (IAA) are shown below. [Fig.1-224] Representative compounds of formula (IAA) are shown below. [Fig.1-225] Representative compounds of formula (IAA) are shown below. [Fig.1-226] Representative compounds of formula (IAA) are shown below. [Fig.1-227] Representative compounds of formula (IAA) are shown below. [Fig.1-228] Representative compounds of formula (IAA) are shown below. [Fig.1-229]Representative compounds of formula (IAA) are shown below. [Fig.1-230] Representative compounds of formula (IAA) are shown below. [Fig.1-231] Representative compounds of formula (IAA) are shown below. [Fig.1-232] Representative compounds of formula (IAA) are shown below. [Fig.1-233] Representative compounds of formula (IAA) are shown below. [Fig.1-234] Representative compounds of formula (IAA) are shown below. [Fig.1-235] Representative compounds of formula (IAA) are shown below. [Fig.1-236] Representative compounds of formula (IAA) are shown below. [Fig.1-237] Representative compounds of formula (IAA) are shown below. [Fig.1-238] Representative compounds of formula (IAA) are shown below. [Fig.1-239] Representative compounds of formula (IAA) are shown below. [Fig.1-240] Representative compounds of formula (IAA) are shown below. [Fig.1-241] Representative compounds of formula (IAA) are shown below. [Fig.1-242] Representative compounds of formula (IAA) are shown below. [Fig.1-243] Representative compounds of formula (IAA) are shown below. [Fig.1-244] Representative compounds of formula (IAA) are shown below. [Fig.1-245] Representative compounds of formula (IAA) are shown below. [Fig.1-246] Representative compounds of formula (IAA) are shown below. [Fig.1-247] Representative compounds of formula (IAA) are shown below. [Fig.1-248] Representative compounds of formula (IAA) are shown below. [Fig.1-249] Representative compounds of formula (IAA) are shown below. [Fig.1-250] Representative compounds of formula (IAA) are shown below. [Fig.1-251] Representative compounds of formula (IAA) are shown below. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0067] Further definitions In order to facilitate understanding of the disclosure described herein, some additional terms are defined below.Generally, the nomenclature used herein and the experimental methods in organic chemistry, medicinal chemistry, and pharmacology described herein are well known and commonly used in the art.Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as those commonly understood by those skilled in the art to which this disclosure belongs.The patents, applications, application publications, and other publications mentioned throughout this specification and appendix are each incorporated herein in their entirety by reference.

[0068] The term "GLP-1R" as used herein is intended to include, but is not limited to, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands, complementary sequences, peptides, polypeptides, proteins, homologous and / or orthologous GLP-1R molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.

[0069] The term "GIPR" as used herein is intended to include, but is not limited to, nucleic acids, polynucleotides, oligonucleotides, sense and antisense polynucleotide strands, complementary sequences, peptides, polypeptides, proteins, homologous and / or orthologous GIPR molecules, isoforms, precursors, mutants, variants, derivatives, splice variants, alleles, different species, and active fragments thereof.

[0070] As used herein, the term "acceptable" in reference to a formulation, composition, or ingredient means that there are no lasting adverse effects on the general health of the subject being treated.

[0071] "API" means active pharmaceutical ingredient.

[0072] The term "IC50" or "EC50" refers to the amount, concentration, or dosage of a compound required for 50% inhibition or 50% activation of the maximal response observed for the compound (or the maximal response of a reference compound, as the case may be) in an assay that measures the maximal response.

[0073] The term "effective amount" or "therapeutically effective amount" as used herein means an amount of a chemical entity (e.g., a compound generally or specifically described herein, its pharma- ceutically acceptable salt, or a composition comprising it) administered that is sufficient to alleviate to some extent one or more symptoms of the disease or condition being treated. The result includes a reduction and / or alleviation of the signs, symptoms, or causes of a disease, or any other desired change in a biological system. For example, an "effective amount" in therapeutic applications is the amount of a composition comprising a compound disclosed herein that is necessary to achieve a clinically significant reduction in disease symptoms. The appropriate "effective" amount in any individual case is determined using any suitable technique, such as a dose escalation study.

[0074] The term "excipient" or "pharmaceutically acceptable excipient" means a pharma- ceutically acceptable material, composition, or vehicle, such as a liquid or solid filler, diluent, carrier, solvent, or encapsulating material. In one aspect, each component is "pharmaceutically acceptable" in the sense of being compatible with the other components of a pharmaceutical formulation, suitable for use in contact with the tissues or organs of humans and animals, without excessive toxicity, irritation, allergic response, immunogenicity, or other problems or complications, commensurate with a reasonable benefit / risk ratio. For example, Remington: The Science and Practice of Pharmacy, 21st ed.; Lippincott Williams & Wilkins: Philadelphia, PA, 2005; Handbook of Pharmaceutical Excipients, 6th ed.; Rowe et al., Eds.; The Pharmaceutical Press and the American Pharmaceutical Association: 2009; Handbook of Pharmaceutical Additives, 3rd ed.; Ash and Ash Eds.; Gower Publishing Company: 2007; Pharmaceutical Preformulation and Formulation, 2nd ed.; Gibson Ed.; CRC Press LLC: Boca Raton, FL, 2009.

[0075] The term "pharmaceutical acceptable salt" refers to a formulation of a compound that does not cause significant irritation to the organism to which it is administered and does not abrogate the biological activity and biological properties of the compound. In certain cases, pharmaceutical acceptable salts are obtained by reacting a compound described herein with an acid such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, etc. In some cases, pharmaceutical acceptable salts are obtained by reacting a compound having an acidic group described herein with a base to form a salt, such as an alkali metal salt such as an ammonium salt, a sodium salt or a potassium salt, an alkaline earth metal salt such as a calcium salt or a magnesium salt, a salt of an organic base such as dicyclohexylamine, N-methyl-D-glucamine, tris(hydroxymethyl)methylamine, and a salt with an amino acid such as arginine, lysine, etc., or by other methods already established. There is no particular limit to the pharmacologically acceptable salt, as long as it can be used in medicine. Examples of salts that the compounds described herein form with bases include their salts with inorganic bases such as sodium, potassium, magnesium, calcium, and aluminum; their salts with organic bases such as methylamine, ethylamine, and ethanolamine; their salts with basic amino acids such as lysine and ornithine; and ammonium salts. The salts may be acid addition salts, exemplified by acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, and phosphoric acid; organic acids such as formic acid, acetic acid, propionic acid, oxalic acid, malonic acid, succinic acid, fumaric acid, maleic acid, lactic acid, malic acid, tartaric acid, citric acid, methanesulfonic acid, and ethanesulfonic acid; and acidic amino acids such as aspartic acid and glutamic acid.

[0076] The term "pharmaceutical composition" refers to a mixture of a compound described herein with other chemical components, such as carriers, stabilizers, diluents, dispersing agents, suspending agents, and / or thickening agents (collectively referred to herein as "excipients"). A pharmaceutical composition facilitates administration of the compound to an organism. Multiple techniques of administering a compound exist in the art, including, but not limited to, rectal, oral, intravenous, aerosol, parenteral, ocular, pulmonary, and topical administration.

[0077] The term "subject" refers to an animal, including, but not limited to, a primate (e.g., a human), monkey, cow, pig, sheep, goat, horse, dog, cat, rabbit, rat, or mouse. As used herein, the terms "subject" and "patient" are used interchangeably in reference to a mammalian subject, such as a human.

[0078] The terms "treat," "treating," and "treatment" in the context of treating a disease, disorder, or condition are intended to include alleviating or arresting the disorder, disease, or condition, or one or more symptoms associated with the disorder, disease, or condition; or slowing the progression, metastasis, or worsening of the disease, disorder, or condition, or one or more symptoms thereof.

[0079] The term "halo" means fluoro (F), chloro (Cl), bromo (Br), or iodo (I).

[0080] The term "alkyl" refers to a hydrocarbon chain, which may be a straight or branched chain, containing the indicated number of carbon atoms. For example, C 1~10 indicates that the group may have from 1 to 10 carbon atoms in it. Non-limiting examples include methyl, ethyl, isopropyl, tert-butyl, and n-hexyl.

[0081] The term "haloalkyl" means an alkyl in which one or more hydrogen atoms are replaced with an independently selected halo.

[0082] The term "alkoxy" refers to an -O-alkyl group (e.g., -OCH 3 )

[0083] The term "haloalkoxy" refers to an -O-haloalkyl group, such as -OCH 3 )

[0084] The term "alkylene" refers to a divalent branched or unbranched alkyl (e.g., -CH 2 -).

[0085] Terms such as "arylene" refer to a divalent form of a ring system, herein a divalent aryl.

[0086] The term "alkenyl" refers to a hydrocarbon chain that may be straight or branched, having one or more carbon-carbon double bonds. The alkenyl moiety contains the indicated number of carbon atoms. For example, C 2~6 indicates that the group may have at least 2 but no more than 6 carbon atoms in it.

[0087] The term "alkynyl" refers to a hydrocarbon chain that may be straight or branched, having one or more carbon-carbon triple bonds. The alkynyl moiety contains the indicated number of carbon atoms. For example, C 2~6 indicates that the group may have at least 2 but no more than 6 carbon atoms in it.

[0088] The term "aryl" refers to a 6-carbon monocyclic, 10-carbon bicyclic, or 14-carbon tricyclic aromatic ring system in which 0, 1, 2, 3, or 4 atoms of each ring may be substituted, and in which the ring containing the monocyclic group is aromatic and at least one fused ring containing the bicyclic or tricyclic group is aromatic, e.g., tetrahydronaphthyl. Examples of aryl groups include phenyl, naphthyl, and the like.

[0089] The term "cycloalkyl" as used herein includes optionally substituted saturated cyclic hydrocarbon groups having 3 to 10 carbons, preferably 3 to 8 carbons, and more preferably 3 to 6 carbons. Preferred cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, and cyclooctyl.

[0090] The term "heteroaryl" refers to a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic aromatic ring system having 1-3 heteroatoms in the case of a monocyclic, 1-6 heteroatoms in the case of a bicyclic, or 1-9 heteroatoms in the case of a tricyclic, the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 N, O, or S heteroatoms in the case of a monocyclic, bicyclic, or tricyclic, respectively), in which 0, 1, 2, 3, or 4 atoms of each ring are optionally substituted, and in which the ring containing the monocyclic group is aromatic and at least one fused ring containing the bicyclic or tricyclic group is aromatic (but not necessarily a ring containing a heteroatom, e.g., tetrahydroisoquinolinyl). Examples of heteroaryl groups include pyridyl, furyl or furanyl, imidazolyl, benzimidazolyl, pyrimidinyl, thiophenyl or thienyl, quinolinyl, indolyl, thiazolyl, and the like.

[0091] The term "heterocyclyl" refers to a 5-8 membered monocyclic, 8-12 membered bicyclic, or 11-14 membered tricyclic non-aromatic ring system having 1-3 heteroatoms in the monocyclic, 1-6 heteroatoms in the bicyclic, or 1-9 heteroatoms in the tricyclic, the heteroatoms being selected from O, N, or S (e.g., carbon atoms and 1-3, 1-6, or 1-9 N, O, or S heteroatoms in the monocyclic, bicyclic, or tricyclic, respectively), and 0, 1, 2, or 3 atoms of each ring may be optionally substituted by substituents. Examples of heterocyclyl groups include piperazinyl, pyrrolidinyl, dioxanyl, morpholinyl, tetrahydrofuranyl, and the like.

[0092] Furthermore, the atoms constituting the compounds of this embodiment are intended to include all isotopic forms of the atoms. As used herein, isotopes include atoms having the same atomic number but different mass numbers. By way of general example and without limitation, isotopes of hydrogen include tritium and deuterium, and isotopes of carbon include tritium and deuterium. 13 C and 14 C is an example.

[0093] The details of one or more embodiments of the invention are set forth in the description and drawings which follow, and other features and advantages will be apparent from the claims.

[0094] Detailed Description The present disclosure features chemical entities (e.g., compounds, or pharma- ceutically acceptable salts and / or hydrates and / or prodrugs of the compounds) that modulate (e.g., stimulate, partially stimulate, or antagonize) the glucagon-like peptide 1 receptor ("GLP-1R") and / or gastric inhibitory polypeptide receptor ("GIPR"). The chemical entities are useful, for example, for treating subjects (e.g., humans) with a disease, disorder, or condition, where modulation (e.g., agonism, partial agonism, or antagonism) of GLP-1R and / or GIPR activity is beneficial in treating or preventing the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition. In some embodiments, modulation improves (e.g., increases) the current level (e.g., normal or below normal) of GLP-1R and / or GIPR activity (e.g., signaling). In some embodiments, the chemical entities described herein further modulate (e.g., attenuate, uncouple) β-arrestin signaling relative to that observed with the natural ligand. The disclosure also features compositions and other methods of using and making the chemical entities.

[0095] In one aspect, the disclosure provides a compound having the formula (IAA), or a pharma- ceutically acceptable salt thereof: TIFF2024156720000026.tif36128 formula, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where G is C(O), S(O), or SO 2 and; G and N * and the circular dotted line connecting (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and each independently are C, CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, or CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R dheterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 2' is as defined by (AA) or (BB) below: (AA) R 2' teeth TIFF2024156720000027.tif25128, wherein R 3 -C(O)OH, -C(O)OR 31 , -CH(C(O)OH) 2 or a carboxylic acid isostere (e.g., amide or tetrazolyl); a is 0 to 5; a' is 0 or 1; R 3a and R 3b are each independently H or C 1~3 is alkyl; (BB) R 2' and R 4 together with the atoms connecting them form a ring containing 5-8 ring atoms, where 3-7 are H, halo, hydroxy, oxo, and C 1~3 each ring carbon atom is substituted with 1 to 2 substituents independently selected from alkyl; 0 to 1 are O, -NH, -N(C1~3 (R alkyl), and S; 1 (e.g., R 4 and R 3 form, together with the atom to which each is attached, a ring containing 5 to 8 ring atoms); R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C) containing 5 to 10 ring atoms 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 wherein W' is a sequence of 5 to 60 amino acids, and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, optionally substituted with 1 to 2 modifying groups (eg, 1 to 2 groups selected from an acyl group and a PEG group).

[0096] In some embodiments, the compound has the formula (IIAA). TIFF2024156720000028.tif36128

[0097] In some embodiments, the compound has the formula (IIAA-B). TIFF2024156720000029.tif36128

[0098] In some embodiments, the compound has the formula (IA): TIFF2024156720000030.tif38128In formula, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where G is C(O), S(O), or SO 2 and; G and N * and the circular dotted line connecting (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and each independently are C, CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, and CR. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d heterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 3 -C(O)OH, -C(O)OR 31 , -CH(C(O)OH) 2 or a carboxylic acid isostere (e.g., amide or tetrazolyl); a is 0 to 5; a' is 0 or 1; R 3a and R 3b are each independently H or C 1~3 is alkyl; R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C) containing 5 to 10 ring atoms 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 wherein W' is a sequence of 5 to 60 amino acids, and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, optionally substituted with 1 to 2 modifying groups (eg, 1 to 2 groups selected from an acyl group and a PEG group).

[0099] In some embodiments, the compound has the formula (IIA): TIFF2024156720000031.tif38128

[0100] In some embodiments, the compound has formula (I): TIFF2024156720000032.tif36128 formula, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where G is C(O), S(O), or SO 2 and; G and N* and the circular dotted line connecting (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and each independently are C, CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, and CR. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R dheterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 3 -C(O)OH, -C(O)OR 31 , or a carboxylic acid isostere; where R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C) containing 5 to 10 ring atoms 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; a is 0 to 5; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' is independently selected from H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 wherein W' is a sequence of 5 to 60 amino acids, and R 5is a C-terminal amino acid, amino acid ester, or amino acid amide, optionally substituted with 1 to 2 modifying groups (for example, 1 to 2 groups selected from an acyl group and a PEG group).

[0101] In some embodiments, one or more of the compound conditions described herein (eg, described in the following section) apply.

[0102] Compound conditions In some embodiments, the compound is other than CAS RN 1401463-49-7; and / or CAS RN 1116465-43-0; and / or CAS RN 1614237-35-2, and / or CAS RN 1614237-36-3; and / or CAS RN 1353718-57-6; and / or CAS Registry Number: 1083307-90-7, each of which is incorporated herein by reference.

[0103] In some embodiments, the compound is not any of the compounds disclosed in Nacheva et al., Organic & Biomolecular Chemistry, 2012, 10 (38), 7840-7846; Chopra et al., Bioconjugate Chemistry, 2009, 20 (2), 231-240; and PCT Application Publication No. WO 2013 / 148579, each of which is incorporated by reference.

[0104] In some embodiments, ring A is other than unsubstituted maleimide-1-yl, ie, other than the formula: TIFF2024156720000033.tif40128

[0105] In certain embodiments, L is -(CH 2 ) 2 -, -(CH 2 ) 5 -C(O)NH-CH 2 - or -(CH 2 )2 -C(O)NH-(CH 2 ) 6 -, then ring A is other than unsubstituted maleimid-1-yl.

[0106] In certain embodiments, L is -(CH 2 ) 2 -, -(CH 2 ) 5 -C(O)NH-CH 2 - or -(CH 2 ) 2 -C(O)NH-(CH 2 ) 6 - and a is 1, then ring A is other than unsubstituted maleimid-1-yl.

[0107] In some embodiments, Ring A is other than a substituted maleimide-1-yl (eg, other than 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl, ie, other than the formula: TIFF2024156720000034.tif35128

[0108] In certain embodiments, L is -(CH 2 ) 3 -, then ring A is other than substituted maleimide-1-yl (eg other than 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl).

[0109] In certain embodiments, L is -(CH 2 ) 3 - and a is 1, then ring A is other than substituted maleimide-1-yl (eg other than 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl).

[0110] In some embodiments, ring A is other than optionally substituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl (e.g., other than unsubstituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl, i.e., other than the formula below). TIFF2024156720000035.tif35128

[0111] In certain embodiments, L is -(CH 2 ) 3 -, then ring A is other than optionally substituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl (e.g. other than unsubstituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl).

[0112] In certain embodiments, L is -(CH 2 ) 3 - and a is 0, ring A is other than optionally substituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl (e.g., other than unsubstituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl).

[0113] In some embodiments, ring A is (i) unsubstituted maleimide-1-yl; and (ii) other than substituted maleimide-1-yl (e.g., 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl).

[0114] In some embodiments, ring A is (i) unsubstituted maleimide-1-yl; (ii) substituted maleimide-1-yl (e.g., 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl); and (iii) optionally substituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl (e.g., unsubstituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl]).

[0115] In some embodiments, (i) L is -(CH 2 ) 2 -, -(CH 2 ) 5 -C(O)NH-CH 2 - or -(CH2 ) 2 -C(O)NH-(CH 2 ) 6 -, then ring A is other than unsubstituted maleimide-1-yl; (ii) L is -(CH 2 ) 3 -, then ring A is other than substituted maleimide-1-yl (eg other than 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl).

[0116] In some embodiments, (i) L is -(CH 2 ) 2 -, -(CH 2 ) 5 -C(O)NH-CH 2 - or -(CH 2 ) 2 -C(O)NH-(CH 2 ) 6 - and when a is 1, ring A is other than unsubstituted maleimide-1-yl; (ii) L is -(CH 2 ) 3 - and a is 1, then ring A is other than substituted maleimide-1-yl (eg other than 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl).

[0117] In some embodiments, (i) L is -(CH 2 ) 2 -, -(CH 2 ) 5 -C(O)NH-CH 2 - or -(CH 2 ) 2 -C(O)NH-(CH 2 ) 6 -, then ring A is other than unsubstituted maleimide-1-yl; (ii) L is -(CH 2 ) 3 -, then ring A is other than substituted maleimide-1-yl (e.g. other than 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl); (iii) L is -(CH2 ) 3 -, then ring A is other than optionally substituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl (e.g. other than unsubstituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl).

[0118] In some embodiments, (i) L is -(CH 2 ) 2 -, -(CH 2 ) 5 -C(O)NH-CH 2 - or -(CH 2 ) 2 -C(O)NH-(CH 2 ) 6 - and when a is 1, ring A is other than unsubstituted maleimide-1-yl; (ii) L is -(CH 2 ) 3 - and when a is 1, ring A is other than substituted maleimide-1-yl (e.g. other than 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl); (iii) L is -(CH 2 ) 3 - and a is 0, ring A is other than optionally substituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl (e.g., other than unsubstituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl).

[0119] In some embodiments, the first three amino acids in W' must be glycine-threonine-phenylalanine (GTF).

[0120] In some embodiments, W' must include 11 or more amino acids (e.g., 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 25 or more, 30 or more amino acids).

[0121] In some embodiments, the first three amino acids in W' must be glycine-threonine-phenylalanine (GTF) and W' must contain 11 or more amino acids (e.g., 12 or more, 13 or more, 14 or more, 15 or more, 16 or more, 17 or more, 18 or more, 19 or more, 20 or more, 25 or more, 30 or more amino acids).

[0122] In certain of these embodiments, one or more of the following apply: Ring A is unsubstituted maleimide-1-yl and L is -(CH 2 ) 2 -, -(CH 2 ) 5 -C(O)NH-CH 2 - or -(CH 2 ) 2 -C(O)NH-(CH 2 ) 6 - (optionally, a is 1). Ring A is a substituted maleimide-1-yl (e.g., 3,4-bis(2,4-difluorophenyl)-maleimide-1-yl) and L is -(CH 2 ) 3 - (optionally, a is 1). Ring A is optionally substituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl (e.g., unsubstituted N-[2-(1,3-dioxo-1H-benzo[de]isoquinolin-2(3H)-yl) (optionally, a is 0).

[0123] In certain embodiments, L is (CH 2 ) q In certain embodiments, when ring A is b Substituted with a group or R b If the groups are not both o,p-(di-fluoro)phenyl or ring A is substituted with two o,p-(di-fluoro)phenyl groups, then the first amino acid in sequence W' is not valine; alternatively, if ring A is substituted with two o,p-(di-fluoro)phenyl groups, L is (CH 2 ) 3 or L is (CH2 ) 3 Then the first amino acid in sequence W' is not a valine.

[0124] In certain embodiments, L is -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, m is 5, and X 1 is -C(O)NH-, n and p are each 0, and X 2 CQ 1 Q 2 If so, Q 1 and Q 2 At least one of L is not H. In certain embodiments, L is -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, m is 5, and X 1 is -C(O)NH-, n and p are each 0, and X 2 CH 2 In certain embodiments, when L is -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, m is 5, and X 1 is -C(O)NH-, n and p are each 0, and X 2 CH 2 and when ring A is -N-maleimide, then the first amino acid in sequence W' is not glycine.

[0125] In certain embodiments, L is -(CH 2 ) m -X 1 -(CH 2 ) n-X 2 -(CH 2 ) p -, m is 2, and X 1 is -C(O)NH-, the sum of n and p is 5, and X 2 CQ 1 Q 2 If so, Q 1 and Q 2 At least one of L is not H. In certain embodiments, L is -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, m is 2, and X 1 is -C(O)NH-, the sum of n and p is 5, and X 2 CH 2 In certain embodiments, when L is -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, m is 2, and X 1 is -C(O)NH-, the sum of n and p is 5, and X 2 CH 2 and when ring A is -N-maleimide, then the first amino acid in sequence W' is not alanine.

[0126] In certain embodiments, L is (CH 2 ) q then q is not 2; or L is (CH 2 ) 2 where A is not -N-maleimide; or L is (CH 2 ) 2 and when ring A is -N-maleimide, then the first amino acid in sequence W' is not alanine.

[0127] Ring A In some embodiments, G is C(O). Non-limiting examples of such compounds include compounds of formula (IA), (I-AA), and (I-AB). TIFF2024156720000036.tif156128

[0128] Further non-limiting examples include compounds having the formula (IA-A), (IA-AA), or (IA-AB). TIFF2024156720000037.tif146128

[0129] In some embodiments, G is S(O) or SO 2 Non-limiting examples of such compounds include compounds of formula (IB), (I-BA), or (I-BB). TIFF2024156720000038.tif141128

[0130] Further non-limiting examples include compounds having the formula (IA-B), (IA-BA), or (IA-BB). TIFF2024156720000039.tif147128

[0131] In some embodiments, ring A is a saturated or unsaturated monocyclic ring containing 3 to 8 (eg, 4 to 8, 4 to 7, 5 to 6) ring atoms.

[0132] In some of these embodiments, ring A is a saturated ring. In other embodiments, ring A is an unsaturated ring. In some of these embodiments, ring A contains 4 to 7 ring atoms or 5 to 6 ring atoms.

[0133] In certain embodiments, ring A is a saturated monocyclic ring containing 3 to 8 (eg, 4 to 8, 4 to 7, 5 to 6) ring atoms.

[0134] In certain embodiments, Ring A is a saturated monocyclic ring containing from 5 to 7 ring atoms.

[0135] In certain embodiments, Ring A is a saturated monocyclic ring containing 5-6 ring atoms.

[0136] In certain embodiments, ring A has the formula (III): TIFF2024156720000040.tif34128 formula, A 1 is a bond, A 1A -A 1B , C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 1A and A 1B are independently C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 2 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 3 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; SO 2 ; or N(R a ) and; A 4 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; or N(R a ), except for A 3 and A 4 are all O; S; or N(R a ); or any combination thereof.

[0137] In certain embodiments, ring A has formula (III): TIFF2024156720000041.tif33128 formula, A1 is a bond, C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 2 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 3 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; SO 2 ; or N(R a ) and; A 4 CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; or N(R a ), except for A 3 and A 4 are all O; S; or N(R a ); or any combination thereof.

[0138] In certain embodiments of formula (III), A 1 is a non-bond (i.e., A 1 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ) and ring A contains 6 ring atoms (i.e., ring A is a 6-membered ring).

[0139] In certain six-membered embodiments of formula (III), A 1 CH 2 , C.H.R. b , or C(R b ) 2 For example, A 1 CH 2 In another embodiment, A 1 is C(O).

[0140] In certain six-membered embodiments of formula (III), A 2 CH 2 , C.H.R. b , or C(R b ) 2 For example, A 2 CH 2 It is possible.

[0141] In certain six-membered embodiments of formula (III), A 3 CH 2 , C.H.R. b , or C(R b ) 2 For example, A 3 CH 2 In another embodiment, A 3 O; S; SO 2 ; or N(R a ).

[0142] In certain six-membered embodiments of formula (III), A 4 CH 2 , C.H.R. b , or C(R b ) 2 For example, A 4 CH 2 In another embodiment, A 4 is O; S; or N(R a ).

[0143] In certain six-membered embodiments of formula (III), A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 is selected from the group consisting of:

[0144] In certain embodiments, A 2 , A 3 , and A 4 One or two (e.g., one) of b and C(R b )2 and the rest are selected from the group consisting of CH 2 It is.

[0145] In certain six-membered embodiments of formula (III), A 2 , A 3 , and A 4 are CH 2 It is.

[0146] In certain six-membered embodiments of formula (III), A 2 and A 4 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 3 O; S; SO 2 ; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 4 Both are CH 2 In some of these embodiments, A 3 is N(R a ) (e.g. A 3 In another embodiment, A can be NH. 3 is O. In yet another embodiment, A 3 SO 2 It is.

[0147] In certain six-membered embodiments of formula (III), A 2 and A 3 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 4 is O; S; or N(Ra In some of these embodiments, A 2 and A 3 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 4 is N(R a ) (e.g. A 4 In another embodiment, A can be NH. 4 is O.

[0148] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 is selected from the group consisting of:

[0149] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 One or two (e.g., one) of b and C(R b ) 2 and the rest are selected from the group consisting of CH 2 It is.

[0150] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 are CH 2 It is.

[0151] In certain six-membered embodiments of formula (III), A 1 , A2 , and A 4 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 3 O; S; SO 2 ; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 1 CH 2 In some of these embodiments, A 3 is N(R a ) (e.g. A 3 In another embodiment, A can be NH. 3 is O. In yet another embodiment, A 3 SO 2 It is.

[0152] In certain six-membered embodiments of formula (III), A 1 , A 2 , and A 3 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 4 is O; S; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 1 CH 2 In some of these embodiments, A 4 is N(R a ) (e.g. A 4 In another embodiment, A can be NH. 4 is O.

[0153] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 In certain of these embodiments, A is selected from the group consisting of 2 , A 3 , and A 4 One or two (e.g., one) of b and C(R b ) 2 and the rest are selected from the group consisting of CH 2 It is.

[0154] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 , A 3 , and A 4 are CH 2 It is.

[0155] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 and A 4 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 3 O; S; SO 2; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 4 Both are CH 2 In some of these embodiments, A 3 is N(R a ) (e.g. A 3 In another embodiment, A can be NH. 3 is O. In yet another embodiment, A 3 SO 2 It is.

[0156] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 and A 3 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 4 is O; S; or N(R a In some of these embodiments, A 2 and A 3 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 4 is N(R a ) (e.g. A 4 In another embodiment, A can be NH. 4 is O.

[0157] In certain embodiments of formula (III), A 1 is a bond, ring A contains 5 ring atoms (ie, ring A is a 5-membered ring), and ring A has the formula (III-A): TIFF2024156720000042.tif28128

[0158] In certain embodiments of formula (III-A), A 2 is C(=O). In another embodiment, A 2 CH 2 , C.H.R. b , or C(R b ) 2 For example, A 2 CH 2 It is possible.

[0159] In certain embodiments of formula (III-A), A 3 is O; S; or N(R e ) For example, A 3 can be S. As another example, A 3 is N(R a ) (e.g., A 3 can be NH).

[0160] In certain embodiments of formula (III-A), A 4 CH 2 , C.H.R. b , or C(R b ) 2 For example, A 4 is CHR b or C(R b ) 2 As another example, A 4 CH 2 It is possible.

[0161] In certain embodiments of formula (III-A), A 2 is C(=O); A 3 is O; S; or N(R e ) and; A 4 CH 2 , C.H.R. b , or C(Rb ) 2 In some of these embodiments, A 3 is S. In other embodiments, A 3 is N(R a ) (e.g. A 3 In some of these embodiments, A is 4 CH 2 In another embodiment, A 4 is CHR b or C(R b ) 2 It is.

[0162] In certain embodiments of formula (III-A), A 2 is C(=O); A 3 and A 4 are each independently CH 2 , C.H.R. b , or C(R b ) 2 In some of these embodiments, A is selected from 3 and A 4 are CH 2 In another embodiment, A 3 and A 4 One of them is CH 2 And A 3 and A 4 The other is CHR b or C(R b ) 2 In yet another embodiment, A 3 and A 4 are each independently CHR b or C(R b ) 2 is selected from.

[0163] In certain embodiments of formula (III-A), A 2 CH 2 , C.H.R. b , or C(R b ) 2 For example, A 2 CH 2 A may be 3 and A 4are each independently CH 2 , C.H.R. b , or C(R b ) 2 (e.g., A 3 and A 4 are CH 2 (It is.)

[0164] In some embodiments of formula (III), A 1 A 1A -A 1B It is.

[0165] In some of the embodiments of formula (III) above, A 1A and A 1B are each independently CH 2 , C.H.R. b , or C(R b ) 2 As a non-limiting example, A 1A and A 1B are each independently CH 2 It is possible.

[0166] In some embodiments of formula (III), (A 1 A 1A -A 1B ), A 2 CH 2 , C.H.R. b , or C(R b ) 2 As a non-limiting example, A 2 CH 2 It is possible.

[0167] In some embodiments of formula (III), (A 1 A 1A -A 1B ), A 3 CH 2 , C.H.R. b , or C(R b ) 2 As a non-limiting example, A 3 CH 2 It is possible.

[0168] In some embodiments of formula (III), (A 1 A 1A -A 1B ), A 4 CH 2 , C.H.R. b , or C(R b ) 2 As a non-limiting example, A 4 CH 2 It is.

[0169] In some of the embodiments of formula (III) and (III-A) above, R b Each occurrence of is independently selected from the group consisting of: (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with (iii) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii)-F.

[0170] In some embodiments of formula (III) and (III-A), R b Each occurrence of is independently selected from the group consisting of: (I C 1~6Alkyl; (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii)-F.

[0171] In some of the embodiments of formula (III) above, R b Each occurrence of is independently selected from the group consisting of: 1 to 2 independently selected R e C which may be substituted with 1~6 alkyl; 1 to 5 independently selected R c Phenyl optionally substituted with -OH; -F; -N(R a )(R''); and C 1~4 Alkoxy.

[0172] Non-limiting examples of Ring A moieties having formula (III) or (III-A) are set forth in tabular form below in Table 1.

[0173] (Table 1) TIFF2024156720000043.tif68153

[0174] In some embodiments, ring A is an unsaturated monocyclic ring containing 4 to 8 (eg, 4 to 7, 5 to 6) ring atoms.

[0175] In certain embodiments, Ring A is an unsaturated monocyclic ring containing from 4 to 7 ring atoms.

[0176] In certain embodiments, Ring A is an unsaturated monocyclic ring containing 5-6 ring atoms.

[0177] In certain embodiments, ring A is an unsaturated monocyclic ring containing 6 ring atoms.

[0178] In certain embodiments, ring A is other than an unsaturated monocycle containing 5 ring atoms (eg, other than a maleimide, eg, other than an unsubstituted or disubstituted maleimide).

[0179] In certain of these embodiments, ring A has formula (IV): TIFF2024156720000044.tif33128 formula, A 6 and A 7 are independently CH and CR b More selected; A 5 and A 8 are each independently N, CH, or CR b It is.

[0180] In certain of these embodiments, ring A has formula (IV): TIFF2024156720000045.tif33128 formula, A 5 , A 6 , and A 7 are independently CH and CR b More selected; A 8 is N, CH, or CR b It is.

[0181] In certain embodiments of Formula (IV), A 5 , A 6 , A 7 , and A 8 are independently CH and CR b For example, A 5 , A 6 , A 7 , and A 8 One or two of the CRs are independently selected. b and the rest are CH. As another example, A 5 , A 6 , A 7 , and A 8 are CH, respectively.

[0182] In other embodiments of Formula (IV), A 5 , A 6 , and A 7 are independently CH and CR b Selected from A 8 is N. For example, A 5 , A 6 , and A 7 One or two of the CRs are independently selected. b and the rest are CH. As another example, A 5 , A 6 , and A 7 are CH, respectively.

[0183] In yet another embodiment of Formula (IV), A 5 is N; A 6 , A 7 , and A 8 are independently CH and CR b (e.g., A 6 , A 7 , and A 8 One of them is CR b (e.g. C-OH).

[0184] In some of the embodiments of formula (IV) above, R b Each occurrence of is independently selected from the group consisting of: 31 ; C 1~4 Haloalkyl; -OH; -N(R a )(R''); C 1~4 Alkoxy; and C 1~4 Haloalkoxy.

[0185] In some of the embodiments of formula (IV) above, R b Each occurrence of is independently selected from the group consisting of: 31 -OH; -N(R a )(R''); C 1~4 Alkoxy; and C 1~4 Haloalkoxy.

[0186] In some of the embodiments of formula (IV) above, Rb Each occurrence of is independently selected from the group consisting of: (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with (iii) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii)-F.

[0187] In certain of these embodiments, ring A has the formula (V): TIFF2024156720000046.tif35128In formula, A 6 and A 7 are independently CH and CR b More selected; A 8 is N, CH, or CR b It is.

[0188] In other embodiments of Formula (V), A 6 and A 7 In another embodiment of Formula (IV), A 6 and A 7 Both cannot be CH.

[0189] In certain embodiments of Formula (V), A 6 and A 7 One of them is CR b And A 6 and A 7 The other of these is CH.

[0190] In other embodiments of Formula (IV), A 6 and A 7 are each independently selected CR b In another embodiment of formula (IV), A 6 and A 7 Both are independently selected CR b In some of these aspects, A 6 and A 7 are independently selected CR b If both R b The substituents are 1 to 5 independently selected R c C replaced with 6~10 As another example, both R b The substituents are 1 to 3 or 1 to 2 independently selected R c C replaced with 6~10 aryl (e.g., phenyl). For example, both R b The substituents are C substituted with 1 to 5 independently selected halo (e.g., fluoro). 6~10 As another example, both R b The substituents are C substituted with 1-3 or 1-2 independently selected halo (e.g., fluoro). 6~10 aryl (e.g., phenyl). For example, both R b The substituent cannot be difluorophenyl, such as o,p-(di-fluoro)phenyl.

[0191] In some embodiments, ring A is a saturated or unsaturated bicyclic or tricyclic ring containing 7-9 (eg, 7-8, eg, 7) ring atoms.

[0192] In some of these embodiments, (A) applies (e.g., three adjacent ring carbon atoms of a divalent group are each independently C, CH, CR b , C.H. 2 , C(R b )H, C(R b ) 2 and is fused to a second ring.

[0193] In certain of these embodiments, ring A has the formula: TIFF2024156720000047.tif31128 where D is: (c) 1 to 4 independently selected R d C which may be substituted with 3~10 cycloalkyl; or (d) heterocyclyl containing 4 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted with

[0194] As a non-limiting example of the above embodiment, ring A is It could be TIFF2024156720000048.tif17128.

[0195] In some embodiments, Ring A is a saturated or unsaturated bicyclic or tricyclic ring containing 8 to 10 ring atoms.

[0196] In certain of these embodiments, ring A is a saturated ring. In other embodiments, ring A is an unsaturated ring.

[0197] In certain of these embodiments, (A) applies (e.g., two adjacent ring carbon atoms of a divalent group are each independently C, CH, and CR b and fused to a second ring). In another embodiment, (B) applies.

[0198] In certain embodiments, ring A is an unsaturated bicyclic or tricyclic ring containing 8 to 10 ring atoms. In some of these embodiments, (A) applies. In some of these embodiments, ring A may be further substituted with one oxo.

[0199] In certain embodiments, where (A) applies, ring A is optionally further substituted with one oxo, and ring A has the formula (VI). TIFF2024156720000049.tif35128

[0200] In certain of these embodiments, the fused ring B is selected from 1 to 5 independently selected R c Optionally substituted condensation C 6~10 For example, the fused ring B is selected from 1 to 5 independently selected R c As a further example, ring A can have the formula (VI-A): TIFF2024156720000050.tif35128 in formula, R c' is H or R c (For example, C 1~6 Alkyl, e.g. CH 3 ).

[0201] In certain embodiments of Formula (VI), ring B is selected from 1 to 5 independently selected R c Optionally substituted (e.g. unsubstituted) fused C 10 It is aryl.

[0202] In certain embodiments of Formula (VI), ring B is a fused heteroaryl containing 5 to 10 (e.g., 6) ring atoms, in which 1 to 4 (e.g., 1) ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c and optionally substituted heteroaryl.

[0203] In certain embodiments, ring A is selected from one of the following: TIFF2024156720000051.tif35138

[0204] In certain of the above embodiments, each fused ring B is independently selected from: A fused heteroaryl containing 5 to 10 (e.g., 6) ring atoms, wherein 1 to 4 (e.g., 1) ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with; 1 to 5 (e.g., 1 to 2) independently selected R c Optionally substituted condensation C 6~10 (For example, C 6 )Aryl.

[0205] As a non-limiting example, each fused ring B can independently be selected from 1 to 5 (e.g., 1 to 2) independently selected R c Optionally substituted condensation C 6~10 (For example, C 6 ) aryl.

[0206] In certain embodiments, ring A is a saturated bicyclic or tricyclic ring containing 8 to 10 ring atoms. In some of these embodiments, (A) applies. In other embodiments, (B) applies. In some of these embodiments, ring A may be further substituted with one oxo.

[0207] In certain embodiments, where (A) applies, ring A is optionally further substituted with one oxo, and ring A has the formula (VI). TIFF2024156720000052.tif35128

[0208] In certain of these embodiments, the fused ring B is selected from 1 to 4 independently selected R d Optionally substituted condensation C 3~10 For example, the fused ring B is 1 to 4 independently selected R dOptionally substituted condensation C 3~6 Cycloalkyl (e.g. C 3~4 cycloalkyl) (e.g., R d is C 1~3 (which may be alkyl).

[0209] In other embodiments, (B) applies, and ring A is optionally further substituted with one oxo, and ring A has the formula (VII). TIFF2024156720000053.tif41128

[0210] In certain of these embodiments, the spiro-fused ring B is selected from 1 to 4 independently selected R d Optionally substituted spiro-fused C 3~10 For example, the spiro-fused ring B can be 1 to 4 independently selected R d Optionally substituted spiro-fused C 3~6 Cycloalkyl (e.g. C 3~4 cycloalkyl) (e.g., R d is C 1~3 (which may be alkyl).

[0211] Variable factor L In some embodiments, L is a group represented by formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -Has.

[0212] In certain embodiments of Formula (VIII), m is 2 to 6 (eg, m can be 2).

[0213] In certain embodiments of formula (VIII), m is 1.

[0214] In certain embodiments of formula (VIII), X 1 is -N(R')C(O)- (e.g., X 1can be -N(H)C(O)-).

[0215] In certain embodiments of formula (VIII), n + p > 2. For example, n + p = 2 (e.g., n and p are each 1). As another example, n + p > 2 (e.g., n + p = 3, 4, 5, 6, 7, 8, 9, or 10).

[0216] In another embodiment, n+p<2.

[0217] In yet other embodiments, n+p=0.

[0218] In certain embodiments of formula (VIII), X 2 is -O-; -S-; or -S(O) t -, where t is 1 or 2. For example, X 2 can be -S-.

[0219] In certain embodiments of formula (VIII), X 2 -C(Q 1 )(Q 2 )-.

[0220] In some of these aspects, Q 1 and Q 2 are each independently H and C 1~4 For example, Q is selected from the group consisting of alkyl. 1 and Q 2 One of them can be H, and Q 1 and Q 2 The other is C 1~4 Alkyl (e.g. CH 3 ) can be used. For example, Q 1 can be H; Q 2 is C 1~4 As another example, Q can be 1 and Q 2 can each be H. As a further example, Q 1 and Q 2 are each independently selected C 1~4It can be alkyl.

[0221] In another embodiment, Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and may be fused to phenyl. For example, Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and may be fused to phenyl.

[0222] In some of the above aspects, Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 4~6 (For example, C 4 ) forms a cycloalkyl, the cycloalkyl being selected from 1 to 2 independently selected R d may be substituted with.

[0223] In certain embodiments of formula (VIII), X 2 is: (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 cycloalkylene; or (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with.

[0224] For example, X 2 teeth, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene; or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene It is possible.

[0225] As another example, X 2 teeth, (v) 1 to 5 (e.g., 1 to 3, 1 to 2, 1) independently selected R c phenylene optionally substituted with (vii) 1 to 4 independently selected R d C which may be substituted with 3~6 Cycloalkylene (e.g. C 3~4 Cycloalkylene) (e.g. R d is C 1~3 (which may be alkyl) It is possible.

[0226] In certain embodiments of formula (VIII), X 2 (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d and optionally substituted heterocycloalkylene.

[0227] In certain embodiments of formula (VIII), X 2(viii) heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, wherein 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with X 2 teeth TIFF2024156720000054.tif7128).

[0228] In some embodiments, L is a group of formula (IX): -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p In some of these embodiments, n + p > 2. For example, n + p = 2 (e.g., n and p are each 1). As another example, n + p > 2. In some of these embodiments, X 3 is -S-.

[0229] Non-limiting combinations of L [1] In a particular embodiment of formula (VIII), m is 2 to 6; n + p ≧ 2; X 2 is -O-; -S-; or -S(O) t -It is.

[0230] In certain of these embodiments, m is 2.

[0231] In some of these aspects, X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-).

[0232] In some of these embodiments, n+p>2.

[0233] In some of these embodiments, n+p=2 (eg, n and p are each 1).

[0234] In some of these aspects, X 2 is -S-.

[0235] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), where n + p>2.

[0236] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p>2, and X 2 is -S-.

[0237] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), where n + p = 2 (e.g., n and p are each 1).

[0238] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-.

[0239] For example, L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 -It is possible.

[0240] [2] In a particular embodiment of formula (VIII), m is 2 to 6; n + p<2; X 2 teeth, (i) -C(Q 1)(Q 2 )-, in the formula, Q 1 and Q 2 are each independently selected C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from the group consisting of 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 cycloalkylene; or (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with It is.

[0241] In certain of these embodiments, m is 2.

[0242] In some of these aspects, X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-).

[0243] In some of these embodiments, n+p=0.

[0244] In some of these aspects, X 2 -C(Q 1 )(Q 2 )-.

[0245] In some of these aspects, Q 1 and Q 2 are H, respectively.

[0246] In some of these aspects, Q 1 is C 1~4 It is an alkyl.

[0247] In some of these aspects, Q 2 is C 1~4 It is an alkyl.

[0248] In some of these aspects, Q 1 and Q 2 are each independently selected C 1~4 Alkyl (e.g. CH 3 ).

[0249] In some of these aspects, Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and may be fused to phenyl.

[0250] In some of these aspects, X 2 teeth, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene; or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene It is.

[0251] In some of these aspects, X 2 (viii) heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, wherein 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with X 2 teeth TIFF2024156720000055.tif7128).

[0252] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), where n + p = 0.

[0253] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and may be fused to phenyl.

[0254] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are independently selected C 1~4 Alkyl (e.g. CH 3 ).

[0255] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g., phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 It is a cycloalkylene.

[0256] [3] In certain embodiments of formula (IX), n + p = 2 (e.g., n and p are each 1), and X 3 is -S-.

[0257] [4] In certain embodiments of formula (VIII), m is 1; n + p ≦ 2; X 2 -O-; -S-; -S(O) t -; or C(Q 1 )(Q 2 ).

[0258] In some of these embodiments, n+p=2.

[0259] In some of these aspects, X 2 is -S-.

[0260] In some of these embodiments, n+p<2 (eg, n+p=0; alternatively, n+p=1).

[0261] In some of these above aspects, X 2 is C(Q 1 )(Q 2 ).

[0262] In some of these aspects, Q 1 and Q 2 are H, respectively.

[0263] In some of these aspects, Q 1 and Q 2 are C 1~4 It is an alkyl.

[0264] In some of these aspects, Q 1 is H; Q 2 is C 1~4 It is an alkyl.

[0265] Variable factor R 1 、R 2 、R 2' , and R 4 In some embodiments, R 1 is H. In some embodiments, R 2 is H. In some embodiments, R 4 is H.

[0266] In some embodiments, R 1 , R 2 , and R 4 Two of them are H.

[0267] In some embodiments, R 1 , R 2 , and R 4 are H, respectively.

[0268] In some embodiments, R 2 is unsubstituted C 1~3 It is alkyl (eg, methyl).

[0269] In some embodiments, R 1 and R 4 is H.

[0270] In some embodiments, R 2'is as defined by (AA).

[0271] In certain embodiments, a' is 1.

[0272] In some of these embodiments, R 3a and R 3b are H, respectively.

[0273] In some of these embodiments, R 3a and R 3b are C 1~3 It is alkyl (eg, methyl).

[0274] In other embodiments, a' is 0.

[0275] In some embodiments, R 3 is -C(O)OH. In other embodiments, R 3 is a carboxylic acid isostere. Non-limiting examples of carboxylic acid isosteres include non-carbon acyclic acids such as phosphonic / phosphinic and sulfonic / sulfinic acids, and sulfonamides; modified carbon-based acids such as hydroxamic acids, hydroxamic acid esters, acylureas, acylsulfonamides, and sulfonylureas; optionally substituted heteroaryl and heterocyclyl isosteres, such as isosteres based on optionally substituted tetrazoles, oxadiazole-5(4H)-thiones, thiadiazole-5(4H)-ones, oxathiadiazoles, and their oxidized forms, isoxazoles, thiazolidinediones, oxazolidinedione, tetramic acids, and their derivatives; and optionally substituted cycloalkyl and aryl isosteres, such as isosteres based on optionally substituted cyclopentane-1,3-dione, phenols, and squaric acids, and their derivatives (e.g., tetrazolyls or amides). In certain embodiments, R 3 is an amide. In certain embodiments, R 3 is optionally substituted tetrazolyl (e.g., unsubstituted tetrazolyl). In certain embodiments, R 3is an optionally substituted isoxazolyl (e.g., an isoxazolyl substituted with hydroxy). TIFF2024156720000056.tif14128).

[0276] In some embodiments, a is 1-5 (e.g., 1-4, 1-3, 1-2). In some embodiments, a is 0. In some embodiments, a is 0, 1, or 2. In particular embodiments, a is 1. In other embodiments, a is 2. In still other embodiments, a is 0. In some embodiments, a is 0, 1, 2, or 3 (e.g., a = 0; or a = 1; or a = 2).

[0277] Variables W, W', and R 5 W is of the formula W'-R 5 wherein W' is a sequence of 5 to 60 amino acids, and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, which may be substituted with 1 to 2 modifying groups (e.g., 1 to 2 groups selected from an acyl group and a PEG group). As used herein, a "peptide" refers to a peptide having an N-terminus (NR 4 ) and the C-terminal amino acid residue (R 5 ) means a chain of amino acid monomers (sometimes referred to as "residues") linked by peptide (amide) bonds (or isostere substitutions thereof). The term peptide also includes modified peptides, for example, containing any one or more modifications described herein.

[0278] Constituent amino acids and their modifications In some embodiments, W comprises one or more naturally occurring amino acids found, for example, in polypeptides and / or proteins produced by the organism, such as Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M), Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q), Asp (D), Glu (E), Lys (K), Arg (R), and His (H).

[0279] In some embodiments, W comprises one or more independently selected modifications present in so-called modified peptides, including, but not limited to, (i) incorporation of a lactam bridge; (ii) head-to-tail cyclization; (iii) one or more alternative or non-natural (D- or L-) amino acids, such as synthetic non-natural amino acids, substituted amino acids, and D-amino acids; (iv) peptide bond replacements; (v) targeting groups; and the like. In certain embodiments, W is a substituted or unsubstituted amino acid, such as a substituted or unsubstituted amino acid, such as a substituted or unsubstituted amino acid, such as a synthetic non-natural amino acid, substituted amino acid, and D-amino acid; (v) a peptide bond replacement; and (vi) a targeting group. In certain embodiments, W is a substituted or unsubstituted amino acid, such as a substituted or unsubstituted amino acid, such as a substituted or unsubstituted amino acid, such as a un ... 5 In other embodiments, W contains one modification in the W′ moiety / or R 5 component (e.g., W' component only; or R 5 component only; or W' component and R 5 In some embodiments, the nucleotide sequence includes two or more independently selected modifications occurring on both the nucleotide and nucleotide moieties (e.g., 2 independently selected modifications, 3 independently selected modifications, 4 independently selected modifications, 5 independently selected modifications, 6 independently selected modifications, 7 independently selected modifications, 8 independently selected modifications, 9 independently selected modifications, or 10 independently selected modifications).

[0280] Non-limiting examples of alternative or unnatural amino acids include D-amino acids; β-amino acids; homocysteine, phosphoserine, phosphothreonine, phosphotyrosine, hydroxyproline, γ-carboxyglutamic acid; hippuric acid, octahydroindole-2-carboxylic acid, statins, 1,2,3,4,-tetrahydroisoquinoline-3-carboxylic acid, penicillamine (3-mercapto-D-valine), ornithine, citrulline, α-methyl-alanine, para-benzoylphenylalanine, para-aminophenylalanine, para-fluorophenylalanine, phenylglycine, propargylglycine, sarcosine, and tert-butylglycine), diaminobutyric acid, 7-hydroxy-tetrahydroisoquinoline carboxylic acid, naphthylalanine, biphenylalanine, sialylglycine, cyclohex ... cyclohexylalanine, amino-isobutyric acid, norvaline, norleucine, tert-leucine, tetrahydroisoquinoline carboxylic acid, pipecolic acid, phenylglycine, homophenylalanine, cyclohexylglycine, dehydroleucine, 2,2-diethylglycine, 1-amino-1-cyclopentane carboxylic acid, 1-amino-1-cyclohexane carboxylic acid, amino-benzoic acid, amino-naphthoic acid, gamma-aminobutyric acid, difluorophenylalanine, nipecoic acid, alpha-aminobutyric acid, thienyl-alanine, t-butylglycine, trifluorovaline; hexafluoroleucine; fluorinated analogues; azide modified amino acids; alkyne modified amino acids; cyano modified amino acids; and derivatives thereof (each of which may independently be a D- or L-amino acid, where appropriate).

[0281] Non-limiting examples of peptide bond substitutes include ureas, thioureas, carbamates, sulfonylureas, trifluoroethylamines, ortho-(aminoalkyl)-phenylacetic acids, para-(aminoalkyl)-phenylacetic acids, meta-(aminoalkyl)-phenylacetic acids, thioamides, tetrazoles, boronic esters, olefinic groups, and derivatives thereof.

[0282] Other non-limiting examples of modifications and / or moieties include PEGylation; glycosylation; HESylation; ELPylation; lipidation; acetylation; amidation; end-capping modifications (e.g., amidation at the C-terminus, introduction of C-terminal alcohol moieties, aldehyde moieties, ester moieties, and thioester moieties); cyano groups; phosphorylation; cyclization, conjugation with targeting moieties and / or targeting agents (e.g., agents such as cellulose, fatty acids, polyethylene glycol (PEG), or combinations thereof) that increase retention in the body; and incorporation of a retro-inverso peptide motif (i.e., a peptide with a reversal of the direction of the peptide bond at at least one position).

[0283] In certain embodiments, W comprises only natural amino acids. In other embodiments, W comprises only alternative or non-natural amino acids. In still other embodiments, W comprises one or more natural amino acids and one or more alternative or non-natural amino acids. In some of the above embodiments, W comprises only L-amino acids; alternatively, W comprises both D-amino acids and L-amino acids; alternatively, W comprises only D-amino acids. Without wishing to be bound by theory, it is believed that the incorporation of D-amino acids can improve the in vivo or intracellular stability of the compounds described herein.

[0284] In some embodiments, W comprises an amino acid residue of formula XAA, or the C-terminal amino acid or amino acid ester or amino acid amide thereof, respectively: TIFF2024156720000057.tif25128 in formula, R aa1 and R aa2 are each independently selected from: (a) H; (b) 1 to 3 R ba C which may be substituted with 1~6 Alkyl; (c) 1 to 4 R ba may be substituted with (C 0~3 Alkylene)-C 3~10 Cycloalkyl; (d) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently selected from N(R da ), O, and S, and one or more heterocyclyl ring carbon atoms are each independently selected from 1 to 4 R ba heterocyclyl, optionally substituted by (e) 1 to 4 R ca may be substituted with (C 0~3 Alkylene)-C 6 ~C 10 Aryl; (f) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently selected from N, N(R da ), O, and S, and one or more heteroaryl ring carbon atoms are each independently selected from 1 to 4 R ca heteroaryl, optionally substituted with or, (g) -C(=O)CR aa1 (R aa2 )N(R da )-R in the group aa1 and R da are taken together to form a ring containing 5 to 8 ring atoms, (a) H and C 1~3 1 to 6 ring carbon atoms (CR aa1 (R aa2 ) other than N(R da 0 to 3 ring heteroatoms (R da (other than the nitrogen atom bonded to) forms a ring; R ba Each occurrence of -C(=O)(OH); -C(=O)(C 2~20 alkyl); -C(=O)NR'R''; -NHC(=NR')NR'R''; -C(=O)O(C 2~20 alkyl); -S(O) 0~2 (C 1~6alkyl); oxo; F; C 1~10 Alkoxy; C 1~10 Haloalkoxy; Azide; -N(R ga )(R ha ) selected from the group consisting of; R ca Each occurrence of is independently -OH; -SH; -F; -Cl; -Br; -NR'R''; C 1~4 Alkyl; C 1~4 Haloalkyl; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)O(C 1~4 alkyl); -C(=O)(C 1~4 alkyl); -C(=O)OH; -CON(R')(R''); -S(O) 1~2 (NR'R''); -S(O) 0~2 (C 1~4 Alkyl; Cyano; -NR'C(=NR')NR'R''; Halo, C 1~4 Alkyl, and C 1~4 C optionally substituted with 1 to 4 substituents independently selected from haloalkyl 6~10 aryl; and 1 to 4 independently selected C 1~4 C optionally substituted with alkyl 3~6 cycloalkyl; R da Each occurrence of is independently H; C 1~6 Alkyl; C 3~6 Cycloalkyl; -C(O)(C 1~4 alkyl); -C(O)O(C 1~4 alkyl); -CON(R')(R''); -S(O) 1~2 (NR'R''); -S(O) 1~2 (C 1~4 alkyl); -OH; and C 1~4 alkoxy; or -C(=O)CR aa1 (R aa2 )N(R da )-R in the group aa1 and R da together form a ring containing 5 to 8 ring atoms as defined above; R ga and R ha Each occurrence of is independently H; C 1~4 Alkyl; -C(=O)O(C 2~20 alkyl); and -S(O) 1~2 (C 1~6 alkyl); Each occurrence of R' and R'' is independently H and C 1~4 alkyl; or R′ and R″, taken together with the nitrogen atom to which they are each attached, are a ring containing 3 to 8 ring atoms, selected from the group consisting of: (a) H and C 1~3 and (b) forming a ring containing 0-3 ring heteroatoms (other than the nitrogen atom bonded to R' and R''), each independently selected from the group consisting of N(H), O, and S.

[0285] In some embodiments, W comprises 25 to 45 amino acid residues of formula XAA, or the C-terminal amino acid or amino acid ester or amino acid amide thereof, where R aa2 is H.

[0286] In some of these embodiments, R aa1 is selected from the group consisting of: ·H; -NH 2 , -OH, -SH, -SMe, -NH(C=NH)NH 2 , CO 2 H, and CO 2 NH 2 C which may be substituted with 1 to 2 substituents selected from 1 ~C 6 Alkyl; may be substituted with 1 to 2 -OH groups (C 1 ~C 6 (alkylene)-phenyl; ·(C 1 ~C 6 alkylene)-indolyl; and ·(C1 ~C 6 alkylene)-imidazolyl; or -CH(R aa1 )N(R da )-R in the group aa1 and R da , which together form a pyrrolidine ring.

[0287] As non-limiting examples of the above embodiments, W can include any of the 25-45 naturally occurring amino acids found, for example, in polypeptides and / or proteins produced by an organism, such as Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M), Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q), Asp (D), Glu (E), Lys (K), Arg (R), and His (H); or amino acid esters or amino acid amides thereof.

[0288] In certain embodiments, W comprises one to two (e.g., one) amino acid residues of formula XAA, or the C-terminal amino acid or amino acid ester or amino acid amide thereof, where R aa2 is H; R aa1 is 1 to 2 (for example, 1) R ba C replaced with 1~6 alkyl; R ba Each occurrence of is independently -N(R ga )(R ha ) is selected.

[0289] As a non-limiting example of the above embodiment, W may comprise an amino acid residue selected from the following, or a C-terminal amino acid or amino acid ester or amino acid amide thereof: TIFF2024156720000058.tif19135

[0290] In certain embodiments, W comprises one to two (e.g., one) amino acid residues of formula XAA, or the C-terminal amino acid or amino acid ester or amino acid amide thereof, where R aa2 is C1~3 alkyl (e.g., methyl); R aa1 is other than H.

[0291] Non-limiting examples include TIFF2024156720000059.tif36128; or its C-terminal amino acid, amino acid ester, or amino acid amide.

[0292] Variable factor W' In some embodiments, W' is a sequence of 20 to 60 amino acids (eg, 20 to 55, 20 to 50, 20 to 45, 20 to 40, 20 to 30, 20 to 35).

[0293] In some embodiments, W' is a sequence of 30 to 60 amino acids (e.g., 30 to 55, 30 to 50, 30 to 45, 30 to 40). In certain embodiments, W' is a sequence of 25 to 45 amino acids (e.g., 30 to 45). In certain embodiments, W' is a sequence of 30 to 50 amino acids. For example, W' can be a sequence of 30 to 45 amino acids or 30 to 40 amino acids. In certain embodiments, W' can be a sequence of 34, 35, 36, 37, 38, or 39 amino acids; for example, 36 or 37 amino acids; for example, 36 amino acids. In certain embodiments, W' can be a sequence of 25 to 28 amino acids; for example, 26 or 27 amino acids.

[0294] Variable factor R 5 In some embodiments, R 5 is a C-terminal amino acid amide optionally substituted with one or two modifying groups. 5 is the C-terminal amino acid which may be substituted with 1 to 2 modifying groups.

[0295] In certain embodiments, R 5 is a C-terminal lysyl residue, e.g., a lysylamide residue, optionally substituted with one or two modifying groups. For example, R 5can be a C-terminal L-lysylamide residue optionally substituted with one or two modifying groups. 5 has the formula (XI): TIFF2024156720000060.tif68128 formula, R * is H or a modifying group. In certain of these embodiments, formula (XI) is L. In other embodiments, formula (XI) is D.

[0296] In certain embodiments, R * is H.

[0297] In certain embodiments, a modifying group (e.g., R * ) is an acyl group. For example, an acyl group can be formed by adding 1 to 2 independently selected R f C which may be substituted with 2~30 (For example, C 2~20 , C 2~10 , C 2~6 ) may be an acyl group. f Each occurrence of -C(=O)(OH); -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); -S(O) 1~2 (C 1~6 alkyl); oxo; F; C 1~10 Alkoxy; C 1~10 haloalkoxy; and -N(R g )(R h R g and R h Each occurrence of is independently H; C 1~4 Alkyl; -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); and -S(O) 1~2 (C 1~6 alkyl).

[0298] In certain embodiments, a modifying group (e.g., R * ) is one to two (e.g., two) independently selected R f C replaced with 2~30 (For example, C2~20 , C 2~10 , C 2~6 ) acyl group. In certain embodiments, R f Each occurrence of is independently -C(=O)(OH) and -N(R g )(R h For example, R g and R h One of them is independently -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); and -S(O) 1~2 (C 1~6 alkyl), e.g. -C(=O)(C 2~20 For example, the modifying group (e.g., R * ) can be: TIFF2024156720000061.tif43128

[0299] As a further example, R * can be: TIFF2024156720000062.tif36142

[0300] In some embodiments, R 5 is the C-terminal amino acid, which may be substituted with 1 to 2 modifying groups (for example, 1 to 2 groups selected from an acyl group and a PEG group).

[0301] In certain embodiments, R 5 is a C-terminal lysine, which may be substituted with one or two modifying groups (e.g., one or two groups selected from an acyl group and a PEG group). For example, R 5 may be a C-terminal L-lysine, and may be substituted with 1 to 2 modifying groups (for example, 1 to 2 groups selected from an acyl group and a PEG group).

[0302] In certain embodiments, R 5 has the formula (XI-OH): TIFF2024156720000063.tif71128 formula, R *is H or a modifying group (e.g., an acyl group or a PEG group). In certain of these embodiments, formula (XI-OH) is L. In other embodiments, formula (XI-OH) is D.

[0303] In certain embodiments of formula (XI) and (XI-OH), R * is H.

[0304] In certain embodiments, a modifying group (e.g., R * ) is an acyl group. For example, an acyl group can be formed by adding 1 to 2 independently selected R f C which may be substituted with 2~30 (For example, C 2~20 , C 2~10 , C 2~6 ) may be an acyl group. f Each occurrence of -C(=O)(OH); -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); -S(O) 1~2 (C 1~6 alkyl); oxo; F; C 1~10 Alkoxy; C 1~10 haloalkoxy; and -N(R g )(R h R g and R h Each occurrence of is independently H; C 1~4 Alkyl; -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); and -S(O) 1~2 (C 1~6 alkyl).

[0305] In certain embodiments, a modifying group (e.g., R * ) is one to two (e.g., two) independently selected R f C replaced with 2~30 (For example, C 2~20 , C 2~10 , C 2~6 ) acyl group. In certain embodiments, R f Each occurrence of is independently -C(=O)(OH) and -N(Rg )(R h For example, R g and R h One of them is independently -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); and -S(O) 1~2 (C 1~6 alkyl), e.g. -C(=O)(C 2~20 For example, the modifying group (e.g., R * ) can be: TIFF2024156720000064.tif43128

[0306] As a further example, R * can be: TIFF2024156720000065.tif36143

[0307] Other non-limiting representative examples of acyl modifying groups are listed, for example, in Table 2.

[0308] In other embodiments, the modifying group is PEG. As used herein, the general term "polyethylene glycol" or "PEG" refers to a compound of the general formula H(OCH 2 CH2) n "PEG" refers to a mixture of condensation polymers of ethylene oxide and water, branched or linear, represented by OH. Without further characterization, the term is intended to include polymers of ethylene glycol having a total average molecular weight selected from the range of 5,000 to 40,000 daltons. "Polyethylene glycol" or "PEG" is used in combination with a numeric suffix indicating its approximate average molecular weight. For example, PEG-5,000 refers to polyethylene glycol having a total average molecular weight of about 5,000. As used herein, the term "PEGylated" or similar terms refers to a compound modified from its native state by linking a PEG chain to the peptide. A "PEGylated peptide" refers to a peptide having a PEG chain covalently attached to the peptide itself.

[0309] In certain embodiments, R 5 is a C-terminal amino acid selected from serine, glycine, and arginine.

[0310] In certain embodiments, R 5 is a C-terminal amino acid amide selected from serinylamide, glycylamide, and arginylamide.

[0311] In certain embodiments, R 5 is a C-terminal glycyl residue (eg, C-terminal glycine or C-terminal glycylamide).

[0312] In certain embodiments, R 5 is a C-terminal argininyl residue (eg, C-terminal arginine or C-terminal argininyl amide).

[0313] In certain embodiments, R 5 is a C-terminal serinyl residue (eg, C-terminal serine or C-terminal serinyl amide).

[0314] Non-Limiting Examples of W In some embodiments, the amino acid sequence present in W is the naturally occurring GLP-1-OH or GLP-1-NH 2 In another embodiment, the amino acid sequence present in W is or comprises a sequence present in native GIP. In yet another embodiment, the amino acid sequence present in W is or comprises a sequence present in native GLP-1-OH or GLP-1-NH 2The present disclosure further contemplates variations of the above embodiments, such as W being or including a conservatively substituted variation of the above embodiments, i.e., one or more amino acid residues of the original peptide are replaced with different residues, and the conservatively substituted peptide retains the desired biological activity. Examples of conservative substitutions include substitutions of amino acids that tend not to change the secondary and / or tertiary structure of the compounds described herein, substitutions that do not change the global or local hydrophobicity, substitutions that do not change the global or local charge, substitutions with residues of comparable side chain size, or substitutions with side chains having similar reactive groups.

[0315] A given amino acid can be replaced with a residue having similar physiochemical properties, for example, one aliphatic residue can be replaced with another (e.g., Ile, Val, Leu, or Ala for each other), or one polar residue can be replaced with another (e.g., between Lys and Arg; between Glu and Asp; or between Gln and Asn). Other such conservative substitutions, such as replacement of entire regions with similar hydrophobicity, or replacement of residues with similar side chain volumes, are also within the scope of this disclosure.

[0316] Amino acids can be classified according to similarities in the properties of their side chains (A.L. Lehninger, in Biochemistry, second ed., pp. 73-75, Worth Publishers, New York (1975)): (1) nonpolar: Ala(A), Val(V), Leu(L), Ile(I), Pro(P), Phe(F), Trp(W), Met(M); (2) uncharged polar: Gly(G), Ser(S), Thr(T), Cys(C), Tyr(Y), Asn(N), Gln(Q); (3) acidic: Asp(D), Glu(E); (4) basic: Lys(K), Arg(R), His(H). Alternatively, natural residues can be classified based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile, Phe, Trp; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln, Ala, Tyr, His, Pro, Gly; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that affect chain orientation: Gly, Pro; (6) aromatic: Trp, Tyr, Phe, Pro, His, or hydroxyproline. Non-conservative substitutions would involve exchanging a member of one of these classes for another class.

[0317] In certain embodiments, conservative substitutions used in the variants described herein are as follows: Ala to Gly or Ser; Arg to Lys; Asn to Gln or His; Asp to Glu or Asn; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or Pro; His to Asn or Gln; Ile to Leu or Val; Leu to Ile or Val; Lys to Arg, Gln, or Glu; Met to Leu, Tyr, or Ile; Phe to Met, Leu, or Tyr; Ser to Thr; Thr to Ser; Trp to Tyr or Phe; Tyr to Phe or Trp; and / or Phe to Val, Tyr, Ile, or Leu. In general, conservative substitutions involve replacing a residue with a residue of similar physicochemical properties (ie, replacing a hydrophobic residue with another hydrophobic amino acid).

[0318] In yet other embodiments, the amino acid sequence present in W has at least 0.01% of the GLP-1 receptor activating activity of native GLP-1, e.g., native GLP-1-OH or GLP-1-NH 2 and / or at least 0.01% of the GIP receptor activation activity of GIP, e.g. at least 0.1%, 0.2%, 0.5%, 0.8%, 1%, 3%, 5%, 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 99% of the GLP-1 receptor activation activity of native GIP.

[0319] As used herein, the term "native GLP-1" refers to a peptide comprising the sequence of human GLP-1 (7-36, or 7-37), and the term "native GIP" refers to a peptide comprising the sequence of human GIP (1-42). As used herein, a general reference to "GLP-1" or "GIP" in the absence of further indication is intended to mean native GLP-1 or native GIP, respectively.

[0320] In some embodiments, W is represented by the formula (X): -GTF-W″-R 5 where W″ is a sequence of 30-40 (eg, 31-36, 33) amino acids.

[0321] In certain embodiments, W has formula (XII): TIFF2024156720000066.tif68128Wherein W'' is a sequence of 30 to 40 (e.g., 31 to 35, e.g., 33) amino acids, R * is H or a modifying group (e.g., an acyl group, and a PEG group as described herein).

[0322] In certain embodiments, W has the formula (XII-OH): TIFF2024156720000067.tif71128, where W'' is a sequence of 30 to 40 (e.g., 31 to 35, e.g., 33) amino acids, and R * is H or a modifying group (e.g., an acyl group, and a PEG group as described herein).

[0323] In some embodiments, W has formula (XIII): -GTF-W'''-GPSSGAPPPS-R 5 (SEQ ID NO: 1) In the formula, W''' is a sequence of 20 to 30 (eg, 21 to 25, for example, 23) amino acids.

[0324] In some embodiments, W has the formula (XIV-AA): TIFF2024156720000068.tif19151 (SEQ ID NO: 2A, listed in the sequence listing as SEQ ID NO: 35); During the ceremony, Xaa3 is F; Xaa4 is T or I (e.g., T); Xaa7 is Y, V, L, or K * (e.g. Y); Xaa9 is I or S (e.g., I); Xaa10 is Y, Y * , Q, A, or (Aib) (e.g., Y); Xaa11 is L, M, or L * (e.g. L); Xaa12 is D or E (e.g., D); Xaa13 is K, G, R, or E (e.g., K); Xaa14 is Q or I (e.g., Q); Xaa15 is A, H, or R (e.g., A); Xaa16 is A, Q, or V (e.g., A); Xaa17 is A, (Aib), K * , K, or Q (e.g., (Aib)); Xaa18 is A, D, E, (Aib), or L (e.g., A, D, E, or L (e.g., E)); Xaa19 is F, or A (e.g., F); Xaa20 is V or I (e.g., V); Xaa21 is N, A, Q, K * or E (e.g., N); Xaa24 is I, L, or V (e.g., L); Xaa25 is A, K, or I (e.g., A); Xaa26 is QR, GRGK * , Q, or G (e.g., G); Xaa36 is S or absent (eg, S).

[0325] In some embodiments (e.g., when W has formula (XIV-AA)), W has formula (XIV): TIFF2024156720000069.tif12151In formula, Xaa4 is T or I (e.g., T); Xaa7 is Y, V, or L (e.g., Y); Xaa9 is I or S (e.g., I); Xaa10 is Y, Q, or A (e.g., Y); Xaa11 is L, M, or L * (e.g. L); Xaa12 is D or E (e.g., D); Xaa13 is K, G, or E (e.g., K); Xaa16 is A or V (e.g., A); Xaa17 is (Aib) or K (e.g., (Aib)); Xaa18 is E or L (e.g., E); Xaa20 is V or I (e.g., V); Xaa21 is N, A, or E (e.g., N); Xaa24 is L or V (e.g., L); Xaa25 is A or K (eg, A).

[0326] In certain embodiments, W has formula (XIV-A): TIFF2024156720000070.tif12152, wherein each "Xaa" variable is as defined for formula (XIV). In some of these embodiments, R 5 may be as defined anywhere herein (e.g., formula (XI); e.g., D or L may have formula (XI), and R * may be as defined anywhere in this specification).

[0327] In certain embodiments, W has formula (XIV-B): TIFF2024156720000071.tif5145. In some of these aspects, R 5may be as defined anywhere herein (e.g., formula (XI); e.g., D or L may have formula (XI), and R * may be as defined anywhere in this specification).

[0328] As used herein, "(Aib)" means 2-aminoisobutyric acid (also known as α-aminoisobutyric acid or α-methylalanine or 2-methylalanine).

[0329] As used herein, Y * means 2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid (e.g., (S)-2-amino-3-(4-hydroxyphenyl)-2-methylpropanoic acid). * means 2-amino-2-methylpentanoic acid (e.g., (S)-2-amino-2-methylpentanoic acid), or the C-terminal amino acid or amino acid ester or amino acid amide thereof.

[0330] As used herein, K * is a lysine residue substituted with a modifying group, or the C-terminal amino acid or amino acid ester or amino acid amide thereof.

[0331] K * Non-limiting examples of can include an amino acid residue selected from the following, or the C-terminal amino acid, amino acid ester, or amino acid amide thereof: TIFF2024156720000072.tif19132

[0332] In some embodiments, W is represented by formula (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or any one of SEQ IDs 1-34.

[0333] For example, W can have any one of the sequences set forth in Table 2.

[0334] (Table 2) TIFF2024156720000073.tif136168TIFF2024156720000074.tif218168TIFF2024156720000075.tif216168TIFF2024156720 000076.tif178168TIFF2024156720000077.tif153168TIFF2024156720000078.tif215168TIFF2024156720000079.tif93168

[0335] In some embodiments, W is represented by any one of SEQ IDs 1-34 (e.g., SEQ IDs 5-27; e.g., SEQ IDs 5-29; (e.g., SEQ ID 6); e.g., SEQ IDs 28-29; e.g., SEQ IDs 30-34).

[0336] In some embodiments, W is represented by any one of SEQ IDs 1-27 (eg, SEQ. IDs 5-27; eg, SEQ ID 6).

[0337] In some embodiments, W is represented by any one of SEQ IDs 28-29 (eg, 28, 29).

[0338] In a particular embodiment, W has the sequence of SEQ ID 6.

[0339] Non-limiting combinations of formulae (IAA), (IA), and (I) [1] In some embodiments, the compound has the formula (IA), (I-AA), or (I-AB), wherein ring A is a saturated or unsaturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH.

[0340] [1A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), where ring A is a saturated or unsaturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH. In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0341] [2] In some embodiments, the compound has the formula (IA), (I-AA), or (I-AB), (IA), (I-AA), or (I-AB), wherein ring A is a saturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a group represented by formula (VIII): -(CH 2 ) m -X 1 -(CH2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH.

[0342] [2A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), (IA-B), (IA-BA), or (IA-BB), wherein ring A is a saturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a ring represented by formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH. In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0343] [3] In some embodiments, the compound has the formula (IA), (I-AA), or (I-AB), wherein ring A is a saturated 6-membered monocyclic ring having the formula (III) (i.e., A 1 is not a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH.

[0344] [3A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), and ring A is a saturated 6-membered monocyclic ring having the formula (III) (i.e., A 1 is not a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3is -C(O)OH. In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0345] [4] In some embodiments, the compound has formula (IA), (I-AA), or (I-AB), and ring A is a saturated 5-membered monocyclic ring having formula (III-A) (i.e., A in formula (III) 1 is a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH.

[0346] [4A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), and ring A is a saturated 5-membered monocyclic ring having the formula (III-A) (i.e., A in formula (III) 1 is a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH. In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0347] [5] In some embodiments, the compound has the formula (IA), (I-AA), or (I-AB), wherein ring A is a saturated or unsaturated bicyclic or tricyclic ring containing 6 to 14 (e.g., 8 to 10) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH.

[0348] [5A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), where ring A is a saturated or unsaturated bicyclic or tricyclic ring containing 6 to 14 (e.g., 8 to 10) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) pIn certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH. In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0349] [6] In some embodiments, the compound has the formula (IA), (I-AA), or (I-AB), wherein ring A is a saturated or unsaturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI):

[0350] [6A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), where ring A is a saturated or unsaturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0351] [7] In some embodiments, the compound has formula (IA), (I-AA), or (I-AB), wherein ring A is a saturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 )n -X 2 -(CH 2 ) p -, and W is represented by any one of (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI):

[0352] [7A] In some embodiments, the compound has formula (IA), (I-AA), or (I-AB), wherein ring A is a saturated monocyclic ring containing 3-8 (e.g., 4-8, 4-7, 5-6) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0353] [8] In some embodiments, the compound has the formula (IA), (I-AA), or (I-AB), and ring A is a saturated 6-membered monocyclic ring having the formula (III) (i.e., A 1 is not a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI):

[0354] [8A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), wherein ring A is a saturated 6-membered monocyclic ring having the formula (III) (i.e., A 1 is not a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0355] [9] In some embodiments, the compound has formula (IA), (I-AA), or (I-AB), and ring A is a saturated 5-membered monocyclic ring having formula (III-A) (i.e., A in formula (III) 1 is a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 )n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI):

[0356] [9A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), and ring A is a saturated 5-membered monocyclic ring having the formula (III-A) (i.e., A in formula (III) 1 is a bond), and L is a group of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, R 1 , R 2 , and R 4One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0357]

[10] In some embodiments, the compound has the formula (IA), (I-AA), or (I-AB), wherein ring A is a saturated or unsaturated bicyclic or tricyclic ring containing 6 to 14 (e.g., 8 to 10) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6). 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI):

[0358] [10A] In some embodiments, the compound has the formula (IA-A), (IA-AA), or (IA-AB), where ring A is a saturated or unsaturated bicyclic or tricyclic ring containing 6 to 14 (e.g., 8 to 10) ring atoms, and L is a ring of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -, and W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ. ID 5-27; e.g., SEQ ID 5-29; (e.g., SEQ ID 6); e.g., SEQ ID 28-29; e.g., SEQ ID 30-34). In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0359]

[11] In some embodiments, The compound has the formula (IA), (I-AA), or (I-AB); Ring A is a saturated monocyclic ring containing 3 to 8 (e.g., 4 to 8, 4 to 7, 5 to 6) ring atoms; L is represented by the formula (VIII): -(CH 2 ) m -X1 -(CH 2 ) n -X 2 -(CH 2 ) p -Having; W is represented by any one of formulas (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6); m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with and fused to phenyl; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are independently selected C 1~4 Alkyl (e.g. CH 3 ) or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 (v) 1 to 5 independently selected R cC which may be substituted with 6~10 arylene (e.g., phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 It is a cycloalkylene.

[0360] In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI):

[0361] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-. For example, L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 -It is possible.

[0362] In certain of these embodiments, any one of SEQ IDs 5-27 (eg, SEQ ID 6) represents W.

[0363] [11A] In some embodiments, The compound has the formula (IA-A), (IA-AA), or (IA-AB); Ring A is a saturated monocyclic ring containing 3 to 8 (e.g., 4 to 8, 4 to 7, 5 to 6) ring atoms; L is represented by the formula (VIII): -(CH 2) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -Having W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ. IDs 5-27; e.g., SEQ IDs 5-29; (e.g., SEQ ID 6); e.g., SEQ IDs 28-29; e.g., SEQ IDs 30-34).

[0364] In certain embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with and fused to phenyl; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are independently selected C 1~4 Alkyl (e.g. CH 3 ) or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g., phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 It is a cycloalkylene.

[0365] In certain embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 is a heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, in which 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with X 2 teeth TIFF2024156720000080.tif7128).

[0366] In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3bare H, respectively.

[0367] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-. For example, L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 -It is possible.

[0368] In certain of these embodiments, any one of SEQ IDs 5-34 (eg, SEQ ID 6) represents W.

[0369]

[12] In some embodiments, The compound has the formula (IA), (I-AA), or (I-AB); Ring A is a saturated 6-membered monocyclic ring having the formula (III) (i.e., A 1 is not a join); L is represented by the formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -Having; W is represented by any one of formulas (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6); m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with and fused to phenyl; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are independently selected C 1~4 Alkyl (e.g. CH 3 ) or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g., phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 It is a cycloalkylene.

[0370] In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3is -C(O)OH, and R 5 has the formula (XI):

[0371] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-. For example, L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 -It is possible.

[0372] In certain of these embodiments, any one of SEQ IDs 5-27 (eg, SEQ ID 6) represents W.

[0373] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 is selected from the group consisting of:

[0374] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 One or two (e.g., one) of b and C(R b ) 2 and the rest are selected from the group consisting of CH 2 It is.

[0375] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 are CH 2 It is.

[0376] In certain six-membered embodiments of formula (III), A 1 , A 2 , and A 4 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 3 O; S; SO 2 ; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 1 CH 2 In some of these embodiments, A 3 is N(R a ) (e.g. A 3 In another embodiment, A can be NH. 3 is O. In yet another embodiment, A 3 SO 2 It is.

[0377] In certain six-membered embodiments of formula (III), A 1 , A 2 , and A 3 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 4 is O; S; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 1 CH 2 In some of these embodiments, A 4 is N(R a ) (e.g. A 4 In another embodiment, A can be NH. 4 is O.

[0378] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 In certain of these embodiments, A is selected from the group consisting of 2 , A 3 , and A 4 One or two (e.g., one) of b and C(R b ) 2 and the rest are selected from the group consisting of CH 2 It is.

[0379] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 , A 3 , and A 4 are CH 2 It is.

[0380] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 and A 4 are each independently 2 , C.H.R. b , and C(R b ) 2A is selected from the group consisting of 3 O; S; SO 2 ; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 4 Both are CH 2 In some of these embodiments, A 3 is N(R a ) (e.g. A 3 In another embodiment, A can be NH. 3 is O. In yet another embodiment, A 3 SO 2 It is.

[0381] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 and A 3 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 4 is O; S; or N(R a In some of these embodiments, A 2 and A 3 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 4 is N(R a ) (e.g. A 4In another embodiment, A can be NH. 4 is O. In certain embodiments of the six-membered ring of formula (III), A 1 , A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 is selected from the group consisting of:

[0382] [12A] In some embodiments, The compound has the formula (IA-A), (IA-AA), or (IA-AB); Ring A is a saturated 6-membered monocyclic ring having the formula (III) (i.e., A 1 is not a join); L is represented by the formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -Having; W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ. IDs 5-27; e.g., SEQ IDs 5-29; (e.g., SEQ ID 6); e.g., SEQ IDs 28-29; e.g., SEQ IDs 30-34).

[0383] In certain embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q2 )- and Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with and fused to phenyl; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are independently selected C 1~4 Alkyl (e.g. CH 3 ) or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g., phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 It is a cycloalkylene.

[0384] In certain embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 is a heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, in which 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with X 2 teeth TIFF2024156720000081.tif7128).

[0385] In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0386] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-. For example, L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 -It is possible.

[0387] In certain of these embodiments, any one of SEQ IDs 5-34 (eg, SEQ ID 6) represents W.

[0388] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 is selected from the group consisting of:

[0389] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 One or two (e.g., one) of b and C(R b ) 2 and the rest are selected from the group consisting of CH 2 It is.

[0390] In certain six-membered embodiments of formula (III), A 1 , A 2 , A 3 , and A 4 are CH 2 It is.

[0391] In certain six-membered embodiments of formula (III), A 1 , A 2 , and A 4 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 3 O; S; SO 2 ; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 1 CH 2 In some of these embodiments, A 3 is N(R a ) (e.g. A 3 In another embodiment, A can be NH. 3is O. In yet another embodiment, A 3 SO 2 It is.

[0392] In certain six-membered embodiments of formula (III), A 1 , A 2 , and A 3 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 4 is O; S; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 1 CH 2 In some of these embodiments, A 4 is N(R a ) (e.g. A 4 In another embodiment, A can be NH. 4 is O.

[0393] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 In certain of these embodiments, A is selected from the group consisting of 2 , A 3 , and A 4 One or two (e.g., one) of b and C(Rb ) 2 and the rest are selected from the group consisting of CH 2 It is.

[0394] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 , A 3 , and A 4 are CH 2 It is.

[0395] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 and A 4 are each independently 2 , C.H.R. b , and C(R b ) 2 A is selected from the group consisting of 3 O; S; SO 2 ; or N(R a In some of these embodiments, A 2 and A 4 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 4 Both are CH 2 In some of these embodiments, A 3 is N(R a ) (e.g. A 3 In another embodiment, A can be NH. 3 is O. In yet another embodiment, A 3 SO 2 It is.

[0396] In certain six-membered embodiments of formula (III), A 1 is C(O); A 2 and A 3 are each independently 2 , C.H.R.b , and C(R b ) 2 A is selected from the group consisting of 4 is O; S; or N(R a In some of these embodiments, A 2 and A 3 One or two (e.g., one) of b and C(R b ) 2 and the others (if applicable) are CH 2 In another embodiment, A 2 and A 3 Both are CH 2 In some of these embodiments, A 4 is N(R a ) (e.g. A 4 In another embodiment, A can be NH. 4 is O. In certain embodiments of the six-membered ring of formula (III), A 1 , A 2 , A 3 , and A 4 are each independently 2 , C.H.R. b , or C(R b ) 2 is selected from the group consisting of:

[0397]

[13] In some embodiments, The compound has the formula (IA-A), (IA-AA), or (IA-AB); Ring A is a saturated 5-membered monocyclic ring having the formula (III-A) (i.e., A in formula (III) 1 is a bond); L is represented by the formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -Having; W is represented by any one of formulas (X), (XII), (XIII), (XIV), (XIV-A), (XIV-B), or SEQ ID 1-27 (e.g., SEQ ID 5-27, e.g., SEQ ID 6); m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with and fused to phenyl; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are independently selected C 1~4 Alkyl (e.g. CH 3 ) or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g., phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10It is a cycloalkylene.

[0398] In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI):

[0399] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-. For example, L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 -It is possible.

[0400] In certain of these embodiments, any one of SEQ IDs 5-27 (eg, SEQ ID 6) represents W.

[0401] [13A] In some embodiments, The compound has the formula (IA-A), (IA-AA), or (IA-AB); Ring A is a saturated 5-membered monocyclic ring having the formula (III-A) (i.e., A in formula (III) 1 is a bond); L is represented by the formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH2 ) p -Having W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34 (e.g., SEQ. IDs 5-27; e.g., SEQ IDs 5-29; (e.g., SEQ ID 6); e.g., SEQ IDs 28-29; e.g., SEQ IDs 30-34).

[0402] In certain embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~6 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with and fused to phenyl; or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are independently selected C 1~4 Alkyl (e.g. CH 3 ) or m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2(v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g., phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 It is a cycloalkylene.

[0403] In certain embodiments, m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 is a heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, in which 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from the group consisting of 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with X 2 teeth TIFF2024156720000082.tif7128).

[0404] In certain embodiments, R 1 , R 2 , and R 4 One, two, or three of R 3 is -C(O)OH. In certain embodiments, a is 0, 1, or 2 (e.g., 1). In certain embodiments, R 5 has the formula (XI). In certain embodiments, R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 is -C(O)OH, and R 5 has the formula (XI). In certain embodiments, a' is 1; R 3a and R 3b are H, respectively.

[0405] In certain of these embodiments, m is 2 to 6 (e.g., 2), and X 1is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-. For example, L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 -It is possible.

[0406] In certain of these embodiments, any one of SEQ IDs 5-34 (eg, SEQ ID 6) represents W.

[0407] The embodiments of combinations [1]-

[13] may include any one or more of the features described in the detailed description and / or claims.

[0408] Embodiments of combinations [1A]-[13A] may include any one or more of the features described in the detailed description and / or claims.

[0409] Those skilled in the art will recognize that some of the chemical structures described herein may be represented on paper in one or more other resonance forms, or may exist dynamically in one or more other tautomeric forms, and that these tautomeric forms represent only a small portion of the sample of these compounds. Although these resonance forms or tautomers are not expressly represented herein, these compounds are contemplated as being within the scope of the present disclosure.

[0410] Pharmaceutical Compositions and Administration General In some embodiments, a chemical entity (e.g., a compound, or a pharma- ceutically acceptable salt and / or hydrate and / or prodrug of the compound) that modulates (e.g., stimulates or partially stimulates or antagonizes) the Glucagon-like peptide 1 receptor ("GLP-1R") and / or gastric inhibitory polypeptide receptor ("GIPR") is administered as a pharmaceutical composition comprising the chemical entity, one or more pharma- ceutically acceptable excipients, and, optionally, one or more additional therapeutic agents described herein.

[0411] In some embodiments, chemical entities can be administered in combination with one or more conventional pharmaceutical excipients. Pharmaceutically acceptable excipients include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, self-emulsifying drug delivery systems (SEDDS) such as d-α-tocopherol polyethylene glycol 1000 succinate, surfactants used in pharmaceutical dosage forms such as Tween, poloxamer, or other similar polymer delivery matrices, serum proteins such as human serum albumin, buffer substances such as phosphates, Tris, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, protamine sulfate, salts or electrolytes such as disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene block copolymers, and wool fat. Also, chemically modified derivatives such as cyclodextrins, such as α-, β-, and γ-cyclodextrin, or hydroxyalkyl cyclodextrins, including 2- and 3-hydroxypropyl-β-cyclodextrin, or other solubilizing derivatives, can be used to enhance delivery of the compounds described herein. Dosage forms or compositions can be prepared that contain the chemical entities described herein in the range of 0.005%-100%, with the remainder consisting of non-toxic excipients. Contemplated compositions can contain 0.001%-100%, in one embodiment 0.1-95%, in another embodiment 75-85%, and in a further embodiment 20-80% of the chemical entities provided herein. Actual methods for preparing these dosage forms will be known or apparent to those of skill in the art. For example, see Remington: The Science and Practice of Pharmacy, 22 nd Edition (Pharmaceutical Press, London, UK. 2012).

[0412] Route of Administration and Composition Components In some embodiments, the chemical entities described herein, or pharmaceutical compositions thereof, can be administered to a subject in need thereof by any acceptable route of administration, including buccal, dermal, intracervical, endosinusial, intratracheal, intraintestinal, epidural, intrainterstitial, intraperitoneal, intraarterial, intrabronchial, intravesical, intracerebral, intracisternal, intracoronary, intradermal, intraductal, intraduodenal, intradural, intraepidermal, intraesophageal, intragastric, intragingival, intraileal, intralymphatic, intramedullary, intrameningeal, intramuscular, intraovarian, intraperitoneal, intraprostatic, intrapulmonary, intraantral, intravenous ... These include, but are not limited to, intraasinal, intraspinal, intrasynovial, intratesticular, intrathecal, intraductal, intratumoral, intrauterine, intravascular, intravenous, intranasal, nasogastric, oral, parenteral, percutaneous, peridural, rectal, respiratory (inhalation), subcutaneous, sublingual, submucosal, topical, transdermal, transmucosal, transtracheal, ureteral, urethral, ​​and intravaginal. In certain embodiments, the preferred route of administration is parenteral (e.g., intratumoral).

[0413] Compositions can be formulated for parenteral administration, for example, for injection by intravenous, intramuscular, subcutaneous or even intraperitoneal route.Generally, these compositions can be prepared as injections, as liquid solutions or suspensions, and can also be prepared in solid form suitable for use in preparing liquid solutions or suspensions by adding liquid before injection; preparations can also be emulsified.In light of this disclosure, the preparation of these formulations will be clear to those skilled in the art.

[0414] The pharmaceutical forms suitable for injection include sterile aqueous solutions or dispersions; formulations containing sesame oil, peanut oil, or aqueous propylene glycol; and sterile powders for extemporaneous preparation of sterile injectable solutions or dispersions.Generally, the form must be sterile and fluid enough to be easily syringable.In addition, the form must be stable under the conditions of manufacture and storage, and must be preserved against the contaminating action of microorganisms such as bacteria and fungi.

[0415] The carrier can also be a solvent or dispersion medium, including, for example, water, ethanol, polyol (such as glycerin, propylene glycol, and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils. Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by maintaining the required particle size in the case of dispersions, and by the use of surfactants. Prevention of the action of microorganisms can be achieved by various antibacterial and antifungal agents, for example, parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases, it is preferable to include an isotonic agent, for example, sugar or sodium chloride. Prolonged absorption of the injectable composition can be achieved by the use of an absorption-delaying agent in the composition, for example, aluminum monostearate and gelatin.

[0416] Sterile injectable solution is prepared by incorporating the required amount of active compound in suitable solvent with various other components as listed above as necessary, and then sterilizing by filtration.Generally, dispersion is prepared by incorporating various sterilized active ingredients into a sterile vehicle that contains basic dispersion medium and other necessary components listed above.For the preparation of sterile injectable solution, the preferred preparation method is vacuum drying and freeze-drying technology, which makes the powder of active ingredient and any other desired ingredients from the solution that has already been sterilized and filtered.

[0417] Pharmacologically acceptable excipients that may be used in rectal compositions as gels, creams, enemas, or rectal suppositories include cocoa butter glycerides, synthetic polymers such as polyvinylpyrrolidone, PEG (as in PEG ointment), glycerin, glycerinated gelatin, hydrogenated vegetable oils, poloxamer, mixtures of polyethylene glycols of various molecular weights and polyethylene glycol fatty acid esters, petrolatum, anhydrous lanolin, shark liver oil, sodium saccharinate, menthol, sweet almond oil, sorbitol, sodium benzoate, anoxid These include, but are not limited to, one or more of SBN, vanilla essential oil, aerosol, parabens in phenoxyethanol, sodium methyl p-oxybenzoate, sodium propyl p-oxybenzoate, diethylamine, carbomer, Carbopol, methyl oxybenzoate, macrogol cetostearyl ether, cocoyl caprylocaprate, isopropyl alcohol, propylene glycol, liquid paraffin, xanthan gum, carboxy-metabisulfite, sodium edetate, sodium benzoate, potassium metabisulfite, grapefruit seed extract, methylsulfonylmethane (MSM), lactic acid, glycine, vitamins such as vitamins A and E, and potassium acetate.

[0418] In certain embodiments, suppositories can be prepared by mixing the chemical entities described herein with suitable non-irritating excipients or carriers, such as cocoa butter, polyethylene glycol, or a suppository wax, which are solid at ambient temperature but liquid at body temperature and thus melt in the rectum to release the active compound. In other embodiments, the composition for rectal administration is in the form of an enema.

[0419] In other embodiments, the compounds described herein, or pharmaceutical compositions thereof, are suitable for localized delivery to the digestive or gastrointestinal tract by oral administration (eg, in solid or liquid dosage form).

[0420] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In these solid dosage forms, the chemical entities are mixed with one or more pharma- ceutically acceptable excipients, such as sodium citrate or dicalcium phosphate, and / or a) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; b) binders, such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and gum arabic; c) humectants, such as glycerin; d) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate; e) solution retarding agents, such as paraffin; f) absorption accelerators, such as quaternary ammonium compounds; g) wetting agents, such as, for example, cetyl alcohol and glycerol monostearate; h) absorbents, such as kaolin clay and bentonite clay; and i) lubricants, such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and combinations thereof. In the case of capsules, tablets, and pills, the dosage form may also contain buffering agents. Solid compositions of a similar type may also be employed as fillers in soft- and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols.

[0421] In one embodiment, the composition takes the form of a unit dosage form such as a pill or tablet, and thus the composition may comprise, together with the chemical entities provided herein, a diluent such as lactose, sucrose, dicalcium phosphate; a lubricant such as magnesium stearate; and a binder such as starch, gum arabic, polyvinylpyrrolidine, gelatin, cellulose, cellulose derivatives. In another solid dosage form, a powder, marume, solution or suspension (e.g. in propylene carbonate, vegetable oil, PEG, poloxamer 124, or triglyceride) is enclosed in a capsule (gelatin or cellulose-based capsule). Unit dosage forms in which one or more chemical entities provided herein or additional active agents are physically separated are also envisaged, such as capsules with granules (or tablets in capsules) of each drug; bilayer tablets; bicompartment gel capsules, etc. Enteric-coated oral dosage forms or delayed release oral dosage forms are also envisaged.

[0422] Other physiologically acceptable compounds include wetting agents, emulsifying agents, dispersing agents, or preservatives that are particularly useful for preventing the growth or action of microorganisms. Various preservatives are well known and include, for example, phenol and ascorbic acid.

[0423] In certain embodiments, the excipients are sterile and generally free of undesirable materials. These compositions can be sterilized by conventional, well-known sterilization techniques. Sterility is not required for excipients of various oral dosage forms, such as tablets and capsules. USP / NF standards are usually sufficient.

[0424] Ophthalmic compositions may include, but are not limited to, any one or more of the following: viscogens (e.g., carboxymethylcellulose, glycerin, polyvinylpyrrolidone, polyethylene glycol); stabilizers (e.g., Pluronic (triblock copolymers), cyclodextrin); preservatives (e.g., benzalkonium chloride, ETDA, SofZia (boric acid, propylene glycol, sorbitol, and zinc chloride; Alcon Laboratories, Inc.), Purite (a stabilized oxychloro complex; Allergan, Inc.)).

[0425] Topical compositions can include ointments and creams. Ointments are semi-solid preparations that are usually based on petrolatum or other petroleum derivatives. Creams, which usually contain the active agent of choice, are liquid or semi-solid emulsions, often of the oil-in-water or water-in-oil type. Cream bases are usually washable with water and contain an oil phase, an emulsifier, and an aqueous phase. The oil phase, sometimes called the "internal" phase, is generally composed of petrolatum and a fatty alcohol such as cetyl or stearyl alcohol, and the aqueous phase usually, but not necessarily, exceeds the oil phase in terms of volume and generally contains a humectant. Generally, the emulsifier in a cream formulation is a non-ionic, anionic, cationic, or amphoteric surfactant. As with other carriers or vehicles, ointment bases should be inert, stable, non-irritating, and non-sensitizing.

[0426] In any of the above embodiments, the pharmaceutical compositions described herein may include one or more of the following: lipids, interbilayer cross-linked multilamellar vesicles, biodegradable poly(D,L-lactic-co-glycolic acid) [PLGA]-based or polyanhydride-based nanoparticles or microparticles, and nanoporous particle-supported lipid bilayers.

[0427] Dosage Dosage can vary according to the requirements of the patient, the severity of the condition being treated, and the specific compound being used.The appropriate dosage for a particular situation can be determined by those skilled in the medical field.In some cases, the total daily dosage can be divided and administered in several portions throughout the day, or administered by means of carrying out continuous delivery.

[0428] In some embodiments, the compounds described herein are administered at a concentration of from about 0.0002 mg / Kg to about 100 mg / Kg (e.g., from about 0.0002 mg / Kg to about 50 mg / Kg; from about 0.0002 mg / Kg to about 25 mg / Kg; from about 0.0002 mg / Kg to about 10 mg / Kg; from about 0.0002 mg / Kg to about 5 mg / Kg; from about 0.0002 mg / Kg to about 1 mg / Kg; from about 0.0002 mg / Kg to about 0.5 mg / Kg; from about 0.0002 mg / Kg to about 0.1 mg / Kg; from about 0.001 mg / Kg to about 50 mg / Kg; from about 0.001 mg / Kg to about 25 mg / Kg; from about 0.001 mg / Kg to about 10 mg / Kg; About 0.001mg / Kg~about 5mg / Kg; About 0.001mg / Kg~about 1mg / Kg; About 0.001mg / Kg~about 0.5mg / Kg; About 0.001mg / Kg~about 0.1mg / Kg; About 0.01mg / Kg~about 50mg / Kg; About 0.01mg / Kg~about 25mg / Kg; About 0.01mg / Kg~about 10mg / Kg; About 0.01mg / Kg~about 5mg / Kg; About 0.01mg / Kg~about 1mg / Kg; About 0.01mg / Kg~about 0.5mg / Kg; About 0.01mg / Kg~about 0.1mg / Kg; Approx. 0.1mg / Kg~Approx. 50mg / Kg; It is administered at a dosage of about 0.1 mg / Kg to about 25 mg / Kg; about 0.1 mg / Kg to about 10 mg / Kg; about 0.1 mg / Kg to about 5 mg / Kg; about 0.1 mg / Kg to about 1 mg / Kg; about 0.1 mg / Kg to about 0.5 mg / Kg).

[0429] Regimen The above dosages can be administered daily (e.g., as one or two or more divided doses) or non-daily (e.g., every other day, every second day, every third day, weekly, twice every few weeks, biweekly, monthly).

[0430] In some embodiments, the administration period of the compounds described herein is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In further embodiments, the period of time during which administration is suspended is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In one embodiment, the therapeutic compound is administered to the individual for one period of time, followed by another period of time. In another embodiment, the therapeutic compound is administered for a first period of time, and a second period of time following the first period of time, administration is suspended during the second period of time, followed by administration of the therapeutic compound for a third period of time, followed by administration being suspended for a fourth period of time following the third period of time. In one aspect of this embodiment, the period of administration of the therapeutic compound is repeated for a fixed or indefinite period of time, followed by a period of withdrawal.In a further embodiment, the period of administration is 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In further embodiments, administration is discontinued for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more.

[0431] Treatment The present disclosure features a method for treating a subject (e.g., a human) having a disease, disorder, or condition, where modulation of GLP-1R and / or GIPR activity (e.g., suppressed or impaired and / or elevated or undesired GLP-1R and / or GIPR signaling) is beneficial for treating the underlying pathology and / or symptoms and / or progression of the disease, disorder, or condition. In certain embodiments, the methods described herein may include, or may further include, treating one or more conditions that are associated, comorbid, or secondary to any one or more conditions described herein.

[0432] In certain embodiments, the chemical entities described herein induce hypoglycemia (e.g., reduce blood glucose levels), promote insulin synthesis, stimulate insulin secretion, increase beta cell mass, regulate gastric acid secretion, regulate gastric emptying, and / or reduce glucagon production. In certain embodiments, the chemical entities described herein stabilize serum glucose and serum insulin levels.

[0433] Indications obesity In some embodiments, the condition, disease, or disorder is obesity and obesity-related conditions, diseases, or disorders. Non-limiting examples of obesity and obesity-related conditions include symptomatic obesity, simple obesity, childhood obesity, morbid obesity, and abdominal obesity (central obesity characterized by abdominal fat accumulation). Non-limiting examples of symptomatic obesity include endocrine obesity (e.g., Cushing's syndrome, hypothyroidism, insulinoma, obesity type II diabetes, pseudohypoparathyroidism, hypogonadism), hypothalamic obesity, genetic obesity (e.g., Prader-Willi syndrome, Laurence-Moon-Biedl syndrome), and drug-induced obesity (e.g., steroid-induced obesity, phenothiazine-induced obesity, insulin-induced obesity, sulfonylurea-induced obesity, or beta-blocker-induced obesity).

[0434] In some embodiments, the condition, disease, or disorder is associated with obesity. Examples of these conditions, diseases, or disorders include, but are not limited to, impaired glucose tolerance, diabetes (e.g., type 2 diabetes, obese diabetes), dyslipidemia, hyperlipidemia, hypertension, heart failure, hyperuricemia, gout, fatty liver (including non-alcoholic steatohepatitis (NASH)), coronary heart disease (e.g., myocardial infarction, angina pectoris), cerebral infarction (e.g., cerebral thrombosis, transient ischemic attack), bone or joint disease (e.g., osteoarthritis of the knee, osteoarthritis of the hip, osteospondylitis, lower back pain), sleep apnea syndrome, obesity hypoventilation syndrome (Pickwickian syndrome), menstrual disorders (e.g., menstrual cycle abnormalities, menstrual flow-menstrual cycle abnormalities, amenorrhea, abnormal paramenstrual symptoms), visceral obesity syndrome, and metabolic syndrome. In certain embodiments, the chemical entities described herein can be used to treat subjects who exhibit symptoms of both obesity and insulin deficiency.

[0435] diabetes In some embodiments, the condition, disease, or disorder is diabetes. Non-limiting examples of diabetes include type 1 diabetes, type 2 diabetes (e.g., diet-treated type 2 diabetes, sulfonylurea-treated type 2 diabetes, extreme type 2 diabetes, long-term insulin-treated type 2 diabetes), diabetes mellitus (e.g., non-insulin-dependent diabetes mellitus, insulin-dependent diabetes mellitus), gestational diabetes, obesity diabetes, autoimmune diabetes, and borderline diabetes.

[0436] In some embodiments, the condition, disease or disorder is associated with diabetes (e.g., diabetic complications).Non-limiting examples of disorders associated with diabetes include obesity, obesity-related disorders, metabolic syndrome, neuropathy, nephropathy (e.g., diabetic nephropathy), retinopathy, diabetic cardiomyopathy, cataract, macroangiopathy, osteopenia, hyperosmolar diabetic coma, infectious diseases (e.g., respiratory infection, urinary tract infection, gastrointestinal infection, skin and soft tissue infection, lower limb infection), diabetic gangrene, dry mouth, hearing loss, cerebrovascular disease, diabetic cachexia, delayed wound healing, diabetic dyslipidemia, peripheral circulatory disorder, cardiovascular risk factors (e.g., coronary artery disease, peripheral artery disease, cerebrovascular disease, hypertension, and risk factors related to uncontrolled cholesterol and / or lipid levels and / or inflammation), NASH, fracture, and cognitive impairment.

[0437] Other non-limiting examples of disorders related to diabetes include prediabetes, hyperlipidemia (e.g., hypertriglyceridemia, hypercholesterolemia, hyper-LDL cholesterolemia, hypo-HDL cholesterolemia, postprandial hyperlipidemia), metabolic syndrome (e.g., a metabolic disorder in which activation of GLP-1R is beneficial, metabolic syndrome X), hypertension, impaired glucose tolerance (IGT), insulin resistance, and sarcopenia.

[0438] In some embodiments, the condition, disease, or disorder is diabetes and obesity (diabesity). In certain embodiments, the compounds described herein are also useful in improving the therapeutic effectiveness of metformin.

[0439] Damage to metabolically important tissues In some embodiments, the condition, disease, or disorder is a disorder of a metabolically significant tissue.

[0440] In some embodiments, the condition, disease, or disorder is fatty liver disease, including but not limited to non-alcoholic fatty liver disease (NAFLD), steatohepatitis, non-alcoholic steatohepatitis (NASH), fatty liver disease caused by hepatitis, fatty liver disease caused by obesity, fatty liver disease caused by diabetes, fatty liver disease caused by insulin resistance, fatty liver disease caused by hypertriglyceridemia, abetalipoproteinemia, glycogen storage disease, Weber-Christian disease, Wolman disease, acute fatty liver of pregnancy, and lipodystrophy.

[0441] Nonalcoholic fatty liver disease (NAFLD) is a group of diseases that occur in the absence of alcohol abuse and is usually characterized by the presence of fatty liver (fat in the liver). NAFLD is thought to be associated with various conditions, such as metabolic syndrome (including obesity, diabetes, and hypertriglyceridemia) and insulin resistance. It can cause liver disease in adults and children, eventually resulting in cirrhosis (Skelly et al., J Hepatol 2001; 35: 195-9; Chitturi et al., Hepatology 2002; 35(2):373-9). The severity of NAFLD ranges from a relatively benign, predominantly macrovesicular focal fatty liver (i.e., nonalcoholic fatty liver or NAFL) to nonalcoholic steatohepatitis (NASH) (Angulo et al., J Gastroenterol Hepatol 2002; 17 Suppl:S186-90). In certain embodiments, the subject is a pediatric subject (e.g., between 6 and 16 years old; or between 6 and 12 years old; or between 6 and 10 years old). In certain embodiments, the subject is an adult subject.

[0442] Other non-limiting examples of disorders in metabolically important tissues include joint disorders (e.g. osteoarthritis, secondary osteoarthritis), steatosis (e.g. in the liver); gallstones; gallbladder disorders; gastroesophageal reflux disease; sleep apnea; hepatitis; fatty liver; bone disorders characterized by alterations in bone metabolism, such as osteoporosis, including postmenopausal osteoporosis, reduced bone strength, osteopenia, Paget's disease, osteolytic metastases in cancer patients, osteodystrophy in liver disease, and alterations in bone metabolism caused by renal failure or hemodialysis, fractures, bone surgery, aging, pregnancy, protection against fractures, and malnutrition; polycystic ovary syndrome; renal disease (e.g. chronic renal failure, glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, end stage renal disease); These include muscular dystrophies, angina, acute or chronic diarrhea, testicular dysfunction, respiratory dysfunction, frailty, sexual dysfunction (e.g., erectile dysfunction), and geriatric syndromes. In certain embodiments, the chemical entities described herein can be used to treat surgical trauma by improving post-operative recovery and / or preventing the catabolic response caused by surgical trauma.

[0443] cardiovascular disease In some embodiments, the condition, disease, or disorder is a cardiovascular disease. Non-limiting examples of cardiovascular disease include congestive heart failure, atherosclerosis, arteriosclerosis, coronary heart disease or peripheral artery disease, stroke, coronary artery disease, congestive heart failure, coronary heart disease, hypertension, heart failure, cerebrovascular disease (e.g., cerebral infarction), vascular dysfunction, myocardial infarction, hypertension (e.g., 130 / 85 mmHg or higher), and prothrombotic conditions (indicated by high blood levels of fibrinogen or plasminogen activator inhibitor).

[0444] Neurological disorders In some embodiments, the condition, disease, or disorder is a neurological disorder (e.g., a neurodegenerative disorder) or a psychiatric disorder. Non-limiting examples of neurological disorders include brain insulin resistance, mild cognitive impairment (MCI), Alzheimer's disease (AD), Parkinson's disease (PD), anxiety, dementia (e.g., senile dementia), brain trauma, Huntington's chorea, tardive dyskinesia, hyperkinesia, mania, Morbus Parkinson, Steele-Richard syndrome, Down's syndrome, myasthenia gravis, neurotrauma, brain trauma, vascular amyloidosis, cerebral hemorrhage with amyloidosis, encephalitis, Friedreich's ataxia, acute confusion disorder, amyotrophic lateral sclerosis (ALS), glaucoma, and apoptosis-mediated degenerative diseases of the central nervous system (e.g., Creutzfeldt-Jakob disease, bovine spongiform encephalopathy (mad cow disease), chronic wasting syndrome). See, e.g., US20060275288A1.

[0445] Non-limiting examples of psychiatric disorders include drug dependence / addiction (narcotics and amphetamines) and attention deficit hyperactivity disorder (ADHD).The chemical entities described herein can be useful for improving behavioral responses to addictive drugs, reducing drug dependence, preventing relapse to drug abuse, and reducing the anxiety caused in the absence of a given addictive substance.See, for example, US20120021979A1.

[0446] In certain aspects, the chemical entities described herein are useful in improving learning and memory by enhancing neuroplasticity and promoting cell differentiation, and in preserving dopamine neurons and motor function in Parkinson's disease.

[0447] Insulin-related In some embodiments, the condition, disease, or disorder is impaired fasting glucose (IFG), fasting hyperglycemia (IFG), hyperglycemia, insulin resistance (impaired glucose homeostasis), hyperinsulinemia, high blood levels of fatty acids or glycerol, hypoglycemic states, insulin resistance syndrome, paresthesia caused by hyperinsulinemia, hyperlipidemia, hypercholesterolemia, poor wound healing, leptin resistance, impaired glucose tolerance, elevated fasting glucose, dyslipidemia (e.g., atherogenic dyslipidemia characterized by hyperlipidemia, high triglyceride levels, and low HDL cholesterol levels), glucagonoma, hyperuricemia, hypoglycemia (e.g., nocturnal hypoglycemia), and insulin-related coma endpoints.

[0448] In certain aspects, the chemical entities described herein can reduce or slow the progression of borderline, impaired fasting glucose, or hyperfasting glucose to diabetes.

[0449] Autoimmune disorders In some embodiments, the condition, disease or disorder is an autoimmune disorder.Non-limiting examples of autoimmune disorders include multiple sclerosis, experimental autoimmune encephalomyelitis, autoimmune disorders associated with immune rejection, graft-versus-host disease, uveitis, optic neuropathy, optic neuritis, transverse myelitis, inflammatory bowel disease, rheumatoid arthritis, ankylosing spondylitis, systemic lupus erythematosus, myasthenia gravis and Graves' disease.See, for example, US20120148586A1.

[0450] Stomach and intestinal disorders In some embodiments, the condition, disease, or disorder is a stomach or intestinal-related disorder. Non-limiting examples of these disorders include ulcers of any etiology (e.g., peptic ulcers, Zollinger-Ellison syndrome, drug-induced ulcers, ulcers associated with infections or other pathogens), digestive disorders, malabsorption, short bowel syndrome, blind tract syndrome, inflammatory bowel disease (Crohn's disease and ulcerative colitis), celiac disease, hypogammaglobulinemia, chemotherapy- and / or radiotherapy-induced mucositis and diarrhea, gastroenteritis, short bowel syndrome, ulcerative colitis (colitis ulcerosa), gastric mucosal injury (e.g., gastric mucosal injury caused by aspirin), small intestinal mucosal injury, and cachexia (e.g., cancer cachexia, tuberculosis cachexia, cachexia associated with blood disorders, cachexia associated with endocrine disorders, cachexia associated with infectious diseases, cachexia caused by acquired immune deficiency syndrome).

[0451] body weight In some embodiments, the chemical entities described herein can be used to reduce weight (e.g., excess weight), prevent weight gain, induce weight loss, reduce body fat, or reduce food intake in a subject (e.g., a subject in need thereof). In certain embodiments, the weight gain in a subject can be due to excessive or poor food intake, or can be due to concomitant medication (e.g., insulin sensitizers that exhibit PPARγ agonist-like effects, such as troglitazone, rosiglitazone, englitazone, ciglitazone, pioglitazone, etc.). Alternatively, the weight gain can be prior to reaching obesity, or in an obese subject. The weight gain can be drug-induced weight gain, or can be weight gain after smoking cessation.

[0452] In some embodiments, the condition, disease, or disorder is an eating disorder, such as bulimia, binge eating, binge eating, or compulsive eating.

[0453] inflammatory diseases In some embodiments, the condition, disease or disorder is inflammatory disorder.Non-limiting examples of inflammatory disorder include rheumatoid arthritis, spondylitis degenerativeis, osteoarthritis, back pain, gout, postoperative or post-traumatic inflammation, abdominal distension, neuralgia, pharyngitis, cystitis, pneumonia, pancreatitis, enteritis, inflammatory bowel disease (including inflammatory bowel disease), inflammation in metabolically important tissues including liver, fat, pancreas, kidney and intestine, and proinflammatory condition (for example, high blood levels of inflammatory cytokines or inflammatory-like C-reactive protein markers).

[0454] cancer In some embodiments, the condition, disease, or disorder is cancer. Suitable examples of cancer include breast cancer (e.g., invasive ductal carcinoma, ductal carcinoma in situ, inflammatory breast cancer), prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer, pancreatic cancer (e.g., pancreatic ductal carcinoma), gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma), lung cancer (e.g., non-small cell lung cancer, small cell lung carcinoma, malignant mesothelioma), colon cancer (e.g., gastrointestinal stromal tumor), rectal cancer (e.g., gastrointestinal stromal tumor), and the like. stromal tumors), colorectal cancer (e.g. familial colorectal cancer, hereditary nonpolyposis colorectal cancer, gastrointestinal stromal tumors), small intestine cancer (e.g. non-Hodgkin's lymphoma, gastrointestinal stromal tumors), esophageal cancer, duodenal cancer, tongue cancer, pharyngeal cancer (e.g. nasopharyngeal cancer, oropharyngeal cancer, hypopharyngeal cancer), salivary gland cancer, brain tumors (e.g. pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma), neurilemmoma, liver cancer (e.g. primary liver cancer, extrahepatic bile duct cancer), kidney cancer (e.g. renal cell carcinoma, renal pelvis / ureter transitional cell carcinoma), bile duct cancer, endometrial cancer, cervical cancer, ovarian cancer (e.g. ovarian epithelial cancer, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian low malignant potential tumor), bladder cancer, urethral cancer, skin cancer (e.g. intraocular (intraocular) melanoma, Merkel cell carcinoma), hemangioma, malignant lymphoma, malignant melanoma, thyroid cancer (e.g. medullary thyroid cancer), parathyroid These include cancer, nasal cancer, paranasal sinus cancer, bone tumors (e.g., osteosarcoma, Ewing's sarcoma, uterine sarcoma, soft tissue sarcoma), angiofibroma, retinal sarcoma, penile cancer, testicular tumor, childhood solid tumors (e.g., Wilms' tumor, childhood kidney tumor), Kaposi's sarcoma, Kaposi's sarcoma caused by AIDS, maxillary trunk tumor, fibrous histiocytoma, leiomyosarcoma, rhabdomyosarcoma, and leukemia (e.g., acute myeloid leukemia, acute lymphocytic leukemia).

[0455] Combination therapy The present disclosure contemplates both monotherapy and combination therapy regimens.

[0456] In some embodiments, the methods described herein may further include administering one or more additional therapies (e.g., one or more additional therapeutic agents and / or one or more therapeutic regimens) in combination with the administration of the compounds described herein.

[0457] In some embodiments, the methods described herein include administering a compound described herein in combination with one or more of a dietary regimen (e.g., a diabetic diet), an exercise regimen, blood glucose monitoring, and dietary modification.

[0458] In some embodiments, the compounds described herein can be administered in combination with one or more additional therapeutic agents.

[0459] Representative additional therapeutic agents include, but are not limited to, anti-obesity agents, therapeutic agents for diabetes, therapeutic agents for diabetic complications, therapeutic agents for hyperlipidemia, antihypertensive agents, diuretics, chemotherapy agents, immunotherapy agents, anti-inflammatory agents, antithrombotic agents, antioxidants, therapeutic agents for osteoporosis, vitamins, anti-dementia agents, drugs for erectile dysfunction, therapeutic agents for frequent urination or urinary incontinence, therapeutic agents for NAFLD, and therapeutic agents for dysuria.

[0460] In some embodiments, the one or more additional therapeutic agents include, for example, therapeutic agents useful as anti-obesity agents. Non-limiting examples include: Monoamine uptake inhibitors (e.g. tramadol, phentermine, sibutramine, mazindol, fluoxetine, tesofensine); Serotonin 2C receptor agonists (e.g. lorcaserin); Serotonin 6 receptor antagonists; Histamine H3 receptor modulators; · GABA modulators (e.g. topiramate), including GABA receptor agonists (e.g. gabapentin, pregabalin); · Neuropeptide Y antagonists (e.g. berneperit); Cannabinoid receptor antagonists (e.g. rimonabant, taranabant); Ghrelin antagonists; · Ghrelin receptor antagonists; ·Ghrelin acylation enzyme inhibitors; · Opioid receptor antagonists (e.g. GSK-1521498); ·Orexin receptor antagonists; Melanocortin 4 receptor agonists; · 11β-hydroxysteroid dehydrogenase inhibitors (e.g. AZD-4017, BVT-3498, INCB-13739); Pancreatic lipase inhibitors (e.g. orlistat, cetilistat); ·β3 agonists (e.g. N-5984); ·Diacylglycerol acyltransferase 1 (DGAT1) inhibitors; ·Acetyl CoA carboxylase (ACC) inhibitors; ·Stearoyl CoA desaturase inhibitors; · Microsomal triglyceride transfer protein inhibitors (e.g. R-256918); Sodium-glucose cotransporter type 2 (SGLT-2) inhibitors (e.g. JNJ-28431754, dapagliflozin, AVE2268, TS-033, YM543, TA-7284, ASP1941, remogliflozin); ·NFK inhibitors (e.g. HE-3286); · PPAR agonists (e.g., GFT-505, DRF-11605, gemfibrozil, and fenofibrate); Phosphotyrosine phosphatase inhibitors (e.g. sodium vanadate, trodusquemin); · GPR119 agonists (e.g. PSN-821, MBX-2982, APD597); glucokinase activators (e.g. piragliatin, AZD-1656, AZD6370, TTP-355, compounds described in W0006 / 112549, W0007 / 028135, W0008 / 047821, W0008 / 050821, W0008 / 136428, and W0008 / 156757); Leptin, leptin derivatives (e.g. metreleptin), leptin sensitizers; ·CNTF (Ciliary Neurotrophic Factor); ·BDNF (Brain-derived neurotrophic factor); Cholecystokinin agonists, amylin preparations (e.g. pramlintide, AC-2307); Neuropeptide Y agonists (e.g. PYY3-36, PYY3-36 derivatives, obineptide, TM-30339, TM-30335); · Oxyntomodulin (OXM) preparations; · Appetite suppressants (e.g. ephedrine); FGF21 preparations (e.g. animal FGF21 preparations extracted from bovine or porcine pancreas; human FGF21 preparations genetically synthesized using E. coli or yeast; fragments or derivatives of FGF21); and Anorexics (e.g. P-57).

[0461] In some embodiments, the one or more additional therapeutic agents include therapeutic agents useful, for example, as antidiabetic agents. Non-limiting examples include: Insulin and insulin preparations (e.g. animal insulin preparations extracted from bovine or porcine pancreas; genetically synthesized human insulin preparations using E. coli or yeast; zinc insulin; protamine zinc insulin; insulin fragments or derivatives (e.g. INS-1), oral insulin preparations, synthetic human insulin); Insulin sensitizers (e.g. pioglitazone or its salts); Biguanides (e.g. metformin, buformin, or their salts (e.g. hydrochloride, fumarate, succinate)); a glucagon analogue (e.g., any of the glucagon analogues described, for example, in WO 2010 / 011439); Agents that antagonize the action of glucagon or decrease glucagon secretion; Sulfonylureas (e.g. chlorpropamide, tolazamide, gliclazide, glimepiride, tolbutamide, glibenclamide, gliclazide, acetohexamide, glyclopyramide, glybuzole, glyburide); Thiazolidinedione drugs (e.g. rosiglitazone or pioglitazone); · α-glucosidase inhibitors (e.g. voglibose, acarbose, miglitol, emiglitate); · insulin secretagogues, e.g. postprandial glucose regulators (sometimes called "short-acting secretagogues"), e.g. meglitinides (e.g. repaglinide and nateglinide); · Cholinesterase inhibitors (e.g. donepezil, galantamine, rivastigmine, tacrine); ·NMDA receptor antagonists; · Dual GLP-1 / GIP receptor agonists (e.g. LBT-2000, ZPD1-70); GLP-1R agonists (e.g., exenatide, liraglutide, albiglutide, dulaglutide, AVE-0010, S4P, and Boc5); and Dipeptidyl peptidase IV (DPP-4) inhibitors (e.g. vildagliptin, dutogliptin, gemigliptin, alogliptin, saxagliptin, sitagliptin, linagliptin, berberine, alogliptin, BI1356, GRC8200, MP-513, PF-00734200, PHX1149, SK-0403, ALS2-0426, TA-6666, TS-021, KRP-104, trelagliptin).

[0462] In some embodiments, the one or more additional therapeutic agents include, for example, therapeutic agents useful for treating NAFL and NASH.Non-limiting examples include glycyrrhizin, schizophrenia extract, ascorbic acid, glutathione, silymarin, lipoic acid, and d-α-tocopherol, ascorbic acid, glutathione, vitamin B complex, glitazone / thiazolidinedione (e.g., troglitazone, rosiglitazone, pioglitazone), metformin, cysteamine, sulfonylurea, α-glucosidase inhibitor, meglitinide, vitamin E, tetrahydrolipstatin, milk thistle protein, antiviral agent, and antioxidant.

[0463] In some embodiments, the one or more additional therapeutic agents include, for example, therapeutic agents useful for treating diabetic complications. Non-limiting examples include: Aldose reductase inhibitors (e.g. tolrestat, epalrestat, zopolrestat, fidarestat, CT-112, ranirestat, lidorestat); Neurotrophic factors and their enhancers (e.g., NGF, NT-3, BDNF, neurotrophic factor production / secretion promoters described in WO01 / 14372 (e.g., 4-(4-chlorophenyl)-2-(2-methyl-1-imidazolyl)-5-[3-(2-methylphenoxyl)propyl]oxazole), compounds described in WO2004 / 039365); ·PKC inhibitors (e.g. ruboxistaurin mesylate); ·AGE inhibitors (e.g. ALT946, N-phenacylthiazolium bromide (ALT766), EXO-226, pyridorin, pyridoxamine); Serotonin and noradrenaline reuptake inhibitors (e.g. duloxetine); Sodium channel inhibitors (e.g. lacosamide); · Reactive oxygen scavengers (e.g. thioctic acid); · Cerebral vasodilators (e.g. tiapride, mexiletine); Somatostatin receptor agonists (e.g. BIM23190); and ·Apoptosis signal-regulating kinase 1 (ASK-1) inhibitor.

[0464] In some embodiments, the one or more additional therapeutic agents include, for example, a therapeutic agent useful for treating hyperlipidemia. Non-limiting examples include: HMG-COA reductase inhibitors (e.g. pravastatin, simvastatin, lovastatin, atorvastatin, fluvastatin, rosuvastatin, pitavastatin, or a salt thereof (e.g. sodium or calcium salt)); squalene synthase inhibitors (e.g. compounds described in WO 97 / 10224, e.g. N-[[(3R,5S)-1-(3-acetoxy-2,2-dimethylpropyl)-7-chloro-5-(2,3-dimethoxyphenyl)-2-oxo-1,2,3,5-tetrahydro-4,1-benzoxazepin-3-yl]acetyl]piperidine-4-acetic acid); Fibrate compounds (e.g. bezafibrate, clofibrate, simfibrate, clinofibrate); · Anion exchange resins (e.g. cholestyramine); Nicotinic acid drugs (e.g. Nicomol, Niceritrol, Niaspan); Phytosterols (e.g. soy sterols, gamma oryzanol (γ-oryzanol)); Cholesterol absorption inhibitors (e.g. Zechia); CETP inhibitors (e.g. dalcetrapib, anacetrapib); and · Omega-3 fatty acid preparations (e.g. Omega-3 fatty acid ethyl esters 90).

[0465] In some embodiments, the one or more additional therapeutic agents include a therapeutic agent useful, for example, as an antihypertensive agent. Non-limiting examples include: · Angiotensin-converting enzyme inhibitors (e.g. captopril, enalapril, delapril); · Angiotensin II antagonists (e.g. candesartan cilexetil, candesartan, losartan, losartan potassium, eprosartan, valsartan, telmisartan, irbesartan, tasosartan, olmesartan, olmesartan medoxomil, azilsartan, azilsartan medoxomil); Calcium antagonists (e.g. manidipine, nifedipine, amlodipine, efonidipine, nicardipine, cilnidipine); and Beta-blockers (e.g. metoprolol, atenolol, propranolol, carvedilol, pindolol).

[0466] In some embodiments, the one or more additional therapeutic agents include a therapeutic agent useful, for example, as a diuretic. Non-limiting examples include: Xanthine derivatives (e.g. sodium theobromine salicylate, calcium theobromine salicylate); Thiazide preparations (e.g. ethiazide, cyclopenthiazide, trichloromethiazide, hydrochlorothiazide, hydroflumethiazide, benzylhydrochlorothiazide, penflutizide, polythiazide, methyclothiazide); · Antialdosterone agents (e.g. spironolactone, triamterene); Carbonic anhydrase inhibitors (e.g. acetazolamide); and Chlorobenzenesulfonamides (e.g. chlorthalidone, mefruside, indapamide).

[0467] In some embodiments, the one or more additional therapeutic agents include therapeutic agents useful as, for example, immunotherapeutics. Non-limiting examples include: microbial or bacterial compounds (e.g., muramyl dipeptide derivatives, picibanil); polysaccharides exhibiting immune enhancing activity (e.g., lentinan, schizofiran, krestin); cytokines obtained by genetic engineering approaches (e.g., interferons, interleukins (IL), e.g., IL-1, IL-2, IL-12); and colony stimulating factors (e.g., granulocyte colony stimulating factor, erythropoietin).

[0468] In some embodiments, the one or more additional therapeutic agents include therapeutic agents useful as, for example, antithrombotic agents.Non-limiting examples include: heparin (e.g., heparin sodium, heparin calcium, enoxaparin sodium, dalteparin sodium); warfarin (e.g., warfarin potassium); antithrombin drugs (e.g., argatroban, dabigatran); FXa inhibitors (e.g., rivaroxaban, apixaban, edoxaban, YM150, compounds described in WO02 / 06234, WO2004 / 048363, WO2005 / 030740, WO2005 / 058823, and WO2005 / 113504); thrombolytic agents (e.g., urokinase, tisokinase, alteplase, nateplase, monteplase, pamiteplase); and platelet aggregation inhibitors (eg, ticlopidine hydrochloride, clopidogrel, prasugrel, E5555, SHC530348, cilostazol, ethyl icosapentate, beraprost sodium, sarpogrelate hydrochloride).

[0469] In some embodiments, the one or more additional therapeutic agents include, for example, therapeutic agents useful for treating osteoporosis. Non-limiting examples include: alphacalcidol, calcitriol, elcatonin, salmon calcitonin, estriol, ipriflavone, pamidronate disodium, alendronate sodium hydrate, incadronate disodium, and risedronate disodium. Suitable examples of vitamins include vitamin B1 and vitamin B12. Suitable examples of erectile dysfunction drugs include apomorphine and sildenafil citrate. Suitable examples of urinary frequency or urinary incontinence therapeutic agents include flavoxate hydrochloride, oxybutynin hydrochloride, and propiverine hydrochloride. Suitable examples of urinary disorder therapeutic agents include acetylcholinesterase inhibitors (e.g., distigmine). Suitable examples of anti-inflammatory agents include nonsteroidal anti-inflammatory drugs, such as aspirin, acetaminophen, and indomethacin.

[0470] Other additional therapeutic agents include: · Agents that regulate hepatic glucose balance (e.g. fructose-1,6-bisphosphatase inhibitors, glycogen phosphorylase inhibitors, glycogen synthase kinase inhibitors, glucokinase activators); Agents designed to treat the complications of long-term hyperglycemia, such as aldose reductase inhibitors (e.g. epalrestat and ranirestat); Agents used to treat complications associated with microangiopathy; · Anti-dyslipidemic agents, e.g. HMG-CoA reductase inhibitors (statins, e.g. rosuvastatin); Cholesterol-lowering agents; Bile acid sequestrants (e.g. cholestyramine); · Cholesterol absorption inhibitors (e.g. plant sterols such as phytosterols); ·Cholesteryl ester transfer protein (CETP) inhibitors; ·Ileal bile acid transporter inhibitors (IBAT inhibitors); ·Bile acid binding resin; Nicotinic acid (niacin) and its analogues; Antioxidants, e.g. probucol; ·ω3 fatty acids; · Antihypertensive agents, including adrenergic receptor antagonists such as beta-blockers (e.g. atenolol), alpha-blockers (e.g. doxazosin), and mixed alpha / beta-blockers (e.g. labetalol); · Adrenergic receptor agonists, including alpha-2 agonists (e.g. clonidine); · Angiotensin-converting enzyme (ACE) inhibitors (e.g. lisinopril); ·Calcium channel blockers, such as dihydropyridines (e.g. nifedipine), phenylalkylamines (e.g. verapamil), and benzothiazepines (e.g. diltiazem); · Angiotensin II receptor antagonists (e.g. candesartan); · Aldosterone receptor antagonists (e.g. eplerenone); · Central adrenergic agents, such as central alpha agonists (e.g. clonidine); ·Diuretics (e.g. furosemide); · Hemostatic modulating agents, including antithrombotic agents (e.g., fibrinolytic activators), thrombin antagonists, factor VIIa inhibitors, anticoagulants (e.g., vitamin K antagonists such as warfarin), heparin and its low molecular weight analogues, factor Xa inhibitors, and direct thrombin inhibitors (e.g., argatroban); · Antiplatelet agents (e.g. cyclooxygenase inhibitors (e.g. aspirin)); Adenosine diphosphate (ADP) receptor inhibitors (e.g. clopidogrel); Phosphodiesterase inhibitors (e.g. cilostazol); Glycoprotein IIB / IIA inhibitors (e.g. tirofiban); Adenosine reuptake inhibitors (e.g. dipyridamole); ·Noradrenergic drugs (e.g. phentermine); · Serotonergic drugs (e.g. sibutramine); ·Diacylglycerol acyltransferase (DGAT) inhibitors; Feeding behavior regulators; · Pyruvate dehydrogenase kinase (PDK) regulators; Serotonin receptor modulators; · Monoamine transport modulators, such as selective serotonin reuptake inhibitors (SSRIs) (e.g. fluoxetine), noradrenaline reuptake inhibitors (NARIs), noradrenaline-serotonin reuptake inhibitors (SNRIs) and monoamine oxidase inhibitors (MAOIs) (e.g. toloxatone and amifluramine); - compounds described in WO007 / 013694, WO2007 / 018314, WO2008 / 093639 and WO2008 / 099794; GPR40 agonists (e.g. fasiglifam or its hydrates, compounds described in WO2004 / 041266, WO2004 / 106276, WO2005 / 063729, WO2005 / 063725, WO2005 / 087710, WO2005 / 095338, WO2007 / 013689 and WO2008 / 001931); SGLT1 inhibitors; Adiponectin or its agonists; ·IKK inhibitors (e.g. AS-2868); Somatostatin receptor agonists; ACC2 inhibitors; cachexia-ameliorating drugs, such as cyclooxygenase inhibitors (e.g. indomethacin), progesterone derivatives (e.g. megestrol acetate), glucocorticoids (e.g. dexamethasone), metoclopramide drugs, tetrahydrocannabinol drugs, drugs for improving fat metabolism (e.g. eicosapentaenoic acid), growth hormone, IGF-1, antibodies against cachexia-inducing factors TNF-α, LIF, IL-6, and oncostatin M; · metabolic regulatory proteins or peptides, such as glucokinase (GK), glucokinase regulatory protein (GKRP), uncoupling proteins 2 and 3 (UCP2 and UCP3), peroxisome proliferator-activated receptor α (PPARα); ·MC4r agonists; Insulin receptor agonists; PDE 5 inhibitors; Glycation inhibitors (e.g. ALT-711); Neuroregeneration promoters (e.g. Y-128, VX853, Prosaptide); Antidepressants (e.g. desipramine, amitriptyline, imipramine); Antiepileptic drugs (e.g. lamotrigine, trileptal, keppra, zonegran, pregabalin, harkoseride, carbamazepine); Antiarrhythmic drugs (e.g. mexiletine); · Acetylcholine receptor ligands (e.g. ABT-594); · Endothelin receptor antagonists (e.g. ABT-627); Narcotic painkillers (e.g. morphine); · alpha2 receptor agonists (e.g. clonidine); ·Topical analgesics (e.g. capsaicin); Anti-anxiety drugs (e.g. benzothiazepines); Phosphodiesterase inhibitors (e.g. sildenafil); Dopamine receptor agonists (e.g. apomorphine); · Cytotoxic antibodies (e.g. T cell receptor and IL-2 receptor specific antibodies); · B cell depleting therapeutics (e.g. anti-CD20 antibodies (e.g. Rituxan), i-BLyS antibodies); Drugs that affect T cell migration (e.g. anti-integrin α4 / β1 antibodies (e.g. Tysabri); Drugs acting on immunophilins (e.g. cyclosporine, tacrolimus, sirolimus, rapamycin); ·Interferons (e.g. IFN-β); Immunomodulators (e.g. glatiramer); ·TNF-binding pro...

Claims

1. A compound having the formula (IAA), or a pharma- ceutically acceptable salt thereof: During the ceremony, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where ・G is C(O), S(O), or SO 2 and; ・G and N * and the circular dotted line connecting them is a divalent radical containing 1 to 6 ring atoms; (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and are each independently C, CH, or CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, or CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, in which 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, in which 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d heterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 2' is as defined by (AA) or (BB) below: (AA) R 2' teeth where: R 3 -C(O)OH, -C(O)OR 31 , -CH(C(O)OH) 2 or a carboxylic acid isostere (e.g., amide or tetrazolyl); a is 0 to 5; a' is 0 or 1; R 3a and R 3b are each independently H or C 1~3 is alkyl; (BB) R 2' and R 4 together with the atoms connecting them form a ring containing 5 to 8 ring atoms, where 3 to 7 are H, halo, hydroxy, oxo, and C 1~3 each ring carbon atom is substituted with 1 to 2 substituents independently selected from alkyl; 0 to 1 are O, -NH, -N(C 1~3 (R alkyl), and S 1 (e.g., R 4 and R 3 form, together with the atom to which each is attached, a ring containing 5 to 8 ring atoms); R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 where W' is a sequence of 5 to 60 amino acids and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from acyl groups and PEG groups); However, one or more of the compound definitions detailed herein apply.

2. 2. The compound of claim 1 having the formula (IA), or a pharma- ceutically acceptable salt thereof: During the ceremony, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where ・G is C(O), S(O), or SO 2 and; ・G and N * and the circular dotted line connecting them is a divalent radical containing 1 to 6 ring atoms; (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and are each independently C, CH, or CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, and CR. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, in which 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, in which 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t -, where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d heterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 3 -C(O)OH, -C(O)OR 31 , -CH(C(O)OH) 2 or a carboxylic acid isostere (e.g., amide or tetrazolyl); a is 0 to 5; a' is 0 or 1; R 3a and R 3b are each independently H or C 1~3 is alkyl; R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 where W' is a sequence of 5 to 60 amino acids and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from acyl groups and PEG groups); However, one or more of the compound definitions detailed herein apply.

3. The compound according to any one of claims 1 to 2, having the formula (I), or a pharma- ceutically acceptable salt thereof: During the ceremony, Ring A is (i) 3 to 8 ring atoms (G and a labeled nitrogen atom N * or (ii) 6 to 14 ring atoms (G and a labeled nitrogen atom N * Saturated or unsaturated bicyclic or tricyclic rings containing where ・G is C(O), S(O), or SO 2 and; ・G and N * and the circular dotted line connecting them is a divalent radical containing 1 to 6 ring atoms; (a) 0 to 2 ring atoms of a divalent group are ring heteroatoms and each independently is selected from N, N(R a ), O, S, and SO 2 selected from the group consisting of; (b) 1 to 6 ring atoms of the divalent group are ring carbon atoms and are each independently C, CH, or CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; where (1) When ring A is a monocyclic ring, each of 1 to 6 ring carbon atoms of the divalent group is independently CH, CH 2 , C.R. b , C(R b ) 2 , and C.H.R. b selected from the group consisting of; (2) When ring A is a bicyclic or tricyclic ring, the following (A) or (B) applies: (A) Two or three adjacent ring carbon atoms of a divalent group are each independently C, CH, and CR. b and (a) 1 to 5 independently selected R c C which may be substituted with 6~10 Aryl; (b) Heteroaryl containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (c) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (d) heterocyclyl containing 3 to 10 ring atoms, in which 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by or (B) one ring carbon atom of the divalent group is C, and (a) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkyl; (b) heterocyclyl containing 3 to 10 ring atoms, in which 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d Heterocyclyl, optionally substituted by and is spiro-fused to a second ring selected from the group consisting of: L is (i) -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; n is 0 to 2; p is 0 to 8; (ii) -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p (Formula IX), wherein n is 0 to 2; p is 0 to 8; (iii) -(CH 2 ) q -, where q is 1 to 10; (iv) -C(O)-; or (v) -(CH 2 ) m -X 1 -(CH 2 ) p (Formula VIII), wherein m is 1 to 6; p is 0 to 8. and; X 1 is -C(O)-; -N(R')C(O)-; -C(O)N(R')-; or -N(R')C(O)NR')-; 1~4 selected from the group consisting of alkyl; X 2 teeth, (i) -O-; (ii) -S-; (iii) -S(O) t - where t is 1 or 2; (iv) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently H and C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene; (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d heterocycloalkylene optionally substituted with (ix) 1 to 2 R e C which may be substituted with 2 ~C 4 alkenylene; or (x) 1 to 2 R e C which may be substituted with 2 ~C 4 Alkynylene and; X 3 is -O-; -S-; or -S(O) t -wherein t is 1 or 2; R 1 , R 2 , and R 4 each independently represents H and unsubstituted C 1~3 selected from the group consisting of alkyl; R 3 -C(O)OH, -C(O)OR 31 , or a carboxylic acid isostere; where R 31 teeth, (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 3~10 cycloalkyl, wherein the cycloalkyl is 1 to 4 independently selected R d cycloalkyl, optionally substituted with (iii) -(C 0~3 alkylene)-heterocyclyl, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocyclyl is selected from 1 to 4 independently selected R d heterocyclyl, optionally substituted by (iv) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with; or (v) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c Heteroaryl, optionally substituted with and; a is 0 to 5; R a Each occurrence of is independently H; C 1~4 Alkyl; C 3~6 Cycloalkyl; -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); and -S(O) 1~2 (C 1~6 alkyl); R b Each occurrence of is independently 31 ; C 1~4 Haloalkyl; -OH; oxo; -F; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -C(=O)(C 1~4 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R c Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 3~6 Cycloalkyl; C 1~4 Haloalkyl; -OH; -Halo; -NO 2 ; N 3 ; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Thioalkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R d Each occurrence of is independently selected from 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; C 1~4 Haloalkyl; -OH; -F; Cl; -N(R a )(R''); oxo; C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; R e Each occurrence of is independently -OH; -N(R a )(R''); C 1~4 Alkoxy; C 1~4 Haloalkoxy; -OC(=O)(C 1~6 alkyl); -C(=O)O(C 1~6 alkyl); -C(=O)OH; -C(=O)N(R''')(R''''); -S(O) 1~2 (C 1~6 alkyl); and cyano; Each occurrence of R'', R''', and R'''' independently represents H and C 1~6 selected from the group consisting of alkyl; W is of the formula W'-R 5 where W' is a sequence of 5 to 60 amino acids and R 5 is a C-terminal amino acid, amino acid ester, or amino acid amide, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from acyl groups and PEG groups); However, one or more of the compound definitions detailed herein apply.

4. Formula (IIA) The compound of any one of claims 1 to 2, having the formula:

5. 5. The compound of claim 1, wherein G is C(O).

6. G is S(O) or SO 2 The compound according to any one of claims 1 to 4,

7. The compound of any one of claims 1 to 6, wherein ring A is a saturated or unsaturated monocyclic ring containing from 3 to 8 (eg, from 4 to 8) ring atoms.

8. The compound of any one of claims 1 to 7, wherein ring A is a saturated monocyclic ring containing from 3 to 8 (eg, from 4 to 8) ring atoms.

9. The compound of any one of claims 1 to 8, wherein Ring A is a saturated monocyclic ring containing from 5 to 7 ring atoms.

10. The compound of any one of claims 1, 2, 4, 5, and 7-9, wherein ring A has the following formula (III): During the ceremony, A 1 is a bond, A 1A -A 1B , C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 1A and A 1B are independently C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 2 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 and; A 3 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; SO 2 ; or N(R a ) and; A 4 is C(O), CH 2 , C.H.R. b , or C(R b ) 2 ; O; S; or N(R a ), where A 3 and A 4 are all O; S; or N(R a ); or any combination thereof.

11. A 1 C(O), CH 2 , C.H.R. b , or C(R b ) 2 and ring A is a 6-membered ring.

12. A 1 CH 2 , C.H.R. b , or C(R b ) 2 12. The compound of claim 10 or 11,

13. A 1 CH 2 The compound according to any one of claims 10 to 12, wherein

14. A 1 12. The compound of claim 10 or 11, wherein is C(O).

15. A 2 CH 2 , C.H.R. b , or C(R b ) 2 The compound according to any one of claims 10 to 14, wherein

16. A 2 CH 2 16. The compound of any one of claims 10 to 15, wherein

17. A 3 CH 2 , C.H.R. b , or C(R b ) 2 17. The compound of any one of claims 10 to 16, wherein

18. A 3 CH 2 The compound according to any one of claims 10 to 17, wherein

19. A 3 O; S; SO 2 ; or N(R a 17. The compound according to any one of claims 10 to 16, wherein

20. A 4 CH 2 , C.H.R. b , or C(R b ) 2 20. The compound of any one of claims 10 to 19, wherein

21. A 4 CH 2 The compound according to any one of claims 10 to 20, wherein

22. A 2 , A 3 , and A 4 are independent of each other, CH 2 , C.H.R. b , and C(R b ) 2 12. The compound of claim 10 or 11, selected from the group consisting of:

23. A 2 , A 3 , and A 4 One or two of these are independently CHR b and C(R b ) 2 and the rest are selected from the group consisting of CH 2 23. The compound of claim 22, wherein

24. A 2 , A 3 , and A 4 are CH 2 23. The compound of claim 22, wherein

25. A 1 , A 2 , A 3 , and A 4 are independent of each other, CH 2 , C.H.R. b , and C(R b ) 2 12. The compound of claim 10 or 11, selected from the group consisting of:

26. A 1 , A 2 , A 3 , and A 4 One or two of these are independently CHR b and C(R b ) 2 selected from, others are CH 2 26. The compound of claim 25, wherein

27. A 1 , A 2 , A 3 , and A 4 are CH 2 27. The compound of claim 26, wherein

28. A 1 is a bond, and ring A is of the formula 11. The compound of claim 10, having the formula:

29. A 2 30. The compound of claim 28, wherein is C(=O).

30. A 3 is O; S; or N(R e ) and A 4 CH 2 , C.H.R. b , or C(R b ) 2 30. The compound of claim 29, wherein

31. A 3 The compound of claim 30, wherein is S.

32. A 3 N(R a ) (e.g. A 3 is NH.

33. A 4 CH 2 The compound of any one of claims 30 to 32, wherein

34. A 4 CHR b or C(R b ) 2 The compound of any one of claims 30 to 32, wherein

35. A 3 and A 4 are each independently CH 2 , C.H.R. b , or C(R b ) 2 30. The compound of claim 29, selected from:

36. A 3 and A 4 are CH 2 36. The compound of claim 35, wherein

37. A 3 and A 4 One of them is CH 2 And A 3 and A 4 The other is CHR b or C(R b ) 2 36. The compound of claim 35, wherein

38. A 3 and A 4 are each independently CHR b or C(R b ) 2 36. The compound of claim 35, selected from:

39. A 2 CH 2 , C.H.R. b , or C(R b ) 2 30. The compound of claim 28, wherein

40. A 2 CH 2 40. The compound of claim 39, wherein

41. A 3 and A 4 are each independently CH 2 , C.H.R. b , or C(R b ) 2 (e.g., A 3 and A 4 are CH 2 41. The compound of claim 39 or 40,

42. A 1 A 1A -A 1B 11. The compound of claim 10, wherein

43. A 1A and A 1B are each independently CH 2 , C.H.R. b , or C(R b ) 2 43. The compound of claim 42, wherein

44. A 1A and A 1B are each independently CH 2 44. The compound of claim 43, wherein

45. A 2 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 42 to 44, wherein

46. A 2 CH 2 46. ​​The compound of claim 45, wherein:

47. A 3 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 42 to 46, wherein

48. A 3 CH 2 48. The compound of claim 47, wherein:

49. A 4 CH 2 , C.H.R. b , or C(R b ) 2 The compound of any one of claims 42 to 48, wherein

50. A 4 CH 2 50. The compound of claim 49, wherein

51. The compound of any one of claims 1 to 6, wherein ring A is an unsaturated monocyclic ring containing from 3 to 8 (eg, from 4 to 8) ring atoms.

52. 52. The compound of any one of claims 1-6 and 51, wherein Ring A is an unsaturated monocyclic ring containing 5 to 6 ring atoms.

53. 53. The compound of any one of claims 1-6, 51, and 52, wherein Ring A is an unsaturated monocyclic ring containing 6 ring atoms.

54. The compound of any one of claims 51 to 53, wherein ring A has the formula (IV): During the ceremony, A 6 and A 7 are independently CH and CR b More selected; A 5 and A 8 are each independently N, CH, or CR b It is.

55. A 5 , A 6 , A 7 , and A 8 are independently CH and CR b 55. The compound of claim 54, selected from:

56. A 5 , A 6 , A 7 , and A 8 One or two of the CRs are independently selected. b and the others are CH.

57. A 5 , A 6 , A 7 , and A 8 55. The compound of claim 54, wherein each is CH.

58. A 5 , A 6 , and A 7 are independently CH and CR b Selected from A 8 The compound of claim 54, wherein is N.

59. A 5 is N; A 6 , A 7 , and A 8 are independently CH and CR b (e.g., A 6 , A 7 , and A 8 One of them is CR b (e.g., C-OH),

60. R b Each occurrence of is independently 31 -OH; -N(R a )(R''); C 1~4 Alkoxy; and C 1~4 The compound of any one of claims 54-56 and 58-59, selected from the group consisting of haloalkoxy.

61. R b Each entity of (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with (iii) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii) -F 60. The compound of any one of claims 54-56 and 58-59, selected from the group consisting of:

62. R b Each occurrence of is independently 31 -OH; -N(R a )(R''); C 1~4 Alkoxy; and C 1~4 51. The compound of any one of claims 10 to 50, selected from the group consisting of haloalkoxy.

63. R b Each entity of (i) 1 to 2 independently selected R e C which may be substituted with 1~6 Alkyl; (ii) -(C 0~3 Alkylene)-C 6~10 aryl, wherein the aryl is 1 to 5 independently selected R c aryl, optionally substituted with (iii) -(C 0~3 alkylene)-heteroaryl, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii) -F The compound of any one of claims 10 to 50, selected from the group consisting of:

64. R b Each entity of (I C 1~6 Alkyl; (iv) -OH; (v) -N(R a )(R''); (vi) C 1~4 Alkoxy; (vii) C 1~4 haloalkoxy; and (viii) -F The compound of any one of claims 10 to 50, selected from the group consisting of:

65. The compound of any one of claims 1 to 6, wherein ring A is a saturated or unsaturated bicyclic or tricyclic ring containing from 6 to 14 (eg, from 8 to 10) ring atoms.

66. The compound of any one of claims 1 to 6, wherein Ring A is an unsaturated bicyclic or tricyclic ring containing from 6 to 14 (eg, from 8 to 10) ring atoms.

67. 67. The compound of claim 65 or 66, to which (A) applies.

68. 68. The compound of any one of claims 65-67, wherein ring A is optionally further substituted with one oxo.

69. Ring A is represented by formula (VI) 69. The compound of any one of claims 65 to 68, having the formula:

70. The fused ring B is selected from 1 to 5 independently selected R c Optionally substituted condensation C 6~10 70. The compound of claim 69 which is aryl.

71. The fused ring B is selected from 1 to 5 independently selected R c 71. The compound of claim 69 or 70, which is a fused phenyl optionally substituted with.

72. The compound of any one of claims 69 to 71, wherein ring A has the formula (VI-A): In the formula, R c' is H or R c (For example, C 1~6 Alkyl, e.g. CH 3 ).

73. Ring B is 1 to 5 independently selected R c Optionally substituted (e.g. unsubstituted) fused C 10 71. The compound of any one of claims 69-70, which is aryl.

74. Ring B is a fused heteroaryl containing 5 to 10 (e.g., 6) ring atoms, in which 1 to 4 (e.g., 1) ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c 70. The compound of claim 69, which is heteroaryl, optionally substituted with:

75. Ring A is: The compound of any one of claims 65 to 68, selected from one of:

76. Each fused ring B is independently: fused heteroaryl containing 5 to 10 (e.g., 6) ring atoms, in which 1 to 4 (e.g., 1) ring atoms are each independently selected from N, N(R a ), O, and S, wherein the heteroaryl is selected from 1 to 3 independently selected R c heteroaryl, optionally substituted with; 1 to 5 (e.g., 1 to 2) independently selected R c Optionally substituted condensation C 6~10 (For example, C 6 ) Aryl 76. The compound of claim 75, selected from:

77. Each fused ring B is independently selected from 1 to 5 (e.g., 1 to 2) independently selected R c Optionally substituted condensation C 6~10 (For example, C 6 ) aryl.

78. The compound of any one of claims 1 to 6, wherein Ring A is a saturated bicyclic or tricyclic ring containing from 8 to 10 ring atoms.

79. The compound of claim 78, to which (A) applies.

80. 80. The compound of claim 78 or 79, wherein ring A is optionally further substituted with one oxo.

81. Ring A is represented by formula (VI) The compound of any one of claims 78 to 80, having the formula:

82. The fused ring B is selected from 1 to 4 independently selected R d Optionally substituted condensation C 3~10 82. The compound of claim 81, which is cycloalkyl.

83. The fused ring B is selected from 1 to 4 independently selected R d (For example, C 1~3 Optionally substituted with alkyl) 3~6 Cycloalkyl (e.g. C 3~4 cycloalkyl).

84. The compound of claim 78, to which (B) applies.

85. 85. The compound of claim 84, wherein Ring A contains 5 to 6 ring atoms and is optionally further substituted with one oxo.

86. Ring A is represented by formula (VII) 86. The compound of claim 84 or 85, having the formula:

87. The spiro-fused ring B is selected from 1 to 4 independently selected R d Optionally substituted spiro-fused C 3~10 87. The compound of claim 86, which is cycloalkyl.

88. The spiro-fused ring B is selected from 1 to 4 independently selected R d (For example, C 1~3 spiro-fused C optionally substituted with alkyl 3~6 Cycloalkyl (e.g. C 3~4 cycloalkyl).

89. L is of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p The compound of any one of claims 1 to 88, comprising:

90. 90. The compound of claim 89, wherein m is 2 to 6.

91. 91. The compound of claim 89 or 90, wherein m is 2.

92. 90. The compound of claim 89, wherein m is 1.

93. X 1 93. The compound of any one of claims 89-92, wherein is -N(R')C(O)-.

94. X 1 The compound of any one of claims 89-93, wherein is -N(H)C(O)-.

95. 95. The compound of any one of claims 89-94, wherein n + p > 2.

96. The compound of any one of claims 89-94, wherein n + p = 2 (e.g., n and p are each 1).

97. 95. The compound of any one of claims 89 to 94, wherein n + p<2.

98. The compound of any one of claims 89 to 94, wherein n + p = 0.

99. X 2 -O-; -S-; or -S(O) t -, wherein t is 1 or 2.

100. X 2 The compound of any one of claims 89-99, wherein is -S-.

101. X 2 -C(Q 1 )(Q 2 99. The compound of any one of claims 89 to 98, wherein

102. Q 1 and Q 2 are independently H and C 1~4 102. The compound of claim 101, which is alkyl.

103. Q 1 and Q 2 The compound of claim 101, wherein each is H.

104. Q 1 and Q 2 are each independently selected C 1~4 102. The compound of claim 101, which is alkyl.

105. Q 1 is H; Q 2 C 1~4 103. The compound of claim 102, which is alkyl.

106. Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 3~10 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d 102. The compound of claim 101, optionally substituted with and optionally fused to phenyl.

107. Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 3~6 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d 107. The compound of claim 106, optionally substituted with and optionally fused to phenyl.

108. Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 4~6 (For example, C 4 ) forming a cycloalkyl, the cycloalkyl being selected from 1 to 2 independently selected R d 108. The compound of claim 107, optionally substituted with:

109. X 2 but, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 cycloalkylene; or (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with 99. The compound of any one of claims 89 to 98, wherein

110. X 2 but, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene; or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene 99. The compound of any one of claims 89 to 98, wherein

111. X 2 but, (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with 110. The compound of claim 109,

112. X 2 but, (viii) heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, in which 1 to 3 (e.g., 1) ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with (For example, X 2 but The compound of claim 111,

113. m is 2 to 6; n + p ≧ 2; X 2 -O-; -S-; -S(O) t -; or CH 2 That is, 90. The compound of any one of claims 1 to 89.

114. The compound of claim 113, wherein m is 2.

115. X 1 is -N(R')C(O)- (e.g., X 1 is -N(H)C(O)-.

116. The compound of any one of claims 113 to 115, wherein n + p > 2.

117. The compound of any one of claims 113-115, wherein n + p = 2 (e.g., n and p are each 1).

118. X 2 The compound of any one of claims 113-117, wherein is -S-.

119. m is 2 to 6; n + p < 2; X 2 but, (i) -C(Q 1 )(Q 2 )-, in the formula, Q 1 and Q 2 are each independently selected C 1~4 alkyl; or Q 1 and Q 2 Each carbon atom is bonded to a carbon atom. 3~10 cycloalkyl, which is selected from 1 to 4 independently selected R d and optionally substituted with phenyl; (v) 1 to 5 independently selected R c C which may be substituted with 6~10 Arylene; (vi) Heteroarylene containing 5 to 10 ring atoms, wherein 1 to 4 ring atoms are each independently N, N(R a ), O, and S, wherein the heteroarylene is selected from 1 to 5 independently selected R c heteroarylene, optionally substituted by (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 cycloalkylene; or (viii) heterocycloalkylene containing 3 to 10 ring atoms, wherein 1 to 3 ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with 90. The compound of any one of claims 1 to 89, wherein

120. 120. The compound of claim 119, wherein m is 2.

121. X 1 121. The compound of claim 119 or 120, wherein is -N(R')C(O)- (e.g., -N(H)C(O)-).

122. The compound of any one of claims 119-121, wherein n + p = 0.

123. X 2 -C(Q 1 )(Q 2 123. The compound of any one of claims 119 to 122, wherein

124. Q 1 and Q 2 The compound of claim 123, wherein each is H.

125. Q 1 C 1~4 124. The compound of claim 123, which is alkyl.

126. Q 2 C 1~4 126. The compound of claim 125, which is alkyl.

127. Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 3~6 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d 123. The compound of any one of claims 119-122, optionally substituted with and optionally fused to phenyl.

128. X 2 but, (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene; or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene The compound of any one of claims 119 to 122, wherein

129. X 2 but, (viii) heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, in which 1 to 3 (e.g., 1) ring atoms are each independently N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d Heterocycloalkylene, optionally substituted with (For example, X 2 but The compound of any one of claims 119 to 122, which may be

130. m is 1; n + p ≦ 2; X 2 -O-; -S-; -S(O) t -; or C(Q 1 )(Q 2 ), 90. The compound of any one of claims 1 to 89.

131. The compound of claim 130, wherein n + p = 2.

132. X 2 The compound of claim 131, wherein is -S-.

133. The compound of claim 130, wherein n + p < 2 (e.g., n + p = 0; or alternatively, n + p = 1).

134. X 2 C(Q 1 )(Q 2 ). The compound of claim 133,

135. Q 1 and Q 2 The compound of claim 134, wherein each is H.

136. Q 1 and Q 2 are C 1~4 135. The compound of claim 134, which is alkyl.

137. Q 1 is H; Q 2 C 1~4 135. The compound of claim 134, which is alkyl.

138. L is of formula (IX): -C(O)-(CH 2 ) n -X 3 -(CH 2 ) p 90. The compound of any one of claims 1 to 89, comprising:

139. The compound of claim 138, wherein n + p > 2.

140. The compound of claim 138 or 139, wherein n + p = 2 (e.g., n and p are each 1).

141. X 3 The compound of any one of claims 138-140, wherein is -S-.

142. R 1 The compound of any one of claims 1-141, wherein

143. R 2 The compound of any one of claims 1-142, wherein

144. R 4 The compound of any one of claims 1-143, wherein

145. R 1 , R 2 , and R 4 The compound of any one of claims 1-144, wherein each is H.

146. R 2 is unsubstituted C 1~3 The compound of any one of claims 1 to 142, which is alkyl (e.g., methyl).

147. R 1 and R 4 The compound of claim 146, wherein each is H.

148. R 2' The compound of any one of claims 1 and 5-147, wherein is as defined by (AA).

149. The compound of any one of claims 1-2 and 4-148, wherein a' is 1.

150. R 3a and R 3b The compound of any one of claims 1-2 and 4-149, wherein each is H.

151. R 3a and R 3b are C 1~3 The compound of any one of claims 1, 2, and 4-149, which is alkyl (e.g., methyl).

152. The compound of any one of claims 1, 2, and 4-148, wherein a' is 0.

153. R 3 The compound of any one of claims 1-152, wherein is -C(O)OH.

154. R 3 The compound of any one of claims 1-152, wherein is a carboxylic acid isostere.

155. R 3 is optionally substituted tetrazolyl, amido, or optionally substituted isoxazolyl 155. The compound of any one of claims 1 to 152 and 154, wherein

156. 156. The compound of any one of claims 1-155, wherein a is 0, 1, 2, or 3 (e.g., a = 0; or a = 1; or a = 2).

157. The compound of claim 157, wherein a is 1.

158. The compound of any one of claims 1-157, wherein W is a sequence of 25 to 45 (e.g., 30 to 45) amino acids.

159. The compound of any one of claims 1-158, wherein W is a sequence of 36 amino acids.

160. W is of the formula (X): -GTF-W''-R 5 wherein W″ is a sequence of 30 to 40 (e.g., 31 to 36, 33) amino acids.

161. The compound of any one of claims 1 to 158 and 160, wherein W is represented by any one of SEQ IDs 1 to 34 (e.g. SEQ. IDs 5 to 27; e.g. SEQ IDs 5 to 29; (e.g. SEQ ID 6); e.g. SEQ IDs 28 to 29; e.g. SEQ IDs 30 to 34).

162. R 5 is a C-terminal amino acid amide, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

163. R 5 is a C-terminal lysylamide residue, optionally substituted with one to two modifying groups (e.g., one to two groups selected from an acyl group and a PEG group).

164. R 5 is a C-terminal L-lysylamide residue, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

165. R 5 The compound of any one of claims 1 to 164, wherein the compound has the formula (XI): In the formula, R * is H or a modifying group (e.g., acyl groups and PEG groups).

166. The compound of any one of claims 1 to 165, wherein W has the formula (XII): where W″ is a sequence of 30 to 40 (e.g., 31 to 36, 33) amino acids, and R * is H or a modifying group (e.g., acyl groups and PEG groups).

167. R 5 is the C-terminal amino acid, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

168. R 5 is a C-terminal lysine, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

169. R 5 is a C-terminal L-lysine, optionally substituted with 1-2 modifying groups (e.g., 1-2 groups selected from an acyl group and a PEG group).

170. R 5 The compound of any one of claims 1 to 161 and 168 to 169, wherein the compound has the formula (XI-OH): In the formula, R * is H or a modifying group (e.g., acyl groups and PEG groups).

171. The compound of any one of claims 1-161 and 168-170, wherein W has the formula (XII-OH): where W″ is a sequence of 30 to 40 (e.g., 31 to 36, 33) amino acids, and R * is H or a modifying group (e.g., acyl groups and PEG groups).

172. R * The compound of any one of claims 165-166 and 170-171, wherein

173. R * is one to two independently selected R f C which may be substituted with 2~30 (For example, C 2~20 ) an acyl group; where R f Each occurrence of -C(=O)(OH); -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); -S(O) 1~2 (C 1~6 alkyl); oxo; F; C 1~10 Alkoxy; C 1~10 haloalkoxy; and -N(R g )(R h R g and R h Each occurrence of is independently H; C 1~4 Alkyl; -C(=O)(C 2~20 alkyl); -C(=O)O(C 2~20 alkyl); and -S(O) 1~2 (C 1~6 The compound of any one of claims 165-166 and 170-171, wherein the compound is selected from the group consisting of: alkyl.

174. R * is one to two independently selected R f C replaced with 2~30 (For example, C 2~20 ) A compound according to any one of claims 165 to 166, 170 to 171, and 173, wherein said compound is an acyl group.

175. R f Each occurrence of is independently -C(=O)(OH) and -N(R g )(R h 175. The compound of claim 174, wherein the compound is selected from the group consisting of:

176. R * but, The compound of any one of claims 165-166, 170-171, and 173-175,

177. R * but, 177. The compound of claim 176,

178. R * but, 177. The compound of claim 176,

179. R 5 162. The compound of any one of claims 1-161, wherein is a C-terminal amino acid selected from serine, glycine, and arginine.

180. R 5 162. The compound of any one of claims 1-161, wherein is a C-terminal amino acid amide selected from serinylamide, glycylamide, and arginylamide.

181. having the formula (IA-A), (IA-AA), or (IA-AB); Ring A is a saturated monocyclic ring containing 3 to 8 (e.g., 4 to 8, 4 to 7, 5 to 6) ring atoms; L is of formula (VIII): -(CH 2 ) m -X 1 -(CH 2 ) n -X 2 -(CH 2 ) p -Having A compound according to any one of claims 1-2 and 162-180.

182. The compound of any one of claims 1-2 and 162-181, wherein W is represented by any one of formulas (X), (XII), (XIII), (XIV-AA), (XIV), (XIV-A), (XIV-B), (XV), or SEQ ID 1-34.

183. The compound of any one of claims 1-2 and 162-182, wherein W is represented by any one of SEQ IDs 5-29.

184. The compound of any one of claims 1-2 and 162-183, wherein W is represented by SEQ ID 6.

185. (i) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 is -S-; or (ii) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 Together with the carbon atom to which each is bonded, they form C 3~6 cycloalkyl, wherein the cycloalkyl is selected from 1 to 4 independently selected R d and optionally fused to phenyl; or (iii) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 -C(Q 1 )(Q 2 )- and Q 1 and Q 2 are selected independently, C 1~4 Alkyl (e.g. CH 3 ) or (iv) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 but (v) 1 to 5 independently selected R c C which may be substituted with 6~10 arylene (e.g. phenylene); or (vii) 1 to 4 independently selected R d C which may be substituted with 3~10 Cycloalkylene That is, A compound according to any one of claims 1-2 and 162-184.

186. (iv) m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g. -N(H)C(O)-), n + p = 0, and X 2 is a heterocycloalkylene containing 4 to 6 (e.g., 4) ring atoms, wherein 1 to 3 (e.g., 1) ring atoms are each independently selected from N(R a ), O, and S, wherein the heterocycloalkylene is selected from 1 to 5 independently selected R d and heterocycloalkylene, optionally substituted with X 2 but (which may be A compound according to any one of claims 1-2 and 162-184.

187. m is 2 to 6 (e.g., 2), and X 1 is -N(R')C(O)- (e.g., -N(H)C(O)-), n + p = 2 (e.g., n and p are each 1), and X 2 The compound of any one of claims 1-2 and 162-185, wherein is -S-.

188. L is -CH 2 CH 2 NHC(O)CH 2 SCH 2 The compound of any one of claims 1-2, 162-184, and 187, wherein

189. The compound of any one of claims 1-2 and 162-188, wherein Ring A has the formula (III):

190. The compound of any one of claims 1-2 and 162-189, wherein Ring A is defined as in any one of claims 11-27.

191. The compound of any one of claims 1-2 and 162-189, wherein ring A has the formula (III-A):

192. 190. The compound of any one of claims 1-2 and 162-188 and 190, wherein Ring A is defined as in any one of claims 29-41.

193. The compound of any one of claims 1-2 and 162-189, wherein Ring A is defined as in any one of claims 42-50.

194. R 1 , R 2 , and R 4 The compound of any one of claims 1-2 and 162-193, wherein one, two, or three of are H.

195. R 1 , R 2 , and R 4 The compound of any one of claims 1-2 and 162-194, wherein one, two, or three of are H.

196. R 3 The compound of any one of claims 1-2 and 162-195, wherein is -C(O)OH.

197. a' is 1; R 3a and R 3b The compound of any one of claims 1-2 and 162-196, wherein each is independently H.

198. The compound of any one of claims 1 and 162-197, wherein a is 0, 1, or 2 (e.g., 1).

199. R 1 , R 2 , and R 4 are each H, a is 0, 1, or 2 (e.g., 1), and R 3 The compound of any one of claims 1-2 and 162-198, wherein is -C(O)OH.

200. 2. The compound of claim 1, selected from the group consisting of the compounds depicted in FIG.

201. 201. A pharmaceutical composition comprising a compound or salt according to any one of claims 1-200 and one or more pharma- ceutically acceptable excipients.

202. 201. A method for modulating GLP-1R and / or GIPR activity, comprising contacting GLP-1R and / or GIPR with a compound according to any one of claims 1-200.

203. The method of claim 202, wherein modulating comprises stimulating GLP-1R and / or GIPR.

204. The method of claim 202, wherein modulating comprises partially stimulating or antagonizing GLP-1R and / or GIPR.

205. The method of any one of claims 202 to 204, which is carried out in vitro.

206. The method of any one of claims 202 to 204, which is carried out in vivo.

207. A method for modulating GLP-1R and / or GIPR induced aversion, nausea, and / or vomiting, comprising contacting GLP-1R and / or GIPR with a compound according to any one of claims 1 to 200.

208. A method for modulating (e.g., increasing) insulin levels in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to any one of claims 1-200.

209. A method for modulating (e.g. decreasing) glucose levels in a subject in need thereof, comprising administering to the subject an effective amount of a compound according to any one of claims 1-200.

210. A method for treating a disease, disorder, or condition comprising administering to a subject in need thereof an effective amount of a compound according to any one of claims 1-200, wherein modulation of GLP-1R and / or GIPR signaling may alter the pathology and / or symptoms and / or progression of the disease, disorder, or condition.

211. 211. The method of claim 210, wherein the disease, disorder, or condition or disorder is diabetes.

212. The method of claim 210, wherein the disease, disorder, or condition or disorder is NASH.

213. 211. The method of claim 210, wherein the disease, disorder, or condition or disorder is obesity.

214. The method of claim 210, wherein the disease, disorder, or condition or disorder is fatty liver disease.

215. The method of claim 210, wherein the disease, disorder, or condition or disorder is steatohepatitis.

216. The method of any one of claims 210-215, further comprising identifying the subject.

217. The method of any one of claims 210-216, wherein the subject is a human.

218. A method for treating a disease, disorder, or condition comprising administering to a subject in need thereof an effective amount of a compound of any one of claims 1-200, wherein modulation of GLP-1R and / or GIPR signaling causes aversion, nausea, or vomiting.

Citation Information

Patent Citations

  • Novel glp-1 receptor agonist peptides

    GB2551945A

  • DPP-IV resistant GIP hybrid polypeptide with selectable properties

    JP2010500996A

  • GIP-based mixed agonists for the treatment of metabolic diseases and obesity

    JP2011524420A

  • Modulators of G protein-coupled receptors

    JP7526716B2

  • N-terminally modified GLP-1 derivatives

    WO1999043707A1